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Pompe disease is a progressive metabolic myopa-
thy. It is caused by a deficiency of the enzyme acid 
α-glucosidase and leads to glycogen accumulation, 
predominantly in skeletal muscle. All Dutch patients 
diagnosed with Pompe disease are referred to the 
‘Center of Lysosomal and Metabolic Diseases’ at 
Erasmus MC University Medical Center, which makes 
it possible to study features of this orphan disease 
in a relatively large cohort. The aims of the stud-
ies described in this thesis were to have a better 
understanding of the clinical heterogeneity, geno-
type-phenotype correlations and the role of modifiers 
in Pompe disease. In addition, laboratory diagnostics 
and imaging techniques were studied, such as lung 
MRI in combination with spirometry to obtain insight 
into the function and strength of the respiratory mus-
cles, tonometry of the carotid-femoral pulse wave 
velocity to study arterial stiffness, and the meaning of 
increased plasma cardiac TnT levels.
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Pompe disease (OMIM 232300) is an inheritable lysosomal storage dis-
order and was first described by J.C. Pompe in 1932.1 It is caused by a 
deficiency of the enzyme acid α-glucosidase (GAA) and leads to glycogen 
accumulation in various body tissues, predominantly in skeletal muscle.2, 3 
In the Netherlands, the incidence of Pompe disease is 1 per 40,000 births 
per year.4 Dutch patients diagnosed with Pompe disease are referred to the 
‘Center of Lysosomal and Metabolic Diseases’ at Erasmus MC University 
Medical Center, which is the national centre of expertise for this orphan 
disease. Over the years we have clinically evaluated close to 200 Pompe 
patients and followed a cohort of over 400 patients worldwide using ques-
tionnaires. This has provided us a unique opportunity to study features 
of Pompe disease in a relatively large group of patients. This introductory 
chapter outlines the etiologic, pathophysiological, clinical, diagnostic and 
therapeutic aspects of this rare disorder in relation to the focus of research 
of this thesis. 
etiology and PathoPhysiology
Pompe disease, also known as acid maltase deficiency and glycogen storage 
disorder type II, is an autosomal recessive disorder caused by mutations 
in the GAA gene (OMIM 606800). This gene is located on chromosome 17 
in the region q25.2-q25.3. Because of the autosomal recessive inheritance, 
both alleles of the GAA gene need to carry a pathogenic mutation to 
develop Pompe disease. Mutations can either have an effect on the bio-
synthesis, posttranslational modification or intracellular transport of the 
α-glucosidase protein.5 To a certain extent, the GAA genotype determines 
the phenotype: a heteroallelic combination of two severe mutations gener-
ally results in a complete enzyme deficiency and causes the classic infantile 
Chapter 1
10
form of Pompe disease. If one of the two mutations is not fully deleterious 
some residual enzyme activity remains, resulting in the non-classic or late-
onset form of Pompe disease manifesting at any time during childhood or 
adulthood.5, 6 Under normal conditions the information on the GAA gene 
is copied onto messenger RNA (mRNA). This mRNA is transported to 
the cytoplasm and imported into the endoplasmic reticulum where it is 
translated to a protein and transported into the Golgi complex (110 kDa 
precursor form of GAA). During this transport, the protein undergoes 
multiple posttranslational modifications before it attains its full activ-
ity as GAA in the lysosomes (76 and 70 kDa mature forms).7 Lysosomes 
contain multiple hydrolytic enzymes that are able to break down different 
macromolecules. Over 40 different lyososmal hydrolases have been identi-
fied and one of these hydrolases is GAA.8 This enzyme is needed for the 
degradation of glycogen into glucose molecules in the lysosomes. Due to 
the GAA deficiency in patients with Pompe disease, glycogen accumulates 
in the lysosomes, eventually resulting in the loss of integrity of the muscle 
fibers leading to clinical symptoms of muscle weakness.9
clinical heterogeneity
Pompe disease has a broad clinical spectrum, as it ranges from severely 
affected patients with the classic infantile form to mildly affected patients 
with the non-classic or late-onset form of the disease (Figure 1). In this 
thesis the term ‘non-classic Pompe disease’ is used for patients who de-
velop symptoms in childhood or adulthood.10 Patients with classic infantile 
Pompe disease have a complete GAA deficiency and present with general-
ized hypotonia and a characteristic hypertrophic cardiomyopathy soon 
after birth. If these patients are not being treated with enzyme replacement 
therapye (ERT) they will not reach major motor milestones such as sitting 
and rolling over. Eventually, untreated patients will die in the first year of 
life.3, 11, 12 
The major part of this thesis concerns patients with non-classic Pompe 
disease. These patients experience their first symptoms in childhood 
or adulthood and have a slowly progressive course of the disease.10, 13, 14 
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Figure 1  the clinical spectrum of Pompe disease
This figure was adapted from the publication written by Güngör and Reuser entitled ‘How to 
describe the clinical spectrum in Pompe disease?’ in the American Journal of Medical Genetics 
2013, by permission of John Wiley and Sons. 
Figure 2 muscle weakness in adults with Pompe disease
This figure was adapted from the publication written by van der Beek et al. entitled ‘Clinical fea-
tures and predictors for disease natural progression in adults with Pompe disease: a nationwide 
prospective observational study’ in Orphanet Journal of Rare Diseases 2012, by permission of 
BioMed Central. 
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Limb girdle muscle weakness is the presenting symptom in most patients, 
leading to difficulties in walking, climbing stairs, rising from a chair and 
lifting objects (Figure 2). Other less common features that can be present 
are scapular winging, ptosis and bulbar weakness.15-19 Without treatment 
the majority of patients become wheelchair dependent and ventilator de-
pendent during the course of the disease.14, 18 Particularly in patients with 
non-classic Pompe disease there is a large clinical heterogeneity. Even in 
patients sharing the same GAA genotype and haplotype, the phenotype 
varies widely regarding to age of symptom onset and rate of disease pro-
gression.20, 21 This indicates that modifying factors might play a role in de-
termining the course of the disease; e.g. modulating environmental factors, 
such as exercise and nutrition therapy, have been described to play such a 
role.22, 23 In addition, genetic background factors such as polymorphisms 
in the ACE and ACTN3 gene have been reported to influence the clinical 
picture in patients with Pompe disease.24-26 To gain a better understand-
ing of genotype-phenotype correlations and potential influence of genetic 
background factors, we studied phenotypical variation in 22 families with 
Pompe disease with the same genotype, all living in the Netherlands 
(Chapter 2). We hypothesized that siblings with Pompe disease with the 
same GAA genotype are genetically more identical that non-related pa-
tients and therefore are predisposed to develop more similar phenotypes. 
laboratory diagnostics
A clinical suspicion of Pompe disease can be confirmed by determining 
the enzyme activity of GAA. GAA activity can be measured with the 
artificial substrate 4-methylumbelliferyl-alpha-D-glucopyranoside (4-
MU) or the natural substrate glycogen. Determination of GAA enzyme 
activity in fibroblasts is considered as gold standard test, however, since 
it takes approximately six weeks to culture fibroblasts, GAA activity is 
generally measured in leukocytes. GAA activity in leukocytes can only be 
measured reliably in the presence of acarbose. Without acarbose neutral 
α-glucosidases interfere with the test results. Other possibilities are mea-
suring GAA activity in dried blood spots or muscle tissue.3, 27, 28 Dried blood 
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spots can only be used for screening purposes, not for making a definitive 
diagnosis of Pompe disease. 
Patients with classic infantile Pompe disease have less than 2% residual 
enzyme activity in fibroblasts, while patients with non-classic Pompe 
disease have 5-25% residual enzyme activity. The vast majority of adult 
patients (>90%) carry the common splice site mutation c.-32-13T>G 
(IVS1).3, 5, 21, 28, 29 In our cohort of approximately 100 adult patients, there 
were four adults with unexpectedly low residual GAA activities in the 
range of patients with classic infantile Pompe disease. None of these pa-
tients had the IVS1 mutation. In one of the studies described in this thesis 
we aimed to understand the discrepancy between low fibroblast enzyme 
activity, the slow progression of the disease and the genotype-phenotype 
correlation in three of these patients (Chapter 3).
Over 95% of patients with Pompe disease have increased creatine kinase 
(CK) levels in their blood. Increased CK levels, together with increased 
levels of aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT), indicate skeletal muscle damage.30, 31 These parameters are sensi-
tive, but not specific for Pompe disease. Because AST and ALT can also be 
elevated in patients with liver diseases, some patients with Pompe disease 
are initially misdiagnosed as having a liver disorder. Other biomarkers of 
muscular damage are myoglobulin, lactate dehydrogenase and troponin.30 
Skeletal muscle-specific and cardiac muscle-specific subtypes of troponin 
T and troponin I do exist and are expressed from closely related genes.32, 33 
Although cardiac troponin T (cTnT) is an important biomarker in patients 
with acute myocardial infarction (AMI), increased plasma concentrations 
of cTnT have been observed in a small percentage of the general population 
due to hypertension, diabetes or chronic kidney disease.34-37 In one of our 
adult patients with Pompe disease we found increased plasma concentra-
tions of cTnT at the time she complained of non-specific chest pain. How-
ever, a comprehensive cardiac evaluation did not reveal any abnormalities. 
This is likely compatible with the previously described absence of cardiac 
involvement in patients with non-classic Pompe disease.38, 39 In one of our 
studies we determined if increased cTnT levels are observed in the Pompe 
population and we investigated whether such an increase could be the 
result of skeletal muscle damage and not myocardial damage (Chapter 4). 
Chapter 1
14
imaging
Pompe disease also affects the respiratory muscles leading to a reduced 
pulmonary function. Patients may develop nocturnal hypoventilation 
presenting with symptoms of daytime somnolence and morning headache. 
These patients require nocturnal or continuous mechanical ventilator sup-
port.14, 18, 40-42 The leading cause of death in patients with Pompe disease 
is respiratory failure.43, 44 Therefore, it is extremely important to monitor 
pulmonary function, including functional vital capacity (FVC), forced ex-
piratory volume in one second (FEV1), maximum static inspiratory (MIP) 
and expiratory (MEP) pressures.45, 46 Preferentially, spirometry should be 
performed in sitting and supine position, since there is a prominent reduc-
tion of the pulmonary function in supine position (i.e. postural drop) in 
most patients (Figure 3).18, 40, 41 Weakness of the diaphragm is considered 
to be the major cause of this postural drop in Pompe disease.41, 47 Although 
standard pulmonary function tests may be indicative for diaphragmatic 
weakness, they provide too little insight in dynamics of the diaphragm. 
It has also been found that the effects of ERT on pulmonary function are 
less pronounced compared to the effects on muscle strength; in 35% of the 
patients FVC in supine position deteriorates.42, 48-50 It has been hypothesized 
that ERT in Pompe patients with progressive respiratory insufficiency might 
have been started too late to repair muscle damage of the diaphragm. To 
obtain insight into the function and strength of the respiratory muscles, in 
particular the diaphragm, we performed a pilot study in ten adult Pompe 
patients using magnetic resonance imaging (MRI) in combination with spi-
rometry (Chapter 5). This technique makes it possible to directly assess the 
contribution of individual respiratory muscles during the breathing cycle, 
which is difficult with pulmonary function tests.51-54    
Imaging procedures such as computed tomography (CT) or MRI are not 
part of the diagnostic procedure in Pompe disease, however, these assess-
ments can provide important information. Several studies have been pub-
lished about muscle MRI in which the distribution and severity of affected 
muscles in patients with non-classic Pompe disease is described.43, 55-57 
Recently, it has been shown that MRI also can be used to study the effects 
of enzyme replacement therapy (ERT) on individual muscles.58 In patients 
with classic infantile Pompe disease muscle MRI has not been studied 
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before. We performed a pilot study in a small group of patients with classic 
infantile Pompe disease to investigate whether muscle MRI potentially can 
be a useful tool to study the extent of muscle damage of the upper legs 
(Chapter 6). 
Apart from glycogen accumulation in skeletal and respiratory muscles, 
it has been shown in several morphological studies and autopsy reports 
that glycogen also accumulates in smooth muscle fibers and in the en-
dothelial layer of arteries.9, 59, 60 In some reports it has been hypothesized 
that glycogen accumulation in smooth muscle tissue of arteries leads to 
vascular abnormalities such as aneurysms.59, 61-65 Increased aortic stiffness, 
which is an independent risk factor for cardiovascular disease and mortal-
ity, was earlier demonstrated by our group in a study of 17 patients with 
non-classic Pompe disease using transthoracic Doppler echocardiography, 
a technique to measure aortic stiffness indirectly.66-68 Nowadays, tonometry 
of the carotid-femoral pulse wave velocity (cfPWV) is considered to be 
the gold standard test to directly measure arterial stiffness.69 To determine 
whether structural changes in the arteries of patients with Pompe disease 
lead to functional abnormalities, we measured arterial stiffness and blood 
pressure in 84 patients with non-classic Pompe disease and compared the 
results with 179 age and gender-matched volunteers (Chapter 7). 
treatment
Pompe disease is the first treatable genetic muscle disease. In 2006, ERT 
with recombinant human acid α-glucosidase (rhGAA) (Myozyme®, Gen-
zyme) was approved in the Netherlands for all Pompe patients. ERT is 
administered intravenously once every two weeks. RhGAA binds to the 
mannose 6-phosphate receptor, which is present on the cell surface of 
cardiomyocytes and skeletal muscle cells. The enzyme is then internal-
ized into the myocyte and transported via endocytosis to the lysosome. 
Inside the lysosome, rhGAA breaks down the accumulated glycogen into 
glucose.70-72 The first studies on the effects of ERT in patients with clas-
sic infantile Pompe disease started in 1999 at our center. Over the years 
it has been shown that patients with classic infantile Pompe disease have 
an improved survival, a decrease of the hypertrophic cardiomyopathy to 
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a normal shaped and functioning heart, improved motor functioning and 
increased ventilator-free survival.3, 73-75 The first results of ERT in a large 
international group of 90 patients with non-classic or late-onset Pompe 
disease, including 22 patients of our center, originated from a randomized, 
multicenter, placebo-controlled trial, which was published in 2010. After 
1.5 years, patients receiving ERT had an improved walking distance and 
stabilization of the pulmonary function.42 Several studies have also shown 
similar results with an improvement in walking distance and stabilization 
of muscle strength and pulmonary function after a treatment duration of 
6-54 months. 49, 50, 76-80 Recently, it has been demonstrated that ERT also has 
a significant positive effect on survival in patients with non-classic Pompe 
disease, with a hazard ratio of 0.41. It was estimated that eight years of 
treatment with ERT would result in one extra year of life.81
Since not all patients with Pompe disease respond equally well on ERT, it 
is important to study additional strategies to improve muscle strength and 
daily functioning. It has been shown that exercise training has a positive 
effect on muscle strength and endurance in patients with different neuro-
muscular diseases.82 There is some evidence that exercise training could 
be beneficial for patients with Pompe disease.23, 83 In one study it has even 
been shown that patients receiving ERT had better functional outcomes 
when they were specifically subjected to concomitant physiotherapy.50 
Exercise studies in Pompe disease are limited and comprised only small 
groups of patients and the exercise programs differed between patients. We 
explored with a prospective design whether 23 patients with non-classic 
Pompe disease receiving ERT benefit from a standard exercise program 
(Chapter 8).     
scoPe of the thesis
The aims of the studies described in this thesis were as follows:
Clinical heterogeneity, genotype-phenotype correlations and the role of modifiers
1. To study the phenotypical variation in families with non-classic Pompe 
disease and to determine to what extent siblings and families with the 
Chapter 1
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same GAA genotype have the same clinical presentation and course of 
the disease, and the potential role of genetic background factors.
2. To understand the exceptionally low GAA activity measured in fibro-
blasts of three adult patients with Pompe disease, in relation to the slow 
progressive course of the disease and the genotype.
3. To determine if a standardized exercise program can modify endurance, 
muscle strength and muscle function in adults with Pompe disease 
receiving ERT.
Laboratory diagnostics and imaging
4. To determine whether increased levels of cTnT in patients with Pompe 
disease are an early indicator of subclinical myocardial damage or can 
be attributed to skeletal muscle damage.
5. To obtain insight into the function and strength of the respiratory 
muscles, in particular the diaphragm, in ten adult patients using MRI in 
combination with spirometry.
6. To assess whether muscle MRI can be a useful tool to investigate the 
extent of muscle damage in classic infantile Pompe disease.
7. To investigate whether patients with non-classic Pompe disease have in-
creased arterial stiffness using various techniques including tonometry 
of the cfPWV.
outline of the thesis
Chapter 1 provides a general introduction about Pompe disease. In Chap-
ter 2 the phenotypical variation in families with the non-classic form of 
Pompe disease is described. In Chapter 3 three adult patients with Pompe 
disease having a very low GAA activity in fibroblasts are discussed. Chap-
ter 4 focuses on the increased plasma levels of cTnT and the source of this 
elevation. In Chapter 5 the use of MRI is described to explore dynamic 
respiratory function in adult Pompe patients. The usefulness of muscle 
MRI in classic infantile Pompe disease is studied in Chapter 6. Chapter 
7 focuses on arterial stiffness measured with cfPWV in patients with non-
classic Pompe disease. The effects of exercise training on muscle strength, 
19
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muscle function and exercise tolerance are described in Chapter 8. Finally, 
the general discussion (Chapter 9) summarizes the main findings and 
discusses the clinical implementation and future perspectives.
Chapter 1
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abstract
Introduction Pompe disease has a broad clinical spectrum, in which the 
phenotype is partially explained by the genotype. The aim of this study 
was to describe phenotypical variation among siblings with non-classic 
Pompe disease. We hypothesized that siblings and families with the 
same genotype share more similar phenotypes than the total population 
of non-classic Pompe patients, and that this might reveal genotype-
phenotype correlations.
Methods We identified all Dutch families in which two or three siblings 
were diagnosed with Pompe disease and described genotype, acid 
α-glucosidase activity, age at symptom onset, presenting symptoms, 
specific clinical features, mobility and ventilator dependency. 
Results We identified 22 families comprising two or three siblings. All 
carried the most common mutation c.-32-13T>G in combination with 
another pathogenic mutation. The median age at symptom onset was 
33 years (range 1-62 years). Within sibships symptom onset was either 
in childhood or in adulthood. The median variation in symptom onset 
between siblings was nine years (range 0-31 years). Presenting symp-
toms were similar across siblings in 14 out of 22 families. Limb girdle 
weakness was most frequently reported. In some families ptosis or 
bulbar weakness were present in all siblings. A large variation in disease 
severity (based on wheelchair/ventilator dependency) was observed 
in 11 families. This variation did not always result from a difference 
in duration of the disease since a third of the less affected siblings had 
a longer course of the disease. Enzyme activity could not explain this 
variation either. In most families male patients were more severely af-
fected. Finally, symptom onset varied substantially in twelve families 
despite the same GAA genotype. 
Conclusion In most families with non-classic Pompe disease siblings share 
a similar phenotype regarding symptom onset, presenting symptoms 
and specific clinical features. However, in some families the course and 
severity of disease varied substantially. This phenotypical variation was 
also observed in families with identical GAA genotypes. The commonali-
ties and differences indicate that besides genotype, other factors such as 
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epigenetic and environmental effects influence the clinical presentation 
and disease course. 
introduction
Pompe disease (OMIM 232300: acid maltase deficiency or glycogen storage 
disease type II) is an autosomal recessive disorder caused by a deficiency 
of acid α-glucosidase which leads to accumulation of glycogen in various 
tissues. The deficiency is caused by mutations in the acid α-glucosidase 
(GAA) gene (OMIM 606800).1-7 The combination of mutations in the 
GAA gene determines the phenotype to a certain extent.8,9 A heteroallelic 
combination of two severe mutations that results in a complete enzyme 
deficiency causes classic infantile Pompe disease. Soon after birth these 
infants present with generalized hypotonia, hypertrophic cardiomyopathy, 
feeding difficulties and respiratory problems. If not treated they usually 
die before the age of one year.4,10,11 If one of the two mutations is not fully 
deleterious and some residual enzyme activity remains, the disease can 
manifest at anytime during childhood or adulthood. This is referred to as 
non-classic Pompe disease and patients develop slowly progressive limb 
girdle weakness and respiratory problems.12,13 Thus, the GAA genotype is 
the first level at which clinical heterogeneity arises. 
In the Netherlands, about 95% of adult patients with Pompe disease 
and 68% of affected children under 18 years have the mild and common 
mutation c.-32-13T>G in one GAA allele combined with a far more severe 
mutation in the other allele. c.-32-13T>G is a so called ‘leaky splice’ muta-
tion, producing only 5-15% of the normal amount of messenger RNA and 
resulting in a proportional amount of structurally and functionally normal 
acid α-glucosidase.8,14 The phenotype of patients with one c.-32-13T>G 
mutation combined with a fully deleterious mutation varies widely in 
age of symptom onset and rate of disease progression despite the similar 
GAA genotype and haplotype.14,15 Since siblings with Pompe disease are 
genetically more identical than non-relatives, we assumed that they would 
develop more similar phenotypes. Some phenotypical variation within af-
fected families has been described in case reports.16-21
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The aims of our study were to describe the phenotypical variation in a 
large group of families, to determine to what extent the disease in siblings 
and families with the same GAA genotype had the same clinical presen-
tation and followed the same course, and to identify possible genotype-
phenotype correlations. 
methods 
study population
In the Netherlands, all patients diagnosed with Pompe disease are referred 
to Erasmus MC University Medical Centre, which is the national centre of 
expertise for this orphan disease. For our study we identified all families 
with non-classic Pompe disease in which two or three siblings were af-
fected. We used the definition of non-classic Pompe disease as described 
in a previously published letter.13 Patients with non-classic Pompe disease 
have onset of symptoms in childhood or adulthood. Onset of symptoms 
can also be in the first year of life, however, these patients do not have 
persisting and progressive cardiac hypertrophy such as in classic infantile 
Pompe disease. In literature, non-classic Pompe disease is also referred as 
late-onset Pompe disease, although onset of disease can also be in child-
hood. All patients were seen between October 2004 and December 2012. 
The Medical Ethical Committee of Erasmus University Medical Center 
approved the study protocols.    
enzyme and mutation analyses
Enzyme activity in fibroblasts was measured with 4-methylumbelliferyl-
α-D-glucopyranoside (4-MU) as substrate.14 GAA sequence analyses were 
performed using genomic DNA isolated from white blood cells as previ-
ously described.22,23
clinical features
At the first visit, a thorough medical history was obtained. Patients were 
asked at what age they first experienced symptoms and what the nature of 
these symptoms was. The duration of the disease was calculated from the 
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onset of symptoms to the current age of the patient. Distribution of weak-
ness and specific symptoms such as ptosis, bulbar weakness and scapular 
winging were recorded. Where applicable, the age at start of wheelchair or 
ventilator use was recorded. 
statistical analyses
The data were analysed using SPSS 20. Descriptive statistics were used 
for all calculations and data are presented as medians with ranges. The 
following parameters were assessed whether they had an influence on 
the phenotypical variation in and/or between families: disease duration, 
gender, genotype, enzyme activity in fibroblasts and co-morbidity. 
results
study population
Among a total of 126 patients with Pompe disease cared for at our centre, 
we identified 23 families with two or three affected siblings. Because in one 
family a patient was already wheelchair dependent due to other causes, 
we did not include this family in our analyses. The common c.-32-13T>G 
mutation was encountered in all families; in 12 families in combination 
with c.525delT (r.0), and in 10 families with another equally detrimental 
second mutation.24 Four patients from different families died before they 
were referred to our centre and these patients were not included because of 
lack of data. The remaining 22 families comprised 50 patients. The median 
age at first visit was 49 years (range 0-72 years). None of the patients was 
being treated with enzyme replacement therapy (ERT) at this time. The 
characteristics of the study population are presented in Table 1.
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symptom onset and clinical features
Figure 1 gives an overview of the disease course of each family: from 
symptom onset, to the age of diagnosis and the age siblings became wheel-
chair or ventilator dependent. The youngest patient developed symptoms 
in the first year of life, while the oldest patient developed symptoms at the 
age of 62 years. The median difference in symptom onset was nine years 
between siblings (range 0-31 years). All siblings within a family developed 
first symptoms either in childhood (4/22) or in adulthood (18/22). The age 
of diagnosis varied between 0 and 72 years (median 39 years). The median 
delay between symptom onset and diagnosis was four years (range 0-43 
years) for all patients. The median time between diagnosis of the first 
sibling and of the second or third family member was one year (range 0-19 
years).
Table 1  Patient characteristicsa
Total
Patients 50
Gender: males (%) 24 (48)
Median age at symptom onset in years (range)b 33 (1-62)
Median age at diagnosis in years (range)c 39 (0-72)
Current median age in years (range) 53 (5-79)
Mobility (%)
• ambulant
• walking aids 
• wheelchair dependent
30 (60)
6 (12)
14 (28)
Ventilator dependent (%) 14 (28)
α-Glucosidase activity in fibroblasts (nmol MU/mg.h)d 13 (8-18)
Families 22
Families with genotype (%)
• c.-32-13T>G / c.525delT (r.0)
• c.-32-13T>G / c.378_379del (p.Cys127LeufsX18)
• c.-32-13T>G / c.925G>A (p.Gly309Arg)
• c.-32-13T>G / other pathogenic mutation
12 (55)
2 (9)
2 (9)
6 (27)
a Data are numbers with percentages or medians with ranges. b The median age at onset of symp-
toms is calculated for 47 patients because three patients are asymptomatic. c One patient was 
diagnosed at birth because she had a brother with Pompe disease, but she was asymptomatic.  
d Control range 40-180 nmol MU/mg.h.
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Figure 1 course of the disease in 22 families with non-classic Pompe disease
Families 1-4 are childhood-onset patients and families 5-22 are adult-onset patients. Each dot 
represents an event during the course of the disease. Families highlighted with * share the same 
GAA genotype. 
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Table 2 shows the similarities and differences in clinical characteristics 
within families. In 13 families all siblings presented with skeletal muscle 
weakness (i.e. limb girdle weakness or delayed motor development). In 
one family all three siblings presented with a combination of limb girdle 
weakness and bulbar weakness. Bulbar weakness comprised dysarthria, 
dysphagia and chewing difficulties. In the eight remaining families there 
was a variation in the nature of first symptoms, including three families 
with a pre-symptomatic sibling (only enzyme and genetic diagnosis, no 
clinical signs). Specific clinical features seen throughout the course of dis-
ease such as ptosis, bulbar weakness and scapular winging were clustered 
within some families.
severity of the disease and possible influencing factors
As shown in Table 2, in approximately 50% of the families there was at 
least one wheelchair or ventilator dependent patient. The majority of these 
wheelchair and/or ventilator dependent patients (93% and 86%) had a 
sibling who was ambulant and not using ventilator support at the same 
age that they became dependent themselves. In one family co-morbidity 
Table 2  clinical characteristics within 22 familiesa
Total of families (%)
Presenting symptoms in all siblings (%)
• skeletal muscle weaknessb
• skeletal muscle + bulbar weakness
• variation in first symptomsc
13 (59)
1 (5)
8 (36)
Clinical features (%)
• all siblings had a ptosis 
• all siblings had bulbar weakness
• all siblings had scapular winging
4 (18)
2 (9)
1 (5)
Mobility (%)
• All siblings were ambulant
• One or two siblings were wheelchair dependentd
• All siblings were wheelchair dependent
11 (50)
10 (45)
1 (5)
Ventilation (%)
• None of the siblings was ventilator dependent
• One or two siblings were ventilator dependentd
• All siblings were ventilator dependent
12 (54)
9 (41)
1 (5)
a Data are numbers with percentages. b Limb girdle weakness, delayed motor development. c In 
three families one sibling was still asymptomatic. d In five families consisting of three siblings, one 
or two siblings were wheelchair or ventilator dependent, while the other sibling was not.
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played a role in clinical variability between siblings, as one sibling acquired 
kyphoscoliosis after vertebral spondylitis and became wheelchair depen-
dent (Figure 1, family 22). We have added a movie file that illustrates the 
marked differences in disease course within some sibships (see Additional 
file 1).
In a subgroup of 11 families representing the largest variation in disease 
severity, with at least one wheelchair or ventilator dependent sibling 
and one ambulant and ventilator independent sibling, we compared the 
characteristics of the siblings. The most severely affected sibling had the 
longest duration of the disease in 64% of these families. Males were more 
severely affected than females in seven families (64%). In the majority of 
families (60%), the patient with the highest enzyme activity in fibroblasts 
was more severely affected. 
Twelve families shared genotype c.-32-13T>G / c.525delT (r.0). The onset 
of symptoms varied substantially between these families with the same set 
of GAA mutations (Figure 1); e.g. families 2-4 had symptom onset in child-
hood, while in families 11, 12, 15, 18 and 19 the first symptoms presented 
later in adulthood.   
discussion
This is the first study that describes phenotypical commonalities and varia-
tion in a large cohort of families representing 50 patients with non-classic 
Pompe disease. We confirmed the presence of phenotypical commonalities 
within sibships, including: symptom onset either in childhood or in adult-
hood, similar presenting symptoms (in 70% of families), and the occurrence 
of particular symptoms such as ptosis and bulbar weakness. However, the 
rate of disease progression varied substantially within some families and 
also between families with the same GAA genotype.
Infants with classic infantile Pompe disease show a consistent pheno-
type, also within sibships, while the clinical spectrum of non-classic Pompe 
disease is much more variable regarding onset and progression of the dis-
ease.3,6-8,12 Since siblings share the same set of GAA mutations and are ge-
netically more related than non-relatives, we expected to find less variation 
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in phenotype within sibships compared to the overall Pompe population. 
In our 22 Dutch families the presenting symptoms were often the same. As 
limb girdle weakness is known to be the most frequently occuring initial 
symptom in Pompe disease, it is not surprising this was found frequently 
in all siblings of a family.3,5-7,12 Other symptoms also seemed to cluster 
within families. Remarkably, bulbar weakness was a presenting symptom 
in all three siblings of one family. Bulbar weakness has been reported in 
approximately 25% of adult Pompe patients, but rarely as first symptom 
(1-2%).6,12,25 It was also found in all siblings of a second family but later 
on in the course of the disease. The same applies to ptosis.26-28 Ptosis has 
been reported in 23% of the Dutch adults with Pompe disease.12 In our 
cohort of families we found the same percentage. In four families ptosis 
was present in all siblings. All carried the c-32-13T>G mutation, but the 
second GAA mutation differed between the families. The same applied to 
the two families with bulbar weakness, suggesting a role for (epi)genetic 
factors in the clustering of symptoms within families.  
We also found differences in phenotype within the same family. The me-
dian difference in symptom onset between siblings was nine years, with 
extremes of 20 to 31 years in three families. Since time of symptom onset 
was based on patients reporting their own history, there may be a recall 
bias leaving some uncertainty in the differences between time of symptom 
onset between siblings. However, it is inevitable that large differences will 
occur within some families. The majority of wheelchair and/or ventilator 
dependent patients had an ambulant or non-ventilated sibling, while they 
had already been using these supportive measures when they were the 
same age. The duration of the disease (time from symptom onset) could not 
always explain this difference, since a third of the patients were wheelchair 
or ventilator dependent and needed these resources at an earlier stage of 
their disease than their ambulant or non-ventilated sibling
We looked for possible factors explaining the observed phenotypical 
variation between siblings. Siblings who had the disease for longer were 
often more severely affected. However, this does not explain why these 
siblings developed symptoms at a younger age and why their disease pro-
gressed more rapidly. Gender could play a role since twice as many males as 
females were more severely affected. Earlier studies on the natural course 
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of Pompe disease also show male gender to be a predictive factor for a 
more severe respiratory status.12,29 GAA activity did not explain differences 
in phenotype, since in only three families did the most severely affected 
patient have the lowest amount of enzyme activity in fibroblasts. This is in 
accordance with previously published data on Pompe patients, describing 
the absence of a correlation between the clinical course and residual activ-
ity in patients with the c-32-13T>G/null genotype.5 Other co-morbidities 
contributed to phenotypical differences in only one family.
The substantial differences in age of symptom onset observed in the 12 
families with an identical GAA genotype (c.-32-13T>G / c.525delT (r.0)) 
suggest that other factors such as variability in genetic background, 
modifying genes or environmental factors are likely to play a role.5,8,14,16,20,30 
An example of a potential modifying gene is the angiotensin-converting 
enzyme gene, which has been described as playing a role in modulating 
phenotype and prognosis in Pompe disease.31,32 This and other modifying 
genes might also explain the clear differences between families with the 
same GAA genotype, and the clustering of symptoms such as ptosis and 
bulbar weakness in certain families.
conclusion
This study in families with non-classic Pompe disease showed that onset of 
symptoms within a family appeared to be either in childhood or adulthood, 
presenting symptoms of siblings were often similar and some specific clini-
cal features clustered in certain families. However, the course and severity 
of disease can vary substantially within some families and between families 
with the same GAA genotype. This phenotypical consistency and variation 
within sibships indicates that other factors such as epigenetic and environ-
mental effects influence the course of clinical disease. Additional studies 
are needed to identify these factors and to determine which prognostic 
factors will predict the disease course.
Chapter 2
38
references
 1.  American Association of Neuromuscular, Electrodiagnostic M. Diagnostic criteria for late-
onset (childhood and adult) Pompe disease. Muscle Nerve 2009; 40: 149-160.
 2.  Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis 
and management guideline. Genet Med 2006; 8: 267-288.
 3.  Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, Van der Ploeg 
AT. Clinical manifestation and natural course of late-onset Pompe’s disease in 54 Dutch 
patients. Brain 2005; 128: 671-677.
 4.  Hirschhorn R, Reuser AJ. Glycogen storage disease type II: acid alpha- glucosidase (Acid 
Maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and 
molecular bases of inherited disease. New York: Mc Graw-Hill, 2001; 3389-3420
 5.  van der Ploeg AT, Reuser AJ. Pompe’s disease. Lancet 2008; 372: 1342-1353.
 6.  Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg 
AT. The natural course of non-classic Pompe’s disease; a review of 225 published cases. J 
Neurol 2005; 252: 875-884.
 7.  Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, et al. Clinical 
features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008; 38: 
1236-1245.
 8.  Kroos M, Hoogeveen-Westerveld M, van der Ploeg A, Reuser AJ. The genotype-phenotype 
correlation in Pompe disease. Am J Med Genet C Semin Med Genet 2012; 160C: 59-68.
 9.  Hermans MM, van Leenen D, Kroos MA, Beesley CE, Van Der Ploeg AT, Sakuraba H, et al. 
Twenty-two novel mutations in the lysosomal alpha-glucosidase gene (GAA) underscore 
the genotype-phenotype correlation in glycogen storage disease type II. Hum Mutat 2004; 
23: 47-56.
 10.  van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, et al. The 
natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from 
the literature. Pediatrics 2003; 112: 332-340.
 11.  Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D. Infantile-Onset Pompe 
Disease Natural History Study G: A retrospective, multinational, multicenter study on the 
natural history of infantile-onset Pompe disease. J Pediatr 2006; 148: 671-676.
 12.  van der Beek NA, de Vries JM, Hagemans ML, Hop WC, Kroos MA, Wokke JH, et al. Clini-
cal features and predictors for disease natural progression in adults with Pompe disease: a 
nationwide prospective observational study. Orphanet J Rare Dis 2012; 7: 88.
 13.  Gungor D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med 
Genet A 2013; 161A: 399-400.
 14.  Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M, DeRiso M, et al. Broad 
spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 
2007; 68: 110-115.
 15.  Montalvo AL, Bembi B, Donnarumma M, Filocamo M, Parenti G, Rossi M, et al. Mutation 
profile of the GAA gene in 40 Italian patients with late onset glycogen storage disease type 
II. Hum Mutat 2006; 27: 999-1006.
 16.  Ausems MG, ten Berg K, Beemer FA, Wokke JH. Phenotypic expression of late-onset gly-
cogen storage disease type II: identification of asymptomatic adults through family studies 
and review of reported families. Neuromuscul Disord 2000; 10: 467-471.
39
Phenotypical variation within 22 families with Pompe disease
2
 17.  Barohn RJ, McVey AL, DiMauro S. Adult acid maltase deficiency. Muscle Nerve 1993; 16: 
672-676.
 18.  Felice KJ, Alessi AG, Grunnet ML. Clinical variability in adult-onset acid maltase deficiency: 
report of affected sibs and review of the literature. Medicine (Baltimore) 1995; 74: 131-135.
 19.  Wokke JH, Ausems MG, van den Boogaard MJ, Ippel EF, van Diggelene O, Kroos MA, et al. 
Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 1995; 
38: 450-454.
 20.  Papadimas GK, Spengos K, Konstantinopoulou A, Vassilopoulou S, Vontzalidis A, Papado-
poulos C, et al. Adult Pompe disease: clinical manifestations and outcome of the first Greek 
patients receiving enzyme replacement therapy. Clin Neurol Neurosurg 2011; 113: 303-307.
 21.  Sampaolo S, Esposito T, Farina O, Formicola D, Diodato D, Gianfrancesco F, et al. Distinct 
disease phenotypes linked to different combinations of GAA mutations in a large late-onset 
GSDII sibship. Orphanet J Rare Dis 2013; 8: 159.
 22.  Hermans MM, van Leenen D, Kroos MA, Reuser AJ. Mutation detection in glycogen 
storage-disease type II by RT-PCR and automated sequencing. Biochem Biophys Res Commun 
1997; 241: 414-418.
 23. Kroos MA, Waitfield AE, Joosse M, Winchester B, Reuser AJ, MacDermot KD. A novel acid 
alpha-glucosidase mutation identified in a Pakistani family with glycogen storage disease 
type II. J Inherit Metab Dis 1997; 20: 556-558.
 24.  Hermans MM, De Graaff E, Kroos MA, Mohkamsing S, Eussen BJ, Joosse M, et al. The effect 
of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on 
the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease 
type II. Hum Mol Genet 1994; 3: 2213-2218.
 25.  Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-
onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord 2013; 
 26.  Groen WB, Leen WG, Vos AM, Cruysberg JR, van Doorn PA, van Engelen BG. Ptosis as a 
feature of late-onset glycogenosis type II. Neurology 2006; 67: 2261-2262.
 27.  Ravaglia S, Repetto A, De Filippi P, Danesino C. Ptosis as a feature of late-onset glycogeno-
sis type II. Neurology 2007; 69: 116; author reply 116.
 28.  Yanovitch TL, Banugaria SG, Proia AD, Kishnani PS. Clinical and histologic ocular findings 
in pompe disease. J Pediatr Ophthalmol Strabismus 2010; 47: 34-40.
 29.  van der Beek NA, van Capelle CI, van der Velden-van Etten KI, Hop WC, van den Berg 
B, Reuser AJ, et al. Rate of progression and predictive factors for pulmonary outcome in 
children and adults with Pompe disease. Mol Genet Metab 2011; 104: 129-136.
 30.  Smith WE, Sullivan-Saarela JA, Li JS, Cox GF, Corzo D, Chen YT, Kishnani PS. Sibling 
phenotype concordance in classical infantile Pompe disease. Am J Med Genet A 2007; 143A: 
2493-2501.
 31.  de Filippi P, Ravaglia S, Bembi B, Costa A, Moglia A, Piccolo G, et al. The angiotensin-
converting enzyme insertion/deletion polymorphism modifies the clinical outcome in 
patients with Pompe disease. Genet Med 2010; 12: 206-211.
 32.  Ravaglia S, De Filippi P, Pichiecchio A, Ponzio M, Saeidi Garaghani K, Poloni GU, et al. Can 
genes influencing muscle function affect the therapeutic response to enzyme replacement 
therapy (ERT) in late-onset type II glycogenosis? Mol Genet Metab 2012; 107: 104-110.

 Chapter 3
remarkably low fi broblast 
acid α-glucosidase activity 
in three adults with Pompe 
disease
S.C.A. Wens
M.A. Kroos
J.M. de Vries
M. Hoogeveen-Westerveld
G.J.M. Wijgerde
P.A. van Doorn
A.T. van der Ploeg
A.J.J. Reuser
Molecular Genetics and Metabolism, 2012
Chapter 3
42
abstract 
Introduction Most adults with Pompe disease are compound heterozygotes 
in which one acid α-glucosidase (GAA) allele harbors the c.-32-13T>G 
mutation, causing partial loss of GAA, and the other allele harbors a 
fully deleterious mutation. The fibroblast GAA activity in these patients 
is usually between 5% and 25% of the average in healthy individuals. 
In some adult patients, however, the fibroblast GAA activity is much 
lower and is in the range that is normally observed in classic infantile 
Pompe disease. We investigated the genotype-phenotype correlation in 
three such adult patients and measured the GAA activity as well as the 
glycogen content in muscle and fibroblasts in order to better understand 
the clinical course. 
Methods DNA was sequenced and GAA activity and glycogen content were 
measured in leukocytes, fibroblasts and muscle. Muscle biopsies were 
microscopically analyzed and the biosynthesis of GAA in fibroblasts 
was analyzed by immunoblotting. GAA activity and glycogen content 
in fibroblasts and muscle tissue in healthy controls, adult patients with 
Pompe disease and classic infantile patients were compared with those 
of the three index patients. 
Results One patient had genotype c.525delT / c.671G>A (r.0 / p.Arg224Gln). 
Two affected brothers had genotype c.569G>A / c.1447G>A (p.Arg190His 
/ p.Gly483Arg). In all three cases the GAA activity and the glycogen 
content in fibroblasts were within the same range as in classic infantile 
Pompe disease, but the activity and glycogen content in muscle were 
both within the adult range. In fibroblasts, the first step of GAA synthesis 
appeared unaffected but lysosomal forms of GAA were not detectable 
with immunoblotting.
Conclusion Some adult patients with mutations other than c.-32-13T>G 
can have very low GAA activity in fibroblasts but express higher activity 
in muscle and store less glycogen in muscle than patients with classic 
infantile Pompe disease. This might explain why these patients have a 
slowly progressive course of Pompe disease.
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introduction
Pompe disease (OMIM 232300: acid maltase deficiency or glycogen storage 
disease type II) is an autosomal recessive metabolic disorder caused by the 
deficiency of acid α-glucosidase (GAA) and is characterized by progressive 
accumulation of glycogen in many tissues.1-4 The deficiency results from 
pathogenic mutations in the GAA gene (MIM 606800). The clinical spec-
trum is broad, as it ranges from severely affected classic infantile patients 
presenting in the first months of life with generalized muscle weakness 
and cardiac hypertrophy, to patients whose first symptoms appear in late 
adulthood and usually consist of slowly progressive limb girdle weak-
ness and decreased respiratory function.1-3,5-7 Most adult patients harbor 
the common c.-32-13T>G mutation in one GAA allele and a more severe 
mutation in the other. c.-32-13T>G reduces the fidelity of mRNA splicing 
and also reduces the GAA activity in fibroblasts to 5-25 % of normal (4.2-20 
nmol/mg.h compared to 45-180 nmol/mg.h average normal).8-10 Classic 
infantile patients have two severe mutations, which results in an enzyme 
activity in fibroblasts of less than 1-2 % of average normal.3,4,7 Besides 
measuring GAA activity in fibroblasts, which is considered to be the gold 
standard test, it is also possible to measure the activity in leukocytes, dried 
blood spot or muscle tissue.3,4,11 
In the Netherlands all patients with Pompe disease are referred to 
Erasmus MC University Medical Center, which has been designated the 
expertise center for this orphan disease. We screened our database and 
found that 4 of the 106 adults in our patient cohort have a low GAA activity 
in fibroblasts within the range of classic infantile patients. None of these 
four patients have the common c.-32-13T>G mutation but other pathogenic 
mutations, as described previously.12-15 We described one of the patients 
earlier.16 In this paper we present a study of the other three adult patients in 
which we compared the GAA activity and the glycogen content in muscle 
tissue with that in fibroblasts. We aimed to understand the discrepancy be-
tween low fibroblast GAA activity and the slow progression of the disease. 
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methods
Patients and controls
The three index patients were referred to Erasmus MC University Medical 
Center in Rotterdam between 2007 and 2010 and thereafter were followed 
up every 3-6 months. As control for GAA activity in muscle, muscle biop-
sies from patients with a suspected myopathy were used. Informed consent 
was obtained from the patients and the controls. The study protocols were 
approved by the Medical Ethical Committee at Erasmus MC University 
Medical Center. 
clinical parameters and laboratory testing 
Muscle strength was measured with the Medical Research Council grading 
scale (MRC). Pulmonary function was measured with spirometry in sitting 
and supine position (if possible). The muscle biopsy was taken from the 
quadriceps muscle. The muscle sections were fixed in 4% glutaraldehyde 
and thereafter embedded in glycolmetacrylate (GMA) and stained with 
periodic acid-Schiff (PAS). Acid phosphatase staining was performed on 
muscle cryosections. Serum creatine kinase (CK) was determined. 
enzyme analysis and glycogen content
The GAA activity in leukocytes was measured with glycogen as substrate in 
the presence of acarbose to inhibit the glucoamylase activity (Glyc+ACAB) 
in accordance with previously described procedures.17,18 The GAA activity 
in fibroblasts and muscle was measured with 4-methylumbelliferyl-α-D-
glucopyranoside (4-MU) and/or glycogen as substrates.8 The glycogen 
content of cultured skin fibroblasts was measured after 4 weeks of sustained 
confluence and the glycogen content of muscle biopsies was measured 
after storage at -80 oC. The assay encompasses the measurement of liber-
ated glucose after incubating cell and tissue lysates with amyloglucosidase 
and amylase.19,20 For comparison we measured the enzyme activity and the 
glycogen content in fibroblasts and muscle of patients with classic infantile 
Pompe disease, in samples from patients with juvenile and adult Pompe 
disease who have the c.-32-13T>G mutation, and in samples from healthy 
controls.
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molecular analysis
GAA sequence analysis was performed on genomic DNA isolated from 
white blood cells using routine procedures.21,22 The effect of novel missense 
mutations was investigated by transient expression of site-directed muta-
genized GAA cDNA constructs in HEK293T cells. Cells and media were 
harvested 72 hours after transfection. The synthesis and posttranslational 
modification of GAA in transfected cells and in fibroblasts of the patients 
was investigated by SDS-PAGE followed by immunoblotting as previously 
described.9
results 
Patients
Patient 1 is a 51-year-old Caucasian male who had been referred to our 
hospital in March 2007. He had been diagnosed with Pompe disease at 
the age of 26 years because of slowly progressive limb girdle weakness. 
At the age of 45 years he became wheelchair dependent. One year later he 
was admitted to the hospital with an acute respiratory distress syndrome. 
He subsequently became ventilator dependent. Neurological examination 
revealed facial weakness and severe symmetric limb girdle weakness: arms 
MRC grade 2 and legs MRC grade 1. CK was 256 U/l (normal value <170 
U/l in men). Pulmonary function testing revealed a forced vital capacity 
(FVC) in sitting position of 0.43 L (9% of normal). The GAA activity in 
leukocytes was 0.6 nmol/mg.h measured with Glyc+ACAB as a substrate 
(control range 40-250 nmol/mg.h), and in fibroblasts was 0.5 nmol/mg.h 
measured with 4-MU-α-D-glucopyranoside (control range 45-180 nmol/
mg.h). The muscle biopsy showed irregular hypertrophic muscle fibers 
with some glycogen accumulation as detected by PAS staining (Figure 1D). 
DNA analysis showed heterozygosity for c.525delT (r.0) and the novel mis-
sense mutation c.671G>A (p.Arg224Gln). The biochemical assessment of 
the muscle biopsies of all three patients is described in paragraph 3.2.
The second patient, a 25-year-old Caucasian male (patient 2), had been 
referred in July 2009. Since the age of 15 years he had found it difficult to 
lift heavy objects and a few years later he became unable to run, due to 
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progressive limb girdle weakness. Neurological examination revealed limb 
girdle weakness MRC grade 4 of the upper extremities and MRC grade 3 
of the lower extremities. CK was 1304 U/l. FVC in sitting position was 4.42 
L (75% of normal) and in supine position 3.85 L (65% of normal). The GAA 
activity in leukocytes was 0.0 nmol/mg.h measured with Glyc+ACAB as 
substrate and in fibroblasts was 1.0 nmol/mg.h measured with 4-MU-α-
D-glucopyranoside. The muscle biopsy showed a vacuolar myopathy 
and glycogen accumulation in 5-10% of the muscle fibers as detected by 
PAS staining (Figure 1E). DNA analysis demonstrated heterozygosity for 
c.569G>A and c.1447G>A (p.Arg190His / p.Gly483Arg). 
The third patient, a 23-year-old Caucasian male (patient 3) and brother of 
patient 2, was referred to our hospital in November 2010. At that time he was 
already wheelchair dependent because of a meningomyelocele, tethered 
cord and hydrocephalus for which he had been operated multiple times. 
His clinical condition had been deteriorating for five years: it was becoming 
increasingly difficult for him to transfer from his wheelchair to the toilet or 
to his car. Neurological examination revealed proximal weakness of the 
upper extremities (MRC grade 4) and a pre-existing weakness with sensory 
A B
D E
C
F
Figure 1  lysosomal pathology in muscle biopsies 
Panels A (longitudinal) and B (cross-sectional) show muscle biopsies of a healthy individual 
stained with hematoxylin and eosin (HE). Panels C, D (both longitudinal) and E (cross-sectional) 
are stained with PAS to show lysosomal glycogen storage in a patient with classic infantile 
Pompe disease (C) and in patients 1 and 2 (D and E). Panel F (cross-sectional) shows the 
muscle biopsy of patient 1 stained with acid phosphatase.
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disturbances of the lower extremities. Because of the family history the 
patient was also tested for Pompe disease. The GAA activity in leukocytes 
was 4.0 nmol/mg.h measured with Glyc+ACAB as substrate; in fibroblasts 
it was 0.8 nmol/mg.h measured with 4-MU-α-D-glucopyranoside. He had 
the same genotype as his brother, c.569G>A and c.1447G>A (p.Arg190His 
/ p.Gly483Arg). Serum CK was 735 U/l. Pulmonary function testing re-
vealed an FVC in sitting position of 2.93 L (57% of normal) and an FVC 
in supine position of 2.46 L (48% of normal). His muscle biopsy showed a 
vacuolar myopathy and glycogen accumulation in 50% of the muscle fibers 
as detected by PAS staining (not shown). 
enzyme activities and glycogen content in patients’ samples
Table 1 provides an overview of the GAA activities that we measured in 
leukocytes, fibroblasts and muscle tissue, and the glycogen content of 
fibroblasts and muscle tissue from the three index patients and from pa-
tients with classic infantile, juvenile and adult Pompe disease and healthy 
controls. The enzyme activity in leukocytes, measured with Glyc+ACAB as 
substrate, was deficient in the three index patients as well as in the all other 
patients with Pompe disease. In fibroblasts of the three index patients the 
enzyme activity was within the range of activities that is usually measured 
in classic infantile Pompe disease and in severe childhood cases. Using the 
natural substrate glycogen, GAA activity of the three index patients was 
equally low and far closer to the activities usually measured in infantile 
and childhood cases than in adult cases of Pompe disease. By contrast, the 
enzyme activity in muscle of the three index cases was clearly above the 
range of activities typically measured in classic infantile Pompe disease.23 
Patients 1 and 3 had activities that were even above the adult range. The 
glycogen content of the fibroblasts of the index cases was as high as in clas-
sic infantile Pompe disease, but the glycogen content of muscle was within 
the range of juvenile and adult patients with Pompe disease and far below 
the median content in classic infantile patients (1839 μg/mg).
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molecular analysis and immunoblotting
Like other lysosomal glycoproteins, GAA is cotranslationally imported 
into the endoplasmic reticulum and undergoes a series of posttranslational 
modification events before it attains its full activity in the lysosomes. Pro-
teolytic events can be visualized by immunoblotting and show a stepwise 
conversion of a 110 kDa precursor form, via a 95 kDa intermediate form, 
to a mature enzyme of 76 kDa. Lanes 5-7 in figure 2 depict the synthesis 
of GAA in fibroblasts of the three index patients: the 110 kDa precursor 
is made in normal quantity but processed forms are lacking. By contrast, 
adult patients carrying the most common c.-32-13T>G mutation (lane 2) 
have reduced enzyme synthesis, as demonstrated by significantly reduced 
expression of the 110 kDa precursor, but normal processing. As illustrated 
in lane 3, a selected young adolescent patient with Pompe disease with GAA 
genotype c.861C>T / c.925G>A (p.Pro287Pro / p.Gly309Arg) had normal 
synthesis but impaired maturation of GAA, resulting in weak signals of 
Figure 2  Western blot assay of gaa in fibroblasts
Four distinct forms of GAA were separated by SDS-PAGE. These were revealed by immunoblot-
ting using rabbit anti human GAA antibodies. Equal amounts of protein were loaded in each lane.  
The lanes are labeled as follows: control: healthy individual; adult: affected adult with genotype 
c.-32-13T>G / c.1293_1312del (p.Gln443Aspfs*15); juvenile: affected adolescent with geno-
type c.861C>T / c.925G>A (p.Pro287Pro / p.Gly309Arg); patient 1 with genotype c.525delT 
/ c.671G>A (r.0 / p.Arg224Gln) and patients 2 and 3 with genotype c.569G>A / c.1447G>A 
(p.Arg190His / p.Gly483Arg) are the patients described in this study.
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76 and 70 kDa. The patient with classic infantile Pompe disease (lane 4) 
with genotype c.525delT / c.525delT (r.0 / r.0), does not demonstrate any 
synthesis of GAA.
Upon DNA analysis patient 1 turned out to be compound heterozygote 
for the known pathogenic mutation c.525delT (r.0) and the novel missense 
mutation c.671G>A (p.Arg224Gln). Whereas c.525delT prevents the syn-
thesis of GAA, c.671G>A (p.Arg224Gln) seems to hamper the posttransla-
tional modification of GAA and thereby causes substantial loss of mature 
enzyme and associated loss of activity (Figure 2). In a transient expression 
system of GAA the residual activity of this novel mutation was 1.5% of 
average normal. The two affected brothers were identified as compound 
heterozygotes for c.569G>A (p.Arg190His) and c.1447G>A (p.Gly483Arg). 
Both these mutations are described as less severe mutations in the June 
25th, 2012 version of the Pompe disease mutation database at www.pom-
pecenter.nl. The mutation c.1447G>A (p.Gly483Arg) has previously been 
described in a patient with late-onset Pompe disease in combination with 
c.-32-3C>A, which is also listed as a less severe mutation.24 When we ana-
lyzed the effect of the missense mutations of the two brothers in a transient 
expression system, both mutations sustained a low level of GAA activity: 
20% for c.569G>A (p.Arg190His) and 3% for c.1447G>A (p.Gly483Arg).
discussion
Patients with Pompe disease whose symptoms appear in the second to third 
decade of life or even later, usually have substantially more residual GAA 
activity in cultured fibroblasts than patients with classic infantile Pompe 
disease who manifest symptoms within the first 3 months of life.3 The 
three adult patients that we described fit into the category of exceptional 
cases of adult Pompe disease with very low GAA activity in fibroblasts.12-16 
Whereas the activity in fibroblasts, either measured with 4-MU or glycogen 
as substrates, usually discriminates very well between classic infantile and 
more slowly progressive forms of Pompe disease, it seems that in these 
particular cases the activity in fibroblasts does not reflect the activity in 
muscle. In two of the three cases this is very clear, as the GAA activity 
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in muscle is within or even above the range measured in adult Pompe 
disease, but in all three cases the activity in fibroblasts is within the range 
that is characteristic for classic infantile Pompe disease. In the third case, 
the activity in muscle is also higher than in fibroblasts but the difference 
is less pronounced. We did not measure the GAA activity in muscle with 
glycogen as substrate, because the assay does not discriminate between 
classic infantile Pompe disease and adult Pompe disease due to the high 
background signals.
In line with the view that lysosomal glycogen storage is primarily deter-
mined by the degree of enzyme deficiency, we were able to demonstrate 
glycogen storage in the cultured fibroblasts of the three index patients in 
which the activity was as low as in cells of patients with classic infantile 
Pompe disease. By contrast, the storage of glycogen in muscle tissue of the 
three index patients was no different from that usually found in patients 
with a slowly progressive disease, and the GAA activity was accordingly 
higher. As shown in Table 1 there is an overlap between the ranges for 
glycogen content in muscle in all forms of Pompe disease and even healthy 
controls. However, the values measured in the three index patients are far 
closer to the median glycogen content in juvenile/adult  patients than in 
classic infantile Pompe disease. Thus, the supposed correlation between 
enzyme activity and glycogen storage holds, but the activity in fibroblasts 
does not represent the activity in muscle in these particular cases.
The unbalance between the GAA activities in muscle versus fibroblasts 
is probably related to the GAA genotype of the patients. It is notable that 
none of the adult patients with unexpected low activity in fibroblasts, 
including the thirteen cases recently reported by Bali et al.12, carry the 
most common mutation c.-32-13T>G which is frequently associated with 
a later onset and slowly progressive phenotype.13-16 It is also remarkable 
that in all these exceptional cases, close to normal synthesis of the 110 kDa 
precursor form can be demonstrated in the fibroblasts by immunoblotting, 
but that processed forms of 95 kDa and 76 kDa are virtually lacking. Thus, 
an explanation for the different GAA activities in fibroblasts and muscle 
tissue could be that the posttranslational modification or the stability of 
these mutant forms of GAA would be less compromised in muscle than in 
fibroblasts due to cell-type-specific differences in processing and lysosomal 
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transport events. In the past we found indications of cell-type-specific pro-
cessing in a fourth case of adult onset Pompe disease with unusually low 
enzyme activity in fibroblasts.15 Unfortunately, in the three cases described 
here there was not enough muscle biopsy sample left for us to be able to 
use western blotting to confirm this hypothesis about differential process-
ing. However, the scarcity of glycogen storage in the muscle tissue sections 
together with the modest muscle cell damage support the hypothesis that 
the higher activity in muscle than in fibroblasts delays the age of onset and 
slows disease progression. 
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abstract
Introduction Elevated plasma cardiac troponin T (cTnT) levels in patients 
with neuromuscular disorders may erroneously lead to the diagnosis of 
acute myocardial infarction (AMI) or myocardial injury. 
Methods and results In 122 patients with Pompe disease, the relation-
ship between cTnT, cardiac troponin I (cTnI), creatine kinase (CK), creatine 
kinase myocardial band (CK-MB) levels and skeletal muscle damage was 
assessed. ECG and echocardiography were used to evaluate possible car-
diac disease. Patients were divided into classic infantile, childhood onset 
and adult onset patients. cTnT levels were elevated in 82% of patients 
(median 27 ng/L, normal values <14 ng/L). cTnI levels were normal in 
all patients, while CK-MB levels were increased in 59% of patients. cTnT 
levels correlated with CK levels in all three subgroups (P<.001). None of 
the abnormal ECGs recorded in 21 patients were indicative of AMI, and 
there were no differences in cTnT levels between patients with and with-
out (n=90) abnormalities on ECG (median 28 ng/L in both groups). The 
median left ventricular mass index measured with echocardiography was 
normal in all three subgroups. cTnT mRNA expression was not detectable 
in controls but was strongly induced in Pompe patients. cTnT protein was 
identified by mass spectrometry in patient-derived skeletal muscle tissue. 
Conclusions Elevated plasma cTnT levels in patients with Pompe disease 
are associated with skeletal muscle damage rather than acute myocardial 
injury. Increased cTnT levels in Pompe disease and likely other neuromus-
cular disorders, should be interpreted with caution to avoid unnecessary 
cardiac interventions.
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introduction
Troponin T (TnT), troponin I (TnI) and troponin C form the troponin com-
plex involved in muscle contraction. After depolarization TnT binds tropo-
myosin resulting in interaction between actin and myosin and subsequent 
muscle contraction.1-3 Skeletal muscle-specific and cardiac muscle-specific 
forms of TnT and TnI are expressed from closely related genes.2, 4 Cardiac 
troponins (cTn) are important biomarkers in patients with acute myocar-
dial infarction (AMI), because they are released into the circulation after 
ischemic damage to cardiomyocytes.5, 6 However, increased concentrations 
of cardiac troponin T (cTnT) have been observed in the general popula-
tion and in several patient groups including those with heart failure and 
end-stage renal failure but without AMI.6-8 Recently, an elevation of plasma 
cTnT in the absence of cardiac troponin I (cTnI) in a number of neuro-
muscular diseases has been shown.9 It has been suggested that diseased 
skeletal muscle tissue is an alternative source for elevated cTnT levels in 
certain neuromuscular conditions and dialysis patients.3, 10-13 However, due 
to similarities between members of the troponin family, the presence of 
cTnT in tissue samples has been the subject of debate due to potential cross 
reactivity of antibodies used in immunoblot or ELISA assays. 
Pompe disease is a neuromuscular metabolic disorder with an overall 
disease incidence at approximately 1:40,000 live births. The disease is 
caused by mutations in the acid α-glucosidase (GAA) gene (MIM 606800), 
which encodes a lysosomal enzyme responsible for glycogen degradation.14 
Dysfunctional or low levels of GAA result in glycogen accumulation af-
fecting mainly skeletal muscle tissue. Diagnosis of Pompe disease is based 
on GAA enzymatic activity measurements. Patients with classic infantile 
Pompe disease have a residual enzyme activity of less than 1% leading to 
a severe form of the disease. They present shortly after birth with muscle 
weakness and a hypertrophic cardiomyopathy with progressive cardiac 
failure, which results in death within one year of age if left untreated.15, 16 
Enzyme replacement therapy (ERT) can be life-saving for classic infantile 
patients and the cardiomyopathy responds well to ERT.14, 17 Patients with 
non-classic or late onset Pompe disease have a residual enzyme activity 
of up to 20% and show slower disease progression. They present during 
childhood or adulthood with limb girdle weakness and reduced pulmo-
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nary function.18 In these patients ERT positively alters the natural course 
by increasing muscle strength and stabilizing pulmonary function.19, 20 The 
heart is generally not affected in non-classic Pompe disease.21, 22 Increased 
cTnT concentrations were found in one of our adult patients who reported 
atypical chest pain. However, a comprehensive cardiac evaluation failed 
to reveal cardiac abnormalities.  This discrepancy between elevated cTnT 
concentrations and absence of AMI prompted us to investigate the presence 
of increased cTnT levels in more detail in a large cohort of Pompe patients. 
methods
study population
In the Netherlands, all patients with Pompe disease are referred to the 
Center for Lysosomal and Metabolic Diseases of the Erasmus University 
Medical Center Rotterdam. In total 122 patients at our center participated 
in this study. The patients were subdivided into three groups. The first 
group comprised 14 patients with classic infantile Pompe disease who 
had developed symptoms in the first year of life and had a hypertrophic 
cardiomyopathy. All these patients started treatment with ERT before the 
first year of life. Plasma samples analysed for cTnT in this study were taken 
after ERT, when the left ventricular hypertrophy (LVH) was resolved in ten 
out of 14 patients. The other patients had non-classic or late onset Pompe 
disease: group two comprised 13 patients with symptom onset before the 
age of 18 years (childhood onset), and group three comprised 95 patients 
with symptom onset after the age of 18 years (adult onset).23 Diagnosis 
was confirmed by a deficiency of GAA in leukocytes or fibroblasts and 
mutation analysis. The Medical Ethics Committee at Erasmus University 
Medical Center approved the study protocol. All patients provided written 
informed consent. 
laboratory testing
cTnT levels were measured in heparin plasma samples using a 5th genera-
tion highly sensitive assay of Roche Diagnostics; 99th-percentile 14 ng/L, 
limit of detection (LoD) 5 ng/L.24 In seven adult patients cTnT levels were 
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measured before the start of ERT and up to two years after treatment. Plasma 
cTnI levels were measured using the Access AccuTnI assay of Beckmann 
Coulter with a 99th-percentile cut-off at 0.04 μg/L and LoD of 0.01 μg/L.25 
Creatine kinase (CK) and creatine kinase myocardial band (CK-MB) levels 
were measured using Roche Diagnostic assays. As reference intervals for 
CK we used in children (2-13 years) <230 U/L, male adolescents (13-17 
years) <270 U/L, female adolescents (13-17 years) <123 U/L, male adults 
(>17 years) <200 U/L, and female adults (>17 years) <170 U/L. The sex-
specific 99th-percentiles for CK-MB levels were 7.6 μg/L in male patients 
and 4.7 μg/L in female patients.26   
ecg and echocardiography
Standard 12-lead ECG recordings were examined for signs of ischemia, 
LVH and rhythm or conduction abnormalities. Additionally, 13 patients 
with the classic infantile form underwent echocardiography within one 
month after the plasma samples were taken (Sonos 5500 or 7500 ultra-
sound system, Philips, Best, The Netherlands), as well as 48 patients with 
non-classic Pompe disease with a suspicion of LVH based on the ECG, 
or who already underwent this procedure during a previous study.21 The 
left ventricular mass index (LVMI) was calculated and indexed by body 
surface area.27 As reference values for children and young adults we used 
previously published data.28 Additionally, the left ventricular end diastolic 
dimension (LVID ED), the left ventricular end systolic dimension (LVID 
ES), interventricular septum (IVS), left ventricular posterior wall (LVPW) 
and fractional shortening (FS) were measured.27, 29 
human tissue biopsies
Skeletal muscle biopsies of Pompe patients were taken from the quadriceps 
muscle before the start of ERT. Human adult heart and liver biopsies were 
obtained from the Department of Pathology of Erasmus MC. Biopsies from 
the quadriceps muscle of healthy controls were obtained from Maastricht 
University Medical Center. 
expression of ctnt
Tissue biopsies were homogenized in RLT buffer (Qiagen) at 4°C using a 
PRO200 disruptor. After 2 times extraction using phenol/chlorophorm/
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isoamylalcohol (Sigma P3803), total RNA was isolated using the RNeasy 
Mini Kit with DNase I digestion to remove genomic DNA (Qiagen, Cat. No 
74106). cDNA was synthesized using the iScript cDNA synthesis kit (Bio-
Rad). cTnT mRNA expression was quantified using quantitative PCR with 
the iTaq Universersal SYBR Green Supermix (Bio-Rad) and 10 pmol/ul 
forward and reverse primers as described.30 Primers annealed to separate 
exons to ensure that only cDNA was amplified rather than genomic DNA. 
Two primer sets were used for cTnT mRNA: the C-terminal primer set 
amplified the region encoding the C-terminal part of the cTnT protein that 
is common between different splice forms; the N-terminal cTnT primer set 
amplified the region encoding the N-terminal part of the cTnT protein that 
is known to be differentially spliced. The identity of cTnT qPCR products 
was determined by cloning the PCR fragment into a plasmid vector us-
ing topo cloning (Life Technologies) followed by sequence analysis on an 
AB3130 Genetic Analyzer (Applied Biosystems, Hitachi). Primer sequences 
are listed in Supplemental Table 1.
mass spectrometry
Muscle biopsies were homogenized in 100 ml 4x loading buffer (NuPAGE 
LDS sample Buffer, Lifetechnologies, NP0007) in a 2 ml Eppendorf tube 
filled with stainless steel beads (Qiagen, Cat. No. 69989) using a TissueLy-
ser II (Qiagen, Cat. No. 85300) operated for 2.5 minutes at maximum power 
at 4°C. Beads were removed, homogenates were heated for 10 minutes 
at 70°C, cleared by centrifugation and separated on a 4-12% bis-tris gel 
using MOPS running buffer according to the manufacturer’s instructions 
(Invitrogen). 1D SDS-PAGE gel lanes were cut into 1-mm slices using an 
automatic gel slicer and subjected to in-gel reduction with dithiothreitol, 
alkylation with chloroacetamide and digestion with trypsin (Promega, 
sequencing grade). Nanoflow LC-MS/MS was performed on an ACQUITY 
UPLC system (Waters) coupled to either an Orbitrap Fusion Tribrid mass 
spectrometer (Thermo) operating in positive ion mode. Tryptic peptide 
separation was performed on a BEH C18 column (1.7 µm, 75 µm x 250 mm) 
at 10,000 psi using a linear gradient from 0 to 80% B (A=0.1% formic acid; 
B=80% (v/v) acetonitrile, 0.1% formic acid) in 70 minutes and at a constant 
flow rate of 200 nl/min. The column eluent was directly sprayed into the ESI 
source of the mass spectrometer. Mass spectra were acquired in continuum 
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mode and fragmentation of the peptides was performed in data-dependent 
mode. The MS raw data were analyzed using the MaxQuant software (ver-
sion 1.5.2.8).31 A false discovery rate of 0.01 for proteins and peptides and a 
minimum peptide length of 6 amino acids were required. The Andromeda 
search engine was used to search the MS/MS spectra against the Uniprot 
database (taxonomy: Homo sapiens, release Feb 2015) concatenated with the 
reversed versions of all sequences. A maximum of two missed cleavages 
were allowed and enzyme specificity was set to trypsin. Further modifica-
tions were cysteine carbamidomethylation (fixed) as well as protein N-
terminal acetylation, methionine oxidation and phosphor (STY) (variable). 
statistical analysis
The data were analysed using SPSS 21. Data are presented as medians with 
interquartile ranges (IQR) or numbers with percentages. We calculated the 
proportions of Pompe patients with increased cTnT, cTnI, CK and CK-MB 
levels relative to the 99th-percentiles of these parameters in the general 
population and the corresponding 95% confidence intervals. To compare 
differences in cTnT levels regarding sex, use of ERT, wheelchair use and 
hypertension, the Mann-Whitney Test was used. Median differences of 
cTnT levels before and after two years of ERT were compared using the 
Wilcoxon signed rank test for paired samples. To calculate the relationship 
between cTnT and CK levels, age and disease duration, the Spearman’s 
correlation coefficient rho was used. A p value lower than 0.05 was consid-
ered statistically significant. 
results
study population
The characteristics of 122 Pompe patients are summarized in Table 1. All 
patients with the classic infantile form and the majority of patients with 
non-classic Pompe disease received ERT at a median period of five years. 
None of the patients had renal failure, while 39% of the adult patients had 
hypertension. 
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Plasma parameters and cardiac evaluation
One adult patient experienced exercise-induced chest pain, but cardiac 
evaluation did not reveal any abnormalities. Nevertheless, the cTnT level 
of this patient was elevated (36 ng/L, normally <14 ng/L) and remained 
stable throughout the next day. None of the other patients reported car-
diac symptoms indicative of AMI. This event triggered the current study 
to evaluate plasma and other parameters to monitor cardiac function in a 
large number of patients. The results are summarized in Table 2 and on an 
individual basis in Supplemental Table 2. 
When compared to the 99th-percentile, plasma cTnT levels were elevated 
in 82% (95% confidence interval (CI) 75-88%) of all Pompe patients. cTnT 
levels were elevated in 79% (95% CI 56-95%) of patients with classic infan-
tile Pompe disease, 39% (95% CI 16-64%) of childhood onset patients and 
88% (95% CI 82-94%) of adult onset patients. When using the sex-specific 
99th-percentile limits, cTnT levels were still elevated in 77% (95% CI 66-
86%) of male patients and 88% (95% CI 78-95%) of female patients. In only 
one patient, who was asymptomatic, the cTnT level was below the LoD. 
Next, other parameters of cardiac abnormalities including cTnI and CK-
Table 1  Patient characteristics
Total group
Classic 
infantile
Childhood 
onset Adult onset
No. (%) of patients 122 (100) 14 (11) 13 (11) 95 (78)
No. (%) of males 65 (53) 8 (57) 9 (69) 48 (51)
Age, median (IQR*), years 48 (31-62) 5 (2-10) 14 (10-21) 55 (44-64)
Disease duration, median (IQR), years 14 (8-22) 5 (2-10) 9 (4-12) 16 (12-25)
No. (%) of patients on ERT† 102 (84) 14 (100) 11 (85) 77 (81)
Duration of ERT, median (IQR), years 5 (4-6) 5 (2-10) 6 (3-8) 5 (4-6)
No. (%) of wheelchair dependent patients 33 (27) 5 (36) 0 (0) 28 (29)
No. (%) of ventilator dependent patients 35 (29) 2 (21) 0 (0) 33 (35)
Systolic blood pressure, median (IQR), 
mmHg
127 (112-146) 99 (95-107) 109 (102-119) 133 (120-150)
Diastolic blood pressure, median (IQR), 
mmHg
76 (67-87) 57 (54-61) 63 (60-67) 79 (74-89)
* IQR = interquartile range
† ERT = enzyme replacement therapy
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MB levels were assessed. cTnI values were below the 99th-percentile in all 
patients. When compared to the sex-specific 99th-percentile limits, CK-MB 
levels were elevated in 54% (95% CI 40-68%) of male patients and 66% (95% 
CI 54-78%) of female patients.
Additionally, ECG and echocardiography were assessed. In the adult on-
set patient population, 73% of tested patients showed normal ECGs, while 
89% of tested patients showed a normal LVMI assessed by echocardiogra-
phy. Similar outcomes were seen for childhood onset patients (77% with 
normal ECGs and 100% with a normal LVMI). In classic infantile patients 
79% of tested patients showed normal ECGs and 69% showed a normal 
LVMI. The other parameters that were measured by echocardiography 
are shown in Table 2. Overall, 87% of tested patients showed a normal 
LVMI, 98% showed normal values of LVID ED and LVID ES, 82% showed 
a normal IVS, 95% showed normal LVPW, and finally 97% showed normal 
percentages of FS.  
To determine to what extent cardiac abnormalities could cause elevated 
plasma cTnT, values were compared between patients with and without 
cardiac abnormalities. In adult onset patients, cTnT values did not differ 
between patients with normal and abnormal ECGs (31 versus 30 ng/L, 
P=.24). The four adult patients with LVH on echocardiography showed 
cTnT levels of 7, 14, and twice 19 ng/L, while 28 out of 31 adult onset pa-
tients without LVH contained values above 19 ng/L.  Rhythm or conduction 
abnormalities without LVH were detected in two childhood onset patients, 
with cTnT levels of 21 and 30 ng/L. However, three other childhood onset 
patients without abnormalities contained strongly elevated cTnT levels of 
48, 50, and 138 ng/L. One classic infantile patient showed a conductance 
disturbance on ECG (cTnT 28 ng/L), and four other patients (numbers 
7, 8, 9 and 12 in Suppl. Table 2) showed an increased LVMI assessed by 
echocardiography. Patients 7 and 12 had just started with ERT and showed 
elevated cTnT levels, while patients 8 and 9 suffered from long-term LVH 
with elevated cTnT levels. Other patients in this group without detectable 
cardiac abnormalities contained strongly elevated cTnT levels ranging 
from 20 to 59 ng/L. Taken together, the cardiac abnormalities observed in a 
subset of Pompe patients could not explain the elevated cTnT levels in the 
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majority of patients. This suggested an alternative source of elevated cTnT 
in Pompe patients independent of myocardial muscle damage.
Plasma ctnt levels correlate with cK levels
Most patients with limb girdle muscle weakness, including Pompe dis-
ease, have increased CK levels resulting from skeletal muscle damage.20, 32 
Figure 1 shows that CK and cTnT levels correlated in all three subgroups 
(P<.001). In adult patients a slight negative correlation was found between 
cTnT levels and age (rho=-0.29, P=.005). cTnT levels did not differ when 
adult patients were grouped according to sex (P=.10), treatment with ERT 
(P=.29), wheelchair dependency (P=.57) or hypertension (P=.76). These 
findings suggested that similar to CK, cTnT is released from damaged 
skeletal muscle into the circulation in Pompe patients.
expression of ctnt in skeletal muscle tissue of Pompe patients
To determine whether cTnT is expressed in skeletal muscle tissue, real-time 
quantitative polymerase chain reaction (RT-qPCR) analysis was performed. 
Primers were used that recognize a C-terminal sequence present in all 
known isoforms. Cloning of the RT-qPCR product followed by sequence 
analysis confirmed the identity of the product (Suppl. Figure 1A, B). Strong 
expression of cTnT was detected in normal heart tissue, while cTnT was 
not expressed in the skeletal muscle biopsies taken from healthy controls 
of several ages (Figure 2). In contrast, two out of three skeletal muscle 
biopsies taken from adult Pompe patients with elevated circulating cTnT 
showed strong expression of cTnT mRNA. The cardiac-specific marker 
MYBPC3 was expressed in heart but not in the Pompe skeletal muscle 
biopsies. Surprisingly, albumin, which was highly expressed in liver tissue, 
was expressed in the skeletal muscle biopsy of Pompe patient 1, which was 
the same biopsy that failed to express cTnT. We speculate that this biopsy 
may have contained adipose tissue, known to express albumin. 
cTnT is known to be alternatively spliced. Notably, isoform 6 is expressed 
in normal adult heart, isoforms 1, 7, and 8 are expressed in foetal heart, and 
isoform 7 is also expressed in diseased heart.33 To determine which cTnT 
isoform is expressed in skeletal muscle of Pompe patients, N-terminal 
primers that flank the region of alternative splicing were used in RT-qPCR. 
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Figure 1  Plasma ctnt and cK levels are correlated. 
Spearman correlation analysis was performed for (A) 14 classic infantile patients, (B) 13 child-
hood onset patients, and (C) 95 adult patients. Corresponding p-values are indicated. The 
dashed line represents the 99th-percentile cut-off at 14 ng/L for cTnT. 
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Agarose gel electrophoresis showed a single product of 129 nt for RT-qPCR 
of normal cardiac and Pompe-derived skeletal muscle biopsies (data not 
shown). Cloning and sequencing revealed that the Pompe skeletal muscle 
product was isoform 6 (Suppl. Figure 1B), which is the cTnT isoform ex-
pressed in healthy heart. 
To determine whether the presence of cTnT mRNA also leads to cTnT 
protein expression in skeletal muscle from Pompe patients, mass spectrom-
etry was used. In an unbiased proteomic screen, the cTnT-specific tryptic 
peptide DLNELQALIEAHFENR was unambiguously identified amongst 
many other peptides specific for fast and slow skeletal muscle troponin 
(Suppl. Figure 2). In conclusion, Pompe patients have elevated mRNA 
expression of cTnT in skeletal muscle that is translated into cTnT protein, 
Figure 2  ctnt mrna expression is elevated in skeletal muscle of Pompe patients. 
Tissue biopsies were analyzed using RT-qPCR for expression of cTnT (using C-terminal prim-
ers), MYPBC3 (cardiac muscle-specific marker) and albumin in heart, skeletal (sk) muscle and 
liver. Sixteen individuals are shown: 2 controls (heart biopsy), 3 Pompe patients (skeletal muscle 
biopsy), 5 young controls (Ctrl) (skeletal muscle biopsy), 5 old controls (skeletal muscle biopsy), 
1 control (liver biopsy). Plasma cTnT levels of Pompe patients ranged from 51-68 ng/l and ages 
at sampling ranged from 31-59 years. Age groups of controls are indicated, in which “young” in-
dicates a range of 18-20 years, and “old” a range of 69-80 years. Liver served as positive control 
for albumin and was not assessed for MYPBC3 and cTnT expression. Values are normalized for 
b-actin and are expressed relative to one positive control (heart 2 for cTnT and MYBPC3; liver for 
albumin). Data indicate means +/- SD of three technical replicates.
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consistent with the possibility of leakage of cTnT protein from skeletal 
muscle into the circulation as a result of muscle damage. 
effect of ert on plasma ctnt levels
ERT has been shown to improve skeletal muscle function in adult Pompe 
patients. To determine the effect of ERT on cTnT levels, seven adult Pompe 
patients were tested just before start of ERT, after one and three months of 
treatment, and after two years. In six patients, cTnT levels decreased after 
start of ERT (Figure 3A). Interestingly, CK levels closely followed cTnT 
levels in these patients (Figure 3B). At group level, median decreases of 
cTnT and CK during two years of ERT were 8 ng/L (P=.03) and 136 U/L 
(P=.02), respectively (Suppl. Figure 3).
discussion
We found that plasma cTnT but not cTnI levels were increased in the 
majority of patients with Pompe disease, and that cTnT levels correlated 
with CK levels. Elevated cTnT levels could not be explained by cardiac 
abnormalities. cTnT was expressed in skeletal muscle biopsies taken from 
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Figure 3  effects of ert on plasma ctnt and cK levels. 
Seven adult Pompe patients with elevated plasma cTnT (A) and CK (B) levels at baseline and 
after start of ERT. Individual patients are indicated by a single color. 
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Pompe patients, but not healthy individuals. We conclude that increased 
plasma cTnT levels in Pompe patients are most likely the result of skeletal 
muscle damage rather than myocardial damage.
Cardiac troponins are the preferred biomarkers for detection of AMI. 
According to an expert consensus document for the universal definition 
of myocardial infarction, AMI should be diagnosed if a rise and/or fall of 
cardiac biomarkers is detected (preferably cTnT or cTnI), with at least one 
value above the 99th-percentile cutoff value. These changes need to be ac-
companied by symptoms of ischemia, ECG changes, imaging evidence of 
recent loss of viable myocardium or new regional wall motion abnormali-
ties, and/or identification of an intracoronary thrombus by angiography 
or autopsy.5 The next generation of high-sensitivity assays for detecting 
markers of myocardial damage in blood has improved the early detection 
of AMI. However, by increasing the sensitivity for detection of AMI, the 
specificity of detection has decreased leading to more false-positive results 
caused by pathologies potentially not related to AMI.6, 8 
Increased plasma concentrations of cTnT have been described in 
individual cases and small sample size reports of patients with various 
myopathies.9, 11-13, 34 In some skeletal muscle myopathies such as Duchenne 
muscular dystrophy, the heart is known to be affected, which might explain 
increased cTnT levels.35 Hypertrophic cardiomyopathy is a characteristic 
feature in patients with classic infantile Pompe disease (but not in the 
childhood and adult forms of Pompe disease) and in most cases it is known 
to respond well to ERT.17, 21, 22 In our study all classic infantile patients were 
already being treated with ERT (median five years, IQR 2-10 years), but in 
four patients LVH was not (yet) resolved at the time cTnT levels were mea-
sured. Patient 12 (Suppl. Table 2) had only received two infusions of ERT 
(cTnT 39 ng/L) and patient 7 was treated for six months (cTnT 20 ng/L). 
Both patients showed normalization of LVMI values upon prolonged ERT. 
Patient 9 (cTnT 27 ng/L) started with ERT at the age of seven months and 
was treated for 13 years. At the start of treatment she already had a severe 
hypertrophic cardiomyopathy, which persisted over the years. Patient 8 
showed an increased LVMI after four years of ERT (cTnT 23 ng/L), but 
the LVMI was normalized after an additional two years of ERT. For these 
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patients, the source of plasma cTnT levels, being heart or skeletal muscle-
derived, is unknown.
The high degree of similarity between members of the troponin fam-
ily, especially between fast skeletal, slow skeletal, and cardiac troponin 
(http://www.uniprot.org/), complicates the identification of cTnT in adult 
muscle biopsies using single antibodies because of potential cross reactivity. 
Indeed, our initial experiments using three antibodies for cTnT yielded in-
conclusive results. Reports in the literature using antibody-based detection 
suggested that cTnT can be expressed in diseased skeletal muscle.3, 10, 13, 36, 37 
Here we used sequence-based techniques to exclude detection of troponin 
paralogs. This showed induced mRNA expression of the cTnT isoform 6 
in skeletal muscle of Pompe patients, which is normally expressed in the 
heart of healthy adults, rather than re-expression of an embryonic splice 
form.33, 38 Mass spectrometry analysis confirmed expression of cTnT at the 
protein level. Although the mass spectrometry method is not quantitative 
and it is difficult to predict the ability to detect certain peptides, a higher 
number of cTnT peptides was anticipated based on the high mRNA ex-
pression of cTnT in diseased skeletal muscle. This may indicate protein 
instability or a low efficacy of protein translation. A genome-wide mRNA 
expression study indicated elevated cTnT expression in skeletal muscle 
biopsies taken from untreated classic infantile Pompe patients, who have 
LVH.39 cTnT expression in skeletal muscle from adult, childhood onset, 
and treated classic infantile Pompe patients, who lack a cardiac phenotype, 
has not been reported so far. Accumulating evidence indicates that cTnT 
expression in skeletal muscle is a general phenomenon in several neuro-
muscular diseases. Because these disorders can have various causes, it is 
likely that a more general signal such as muscle tissue injury rather than 
a disease-specific signal plays a role in induction of expression. Future ex-
periments should elucidate how re-expression of cTnT in diseased skeletal 
muscle is regulated and whether it serves a biological function or is merely 
an aberrant side effect.
cTnI and CK-MB were measured as two other biomarkers for possible 
cardiac damage. It has been described that cTnI has a higher specificity 
for cardiac tissue than cTnT and that cTnI is not expressed in healthy or 
diseased skeletal muscle.6, 13, 40 Indeed, we did not find increased cTnI levels 
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in our Pompe patients. Therefore, cTnI might be a better biomarker for 
AMI in Pompe disease and possibly also other neuromuscular disorders, 
as suggested previously.9 CK-MB levels were increased in 59% of Pompe 
patients. Elevation of CK-MB in patients with neuromuscular diseases of 
various etiologies without evidence of acute myocardial injury has previ-
ously been described as a result of regeneration after skeletal muscle dam-
age, providing a possible explanation why these levels are also elevated in 
Pompe patients.3, 9, 41 
Our study has some limitations. First, although all findings point to 
skeletal muscle damage as being the cause of increased plasma cTnT lev-
els in Pompe disease, we cannot fully rule out that there may have been 
subclinical myocardial damage in some patients. However, we consider all 
the evidence together sufficiently convincing to state that diseased skeletal 
muscle tissue is the source of elevated cTnT levels in patients with Pompe 
disease who do not have signs of cardiac involvement. Second, the refer-
ence values for cTnT measured with high-sensitivity assays are based on 
measurements in healthy adults, raising the question how these relate to 
values in childhood onset and infantile patients. Recent studies showed 
that cTnT levels measured with high-sensitivity assays are lowest in indi-
viduals younger than 18 years and that cTnT levels increase with age, sug-
gesting that the number of classic infantile and childhood onset patients 
with elevated cTnT levels may even be underestimated in this study.42 
Another limitation is that we did not use the high-sensitivity troponin I as-
say, which is more sensitive than the assay we used. However, cTnI levels 
were very low in our patient population (median <0.01 μg/L), while the 
99th-percentile limit in the general adult population is 0.04 μg/L, which 
makes it unlikely that the assay used here showed false negative outcomes. 
A final limitation of our study is that we did not use MRI to evaluate myo-
cardial damage. We did not use this technique because a large proportion 
of the Pompe patients had a decreased forced vital capacity, particularly in 
supine position, making it difficult for them to remain in this position in 
the MRI for 30-60 minutes. Moreover, a recent study showed that there was 
no cardiac involvement on MRI in a small group of adult Pompe patients.22 
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conclusions
In the majority of patients with Pompe disease plasma cTnT levels are 
increased due to skeletal muscle damage, while myocardial damage is 
unlikely. Not only in Pompe disease, but likely also in other neuromuscular 
diseases, it is important to take this in consideration and to avoid unneces-
sary and potentially harmful cardiac interventions. 
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suPPlemental material
Supplemental Material 
Supplemental Figure 1. Sequence analysis of cTnT mRNA isoforms. 
Supplemental Figure 1. Sequence analysis of cTnT mRNA isoforms.
A Sequence analysis of the RT-qPCR product from skeletal muscle of Pompe patients using 
C-terminal cTnT primers to verify that cTnT cDNA was amplified. 
B Alignment of the PCR product from A) against cTnT isoform 6.
C Sequence analysis of RT-qPCR products of skeletal muscle of Pompe patients using N-
terminal cTnT primers resulting in identification of the adult cTnT isoform 6. 
D Alignment of the PCR product from C) against cTnT isoform 6. 
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Supplemental Figure 3. Effects of ERT on plasma cTnT and CK levels. 
 
The median differences of plasma cTnT and CK levels before and after two years of ERT in seven adult Pompe patients. 
  
Supplemental Figure 3. effects of ert on plasma ctnt and cK levels.
The median differences of plasma cTnT and CK levels before and after two years of ERT in seven 
adult Pompe patients.
Supplemental Table 1. Primers used for RT-qPCR analysis.
Gene Forward (5’-3’) Reverse (5’-3’)
Product after 
amplification 
(bp)
Albumin AGTGAGGTTGCTCATCGGTT TGGACACTGCTGAAGATACTGA 93
b-Actin GGCAATGTGAAAATGACCCTG AGCAGACCTTCTTTGGCAGAT  101
MYBPC1* CTCCCAGCTGTCCATCTTGT GCCAGGTCCATCCATTTTCC 150
MYBPC3† CCCATTGGCCTCTTCGTGAT CTGCTCAGGTCCACCCATTT 146
C-terminal cTnT AGACTGAGCGGGAAAAGAAGAAG TGCCTCCAAGTTATAGATGCTCTG 131
N-terminal cTnT AAGAGGTGGTGGAAGAGTACGAG CTTCATCTTCTTCTGCCCTGGT 129
* MYBPC1 = skeletal muscle-specific marker
† MYBPC3 = cardiac muscle-specific marker
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abstract
Introduction Pompe disease is a progressive metabolic myopathy. Involve-
ment of respiratory muscles leads to progressive pulmonary dysfunction, 
particularly in supine position. Diaphragmatic weakness is considered 
to be the most important component. Standard spirometry is to some 
extent indicative but provides too little insight into diaphragmatic 
dynamics. We used lung MRI to study diaphragmatic and chest-wall 
movements in Pompe disease.
Methods In ten adult Pompe patients and six volunteers, we acquired two 
static spirometer-controlled MRI scans during maximum inspiration 
and expiration. Images were manually segmented. After normalization 
for lung size, changes in lung dimensions between inspiration and expi-
ration were used for analysis; normalization was based on the cranial-
caudal length ratio (representing vertical diaphragmatic displacement), 
and the anterior-posterior and left-right length ratios (representing 
chest-wall movements due to thoracic muscles).  
Results We observed striking dysfunction of the diaphragm in Pompe 
patients; in some patients the diaphragm did not show any displace-
ment. Patients had smaller cranial-caudal length ratios than volunteers 
(p<0.001), indicating diaphragmatic weakness. This variable strongly 
correlated with forced vital capacity in supine position (r=0.88) and pos-
tural drop (r=0.89). While anterior-posterior length ratios also differed 
between patients and volunteers (p=0.04), left-right length ratios did not 
(p=0.1). 
Conclusion MRI is an innovative tool to visualize diaphragmatic dynam-
ics in Pompe patients and to study chest-wall and diaphragmatic move-
ments in more detail. Our data indicate that diaphragmatic displacement 
may be severely disturbed in patients with Pompe disease. 
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introduction
Pompe disease (OMIM 232300: acid maltase deficiency or glycogen storage 
disease type II) is an inherited progressive metabolic myopathy caused by 
acid α-glucosidase deficiency due to mutations in the acid α-glucosidase 
(GAA) gene (OMIM 606800).1,2 Pulmonary dysfunction caused by progres-
sive weakness of the respiratory muscles is a characteristic feature of the 
disease.1,3,4 In patients with the classic infantile form cardiorespiratory 
failure leads to death within the first year of life.5,6 In patients with late-
onset or non-classic Pompe disease pulmonary dysfunction progresses 
more slowly. The first sign of respiratory involvement in these patients is 
decreased pulmonary function in supine position, eventually necessitating 
respiratory support during sleep. Patients in the end-stage of the disease 
require continuous respiratory support.7-9 Weakness of the diaphragm–the 
main respiratory muscle–is considered to be the major cause of respira-
tory dysfunction in Pompe disease.3,10 Although pulmonary function tests 
(PFTs) may be indicative of diaphragmatic weakness by showing a differ-
ence between forced vital capacity (FVC) in sitting and supine position–i.e. 
postural drop–or by a decreased mean inspiratory pressure (MIP), they 
provide too little insight in dynamics of the diaphragm.11 More insight in 
the function of the diaphragm has become extra relevant since enzyme 
replacement therapy (ERT) has been available for Pompe disease. While 
several studies have shown that ERT has positive effects on skeletal muscle 
function by showing stabilization or improvement of muscle strength or 
the distance walked in six minutes, the effects on lung function especially 
in supine position seem to be less pronounced.7,12-16 In an earlier study 
that compared the effects of ERT on pulmonary function in sitting and 
supine positions, we found that 15% of patients were therapy resistant 
when pulmonary function was measured in sitting position, and that 35% 
were therapy resistant when it was measured in supine position.13 Recent 
MRI sequences and image analysis techniques make it possible to directly 
assess the individual contribution of respiratory muscles–including the 
diaphragm–during the breathing cycle.17-22
The aim of the current study was to determine whether MRI could be 
used as an innovative tool to gain greater insight into the function of the 
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diaphragm in Pompe disease, and to correlate these data with the results 
of PFTs. 
methods
study population
All patients with Pompe disease in the Netherlands are referred to Erasmus 
MC University Medical Centre Rotterdam. For this cross-sectional pilot 
study we selected ten adult patients with various degrees of respiratory 
dysfunction. As controls we included six age and gender-matched vol-
unteers. Informed consent was obtained from all participants. The study 
protocol was approved by the Medical Ethical Committee at our hospital 
(Amendment 7 to protocol MEC-2007-103).    
Pft
An MRI-compatible spirometer was used to standardize lung volumes and 
breathing movements during the MRI (MasterSceen Pneumo spirometer, 
CareFusion, Houten, the Netherlands). Before MRI, FVC and forced expi-
ratory volume in one second (FEV1) were measured according to ATS/ERS 
standards.23,24 Spirometry parameters are expressed in percentages pre-
dicted. Postural drop (ΔFVC) was calculated as (FVCsitting-FVCsupine)/FVCsit-
ting *100%. An ΔFVC of more than 25% is thought to reflect diaphragmatic 
weakness.11,25 Before MRI, a Dwyer pressure gauge was used according 
to ATS/ERS standards to measure maximum static inspiratory (MIP) and 
expiratory pressures (MEP).26 Results are expressed in kilopascal (kPa). 
The carbon dioxide (CO2) fraction in the expired gas was measured with a 
capnograph (ms-capno, Viasys Healthcare, Wurzberg, Germany) at maxi-
mum expiration. In the absence of ventilation irregularities, the expiratory 
CO2 approximates the arterial CO2 pressure. A daytime expiratory CO2 
over 6.0 kPa suggests hypercapnia and chronic alveolar hypoventilation.27 
mri and imaging analysis
Scanning was performed with a 3T GE Signa 750 MRI (General Electric 
Healthcare, Milwaukee, USA) using the whole-body coil for radio-frequen-
cy excitation and a 32-channel torso coil for signal reception. First, a 3-plane 
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localizer was performed during a maximum inspiratory movement (i.e. a 
five-second breath-hold scan); all subsequent volumes imaged were based 
on this localizer. Second, shimming was performed on this localizer, and 
shim settings were maintained throughout scanning. To evaluate changes 
in lung shape and volume, two static scans were acquired. These use two 
12-second breath-hold scans covering the entire thoracic region acquired 
at end-inspiration and end-expiration in a 3D RF-spoiled gradient echo 
sequence with TR/TE=1/0.5 ms, flip angle 2°, sagittal volume acquisition 
with 3 mm slice thickness, 1.5 mm slice separation between slices and pla-
nar pixel resolution between 1.4x1.4 and 1.5x1.5 mm2. Overall acquisition 
time per patient was 20 minutes. 
Each lung was segmented manually at inspiration and expiration using 
3D Slicer (http://www.slicer.org), with segmentation being performed 
every second slice in the axial plane.28 A full 3D segmentation was recon-
structed by interpolating the individual segmentation slices in the cranial-
caudal axis. Using the 3D lung segmentations, the length and volume of 
each independent lung was estimated along the main axes of the MRI 
acquisition (cranial-caudal, anterior-posterior and left-right). To cope for 
variations in lung size due to inter-subject anatomical variations, each 
length at maximum inspiration was divided by the corresponding length 
at maximum expiration. Therefore the normalised value is a rate of length 
increase compared with the expiration point (e.g. a ratio of 1.2 would mean 
an increase of 20% in length). Because of the assumption that the chest-wall 
is responsible for changes in volume in the anterior-posterior and left-right 
directions, and the diaphragm expands the lung in the cranial-caudal di-
rections, it is possible to study the contributions to volume changes of the 
chest-wall and the diaphragm individually.
statistical analysis
Data were analyzed using SPSS version 21 (SPSS, Chicago, IL, USA) and 
are presented as medians with ranges, or as numbers with percentages. 
The Mann-Whitney test was used to analyze differences in PFT results and 
MRI findings between patients and volunteers. The Spearman’s correlation 
coefficient (r) was used to calculate the relationship between PFT outcomes 
and MRI results in Pompe patients. A p-value <0.05 was considered statis-
tically significant. 
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results
study population
Table 1 shows the characteristics of the Pompe patients and the volunteers. 
All Pompe patients had an GAA deficiency and all patients carried the 
common mutation c.-32-13T>G in one GAA allele and a second pathogenic 
mutation in the second allele. In five patients this second pathogenic muta-
tion was c.525delT, in two patients c.1548G>A, and the other three patients 
carried a different second mutation. None of the patients was currently 
smoking and two patients had smoked in the past. None of the patients 
or volunteers had co-morbidities that could influence the function of the 
diaphragm.
Table 1  Patient characteristics and Pft results in patients and volunteers 
Patients Volunteers P-value
Age (years) 46 (32-66) 43 (27-55) 0.25
Gender, (% males) 5 (50) 3 (50) 1.0
Height (cm) 178 (154-196) 177 (175-190) 0.39
Weight (kg) 73 (61-88) 85 (65-94) 0.13
BMI (kg/m2) 23.4 (20.6-25.4) 24.9 (21-25.7) 0.18
Duration of the disease (years) 16 (9-30) - -
Duration of ERT (years) 5.5 (0-7) - -
Wheelchair dependent (%) 1 (10) 0 (0) 0.79
Ventilator dependent (%) 3 (30) 0 (0) 0.37
Pulmonary function test
FVCsitting (%) 60 (45-84) 102 (92-111) 0.001
FVCsupine (%) 43 (27-70) 102 (87-113) 0.001
ΔFVC (%)a 33 (11-44) 0 (0-10) 0.001
FEV1 sitting (l/s) 59 (42-80) 98 (85-117) 0.001
FEV1 supine (l/s) 40 (30-63) 91 (76-112) 0.001
MIP (kPa) 6.9 (3.9-8.3) 8.6 (6.4-11.8) 0.07
MEP (kPa) 10.0 (6.4-11.8) 12.5 (10.3-14.2) 0.02
Continuous variables are expressed as median and range, categorical variables as number and 
percentage. BMI = body mass index, ERT = enzyme replacement therapy, FVC = forced vital 
capacity, FEV1 = forced expiratory volume in one second, MIP = maximum static inspiratory pres-
sure, MEP = maximum static expiratory pressure. 
aΔFVC is calculated as (FVCsitting-FVCsupine) / FVCsitting x 100%. 
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Pft
Table 1 shows PFT in sitting and supine positions. In both these positions, 
patients had lower median values for FVC and FEV1 than healthy volunteers 
did (p=0.001). The median ΔFVC was higher in Pompe patients (p=0.001). 
The median MEP was lower in patients (10.0 kPa) than in volunteers (12.5 
kPa, p=0.02). The median MIP showed a trend towards a lower median 
value for the patients (6.9 kPa) relative to the healthy volunteers (8.6 kPa, 
p=0.07). Three patients had a expiratory CO2 fraction over 6.0 kPa and two 
of these patients were ventilator dependent. 
mri
Figure 1 shows the line-up during the MRI. Participants were placed in su-
pine position with the MRI-compatible spirometer positioned above them. 
Figure 2 shows coronal slices through the carina for the breath-hold scans 
with the corresponding color plots of a Pompe patient and a volunteer. In 
the Pompe patient there was hardly any displacement of the diaphragm. 
Additional file 1 in the online data supplement shows the color plots of 
each individual subject and additional files 2 and 3 demonstrate two ex-
amples of dynamic MRI scans in a healthy volunteer and a patient with 
Pompe disease. 
Figure 3 shows the changes per individual in the three chest-cage direc-
tions between inspiration and expiration. In volunteers, the main contribu-
tor to the changes in lung volume was the diaphragm (white bars). In most 
Figure 1  line-up during the mri
Patients were placed in supine position in the MRI scanner with an MRI-compatible spirometer 
positioned just above the head.
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Figure 2  mr images and color maps at maximum inspiration and expiration
MR images during 12-second breath-holds in inspiration and expiration in a patient with Pompe 
disease and a healthy volunteer. The color maps represent the thickness of the segmentation in 
the anterior-posterior axis (red being the thickest and blue being the thinnest). Note the limited 
increase in vertical length in the Pompe patient relative to the increase in the healthy volunteer.
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Figure 3  ratios between inspiration and expiration in three directions for patients and volun-
teers measured with mri
The length ratios between inspiration and expiration in the cranial-caudal direction (white bars), 
anterior-posterior direction (black bars) and left-right direction (grey bars) are shown for individual 
patients and volunteers. Volunteers are numbered 1 to 6 and patients 7 to 16. The length ratios 
are calculated by dividing the median length during inspiration by the median length during expira-
tion for each axis. 
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Pompe patients, these changes were due mainly to the thoracic muscles 
(grey and black bars), but, as Figure 3 shows, these patients had a large 
variety in diaphragmatic and chest-wall movements. The median cranial-
caudal length change, representing diaphragmatic displacement before 
normalization for lung size, was 82 mm (range 46-90 mm) in volunteers 
and 28 mm (range 5-49 mm) in patients (p=0.002). The median anterior-
posterior length change was 37 mm in volunteers (range 25-42 mm) and 
18 mm (range 13-31 mm) in patients (p=0.006); the median left-right length 
change was 24 mm in volunteers (range 21-34 mm) and 17 mm (10-26 mm) 
in patients (p=0.02). 
Figure 4 shows the different length ratios after normalization for lung 
size. The cranial-caudal length ratio between inspiration and expiration 
(representing diaphragmatic displacement) was lower in Pompe patients 
(median 1.35, range 1.07-1.64) than in volunteers (median 1.82, range 1.66-
2.08) (p=0.001). While the anterior-posterior length ratio was also lower 
in patients (median 1.40, range 1.20-1.58) than in volunteers (median 1.59, 
range 1.42-1.71) (p=0.04), the left-right length ratio did not differ signifi-
cantly between patients (median 1.35, range 1.20-1.56) and volunteers (me-
dian 1.41, range 1.36-1.58) (p=0.1). In the three Pompe patients who were 
ventilator dependent the cranial-caudal length ratio was lower than in the 
other Pompe patients (median 1.22 versus 1.43, p=0.02).  These Ventilator 



  



  




 

Figure 4  median ratios between inspiration and expiration in three directions for both groups
This figure shows the same ratios as Figure 2, but now for the groups of Pompe patients and 
volunteers. The box plots represent the median with the range. The Mann-Whitney test was used 
to calculate the difference in each direction between patients and volunteers.
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dependent patients had a longer duration of the disease (median 29 years 
versus 15 years). There was no correlation between the cranial-caudal 
length ratio and the duration of ERT. 
correlation between Pft and mri
As Figure 5 shows, ΔFVC and FVC supine were strongly correlated with the 
cranial-caudal length ratio (r=0.89 and r=0.88, p<0.001) in Pompe patients, 
but there were no correlation between MIP and the cranial-caudal length 
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Figure 5  correlation between cranial-
caudal length ratios and fVc supine (a), 
postural drop (b) and miP (c)
The dots represent patients and the 
triangles volunteers. Spearman’s correla-
tion coefficient (r) was used to calculate 
the correlation between the cranial-caudal 
length ratio versus FVC in supine position, 
the postural drop (ΔFVC) and MIP. As 
these calculations were performed only 
in the Pompe patients, the volunteers 
were excluded for these analyses. FVC 
= forced vital capacity, MIP = maximum 
static inspiratory pressure.
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ratio (r=0.32, p=0.37), MEP and cranial-caudal length ratio (r=0.23, p=0.53), 
or FVC sitting and cranial-caudal length ratio (r=0.46, p=0.18).  The only 
significant correlation regarding the anterior-posterior length ratio was 
with FVC supine (r=0.74, p=0.02). 
discussion
Our study shows that MRI can be used as an innovative tool to gain 
greater insight into involvement of the diaphragm in Pompe disease. It was 
demonstrated that the diaphragmatic function is severely impaired and in 
some patients there was even hardly any displacement of the diaphragm. 
To a lesser extent, movement of the anterior chest-wall was reduced.  Our 
results suggest that diaphragmatic displacement measured with MRI is 
strongly correlated with the postural drop and FVC in supine position 
measured with common spirometry. 
Decreased pulmonary function is an important feature of Pompe disease. 
Ten or 15 years after onset, half of the adult patients with Pompe disease re-
quire ventilator assistance. The main cause of death in this group of patients 
is respiratory failure, a process in which dysfunction of the diaphragm is 
considered to play an important role.8,9,29 Our MRI study suggests that the 
function of the diaphragm in Pompe disease is more impaired than that 
of the thoracic musculature. It is not clear how and why the diaphragm 
muscles are more severely affected than the other respiratory muscles. Our 
study supports a recent study describing atrophy of the diaphragm and 
reduced lung height on static MRI and computed tomography scans in 
patients with Pompe disease. In this latter study semi-quantitative scoring 
scales were used, and computed tomography was used to measure lung 
height in one direction.30 In our study MRI was performed under spirom-
etry control and lung-shape variations were quantified in three directions. 
This enabled us to show that the cranial-caudal movement related to 
diaphragmatic function in patients with Pompe disease is impaired more 
than the anterior-posterior motions of the anterior chest-wall. Similarly, 
the correlation we found between ΔFVC and FVC in supine position and 
our MRI results suggest that both these parameters might be used as an 
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indirect tool for determining diaphragmatic function, with the advantage 
that MRI also visualizes diaphragmatic and chest-wall movements. 
A striking finding in our study was that displacement of the diaphragm 
was extremely impaired in some of the patients, while still residual pul-
monary function in supine position was measurable. This could have 
important consequences when therapy comes in place and might explain 
why pulmonary function, particularly in supine position, responds poorly 
to ERT in some of the Pompe patients. Therefore, more studies are required 
to investigate at what stage the diaphragm and other respiratory muscles 
become affected in Pompe disease; especially since it has been shown that 
response to ERT is better in patients who are less severely affected.3,13,31 
Another intriguing question is how MIP and MEP relate to diaphragmatic 
weakness. It has been hypothesized that these parameters might be better 
predictors for diaphragmatic weakness than FVC in supine position.30 Our 
study implied a weak correlation between MIP or MEP and diaphragmatic 
displacement. A possible explanation could be that MIP reflects both the 
strength of the diaphragm and other inspiratory muscles, while the cranial-
caudal length ratio only reflects diaphragmatic displacement. In an earlier 
study we found a positive correlation between FVC in upright position 
and MIP an MEP.3 Larger studies are required to explore this relationship 
in more depth. Comparison of diaphragmatic involvement in patients 
with Pompe disease to those with other neuromuscular disorders such as 
Duchenne Muscular Dystrophy might provide insight whether onset and 
the extend of diaphragmatic involvement is disease specific.
A limitation of our pilot study is that we selected a relatively small 
number of adult Pompe patients with variable degrees of respiratory 
dysfunction (FVC in supine position: 27 to 70% of normal). This subset of 
patients may not be fully representative for the total group of Pompe pa-
tients.  In subsequent studies also patients with normal or close to normal 
respiratory function need to be studied to get more insight at what stage 
of the disease the diaphragm becomes affected. The use of MRI to evaluate 
diaphragmatic and chest-wall movements has some limitations. Contrain-
dications such as metal implants, invasive ventilation and claustrophobia 
make it impossible to scan certain patients. Moreover, patients need to be 
able to perform spirometry in supine position. In next studies it might also 
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be considered to include other techniques to measure lung and respiratory 
muscle function in addition to spirometry such as sniff nasal inspiratory 
pressures, transdiaphragmatic pressures or transdiaphragmatic twitch 
pressures.32 Prigent et al. showed that transdiaphragmatic pressures and 
transdiaphragmatic twitch pressures correlated well with all spirometry 
volumes and non-invasive maximal pressures in adult patients with Pompe 
disease.33 Whether transdiaphragmatic pressure measurements show a 
better correlation with the cranial-caudal length ratio measured with lung 
MRI than with spirometry data needs further investigation. 
conclusion
MRI appears to be an innovative tool to visualize diaphragmatic dynamics 
in Pompe patients and to study chest-wall and diaphragmatic movements 
in more detail. Our data indicate that diaphragmatic displacement can be 
very severely impaired in patients with Pompe disease and might explain 
why FVC responds poorly to ERT in some of the patients. As MRI adds de-
tailed dynamic and structural information to data obtained by pulmonary 
function tests, particularly of the diaphragm, it may serve as a valuable tool 
in providing new insights in when the diaphragm starts to be involved in 
the disease process and on its responsiveness to therapy. It may also serve 
as a prognostic tool. More research is warranted to explore these topics.  
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abstract
Objectives Neuromuscular imaging techniques are helpful tools to create a 
better understanding of pathophysiological processes of neuromuscular 
diseases. MRI has been used to study skeletal muscle damage in patients 
with late-onset Pompe disease. We used this technique to investigate the 
upper leg muscles of patients with classic infantile Pompe disease.  
Methods Five patients with classic infantile Pompe disease were included. 
MR images were compared with histopathology sections taken from the 
lateral vastus muscle. For comparison, an MRI was performed in a child 
without a neuromuscular disease. 
Results The median age at the time the MRIs and biopsies were taken was 
four months and none of the infants was treated with enzyme replace-
ment therapy yet. All infants had prominent muscle weakness and strik-
ingly abnormal muscle histopathology. MR images showed hypertrophic 
muscles in four patients and no abnormalities in the fifth.
Conclusion The hypertrophic appearance of the muscles demonstrated 
using MRI in patients with classic infantile Pompe disease, is in accor-
dance with the muscle firmness on clinical examination. Whether the 
hypertrophic appearance of muscles on MRI in classic infantile patients 
is related to glycogen accumulation as observed in muscle biopsies re-
quires further investigation. 
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introduction
Pompe disease (OMIM 232300: acid maltase deficiency or glycogen stor-
age disease type II) is an inherited metabolic disorder with an incidence of 
1:40,000 births per year. It is caused by mutations in the acid α-glucosidase 
gene (GAA). Deficiency of GAA leads to lysosomal accumulation of gly-
cogen predominantly in muscle tissue.1-4 The disease has a broad clinical 
spectrum, which is largely determined by residual GAA activity. In pa-
tients with the most severe classic infantile form, enzyme activity is virtu-
ally absent. These patients present shortly after birth with skeletal muscle 
weakness, which rapidly progresses to total paralysis within a few months. 
Patients eventually die from cardiorespiratory failure.1,2 Milder forms of 
the disease may present at any age from infancy to late adulthood.5 These 
patients have some residual enzyme activity, but usually no more than 30% 
of average normal activity.4 Most often these patients present with limb 
girdle muscle weakness and respiratory insufficiency.6,7 Since 2006, enzyme 
replacement therapy (ERT) has become available. This has improved 
survival and motor outcome significantly in infants, and more recently 
positive effects have also been demonstrated in adults.4,8 These include 
improved distance walked on the six-minute walk test and stabilization 
or improvement of pulmonary function, muscle strength, and better sur-
vival.9-13 However, there is a large variation in response between patients. 
Neuromuscular imaging techniques may be helpful to create a better un-
derstanding of the pathophysiological process and the severity of muscle 
abnormalities. Computed tomography, ultrasound and magnetic resonance 
imaging (MRI) may all provide information on the distribution and sever-
ity of disease in the affected muscles. MRI provides the best soft tissue 
contrast and information on the shape, volume and tissue architecture of 
striated muscles.14 Several cross-sectional studies have been published on 
muscle MRI findings in adult and juvenile patients with Pompe disease, but 
so far muscle MRI has not been used in classic infantile Pompe disease.15-21 
To study whether muscle MRI can be a useful tool to investigate the 
extent of muscle damage in classic infantile Pompe disease, we performed 
MRI of the upper legs of five infants with Pompe disease and compared 
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the findings with the pathology found in muscle biopsy sections of the 
quadriceps muscles from these patients. 
methods
Patients
Five patients with classic infantile Pompe disease participated in this study. 
They were diagnosed with Pompe disease between June 2009 and Septem-
ber 2012. Psychomotor development was assessed using the Alberta Infant 
Motor Scale (AIMS).22 An MRI of an infant without Pompe disease was used 
as a control. Informed consent was obtained from all parents. The Medical 
Ethics Committee at Erasmus University Medical Center Rotterdam, The 
Netherlands, approved the study protocols.
muscle imaging
MR examinations were performed using a 1.5-tesla (1.5T) GE imaging sys-
tem (General Electric Healthcare, Milwaukee, USA) with an eight-channel 
receiving only phased-array cardiac coil. Examination areas ranged from 
the anterior inferior iliac spine to the knee. No intravenous contrast me-
dium or sedative drugs were administered. The infants were placed in 
supine position and supported by a vacuum mattress. The MRI sequence 
protocol included axial and coronal images obtained with the following 
pulse sequences: T1- weighted fast spin-echo images without fat suppres-
sion (repetition time (TR) 500-600ms, echo time (TE) 14-23ms, slice thick-
ness 6-8 mm); T2-weighted fast spin-echo images with fat suppression (TR 
2500-5000ms, TE 64-85ms, echo train length: six to eight, slice thickness 3-5 
mm); and coronal images using a Spin-Echo Inversion Recovery Weighted 
sequence (STIR) (TR 4500ms, TE 35ms, Inversion Time 155ms, echo train 
length eight, slice thickness 3-5 mm). In all sequences a matrix of 256 x 192 
was used with a slice gap of 1-2 mm and a field of view (FOV) of 20-28 cm. 
The average scanning time was 25 minutes per patient. 
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muscle biopsy
Needle biopsies were taken from the lateral vastus muscle as part of the 
standard procedure in patients with Pompe disease at our center. The 
muscle sections were fixed in 4% glutaraldehyde, embedded in glycol-
metacrylate and stained with periodic acid-Schiff (PAS).23
results
Patients
Five patients with classic infantile Pompe disease were included in this 
study (four males and one female). All patients had generalized muscle 
weakness in the first months of life, and the characteristic hypertrophic 
cardiomyopathy. Except for patient 4, all other patients needed nasogastric 
tube feeding and supplemental oxygen. At clinical examination all five 
patients had a generalized hypotonia characterized by slipping through 
and head lag, and the AIMS score was below the 5th percentile (Table 1). In 
all patients except patient 2, the muscles had a firm texture on palpation, 
Table 1  Patient characteristics
Patient Age at MRI GAA activity Mutation 1 Mutation 2 AIMS†
1 5 0 c.2104C>T c.379-380delTG 6
2 4 0 c.2481+102_2646+31del c.del525T 8
3 3 0 c.1209C>G c.del525T 0
4 3 1.4 c.925G>A c.2608C>T 5
5 5 0 c.del525T c.del525T 4
Control 8 NA* NA NA NA
*NA = not applicable. †AIMS = Alberta Infant Motor Scale, reference values in children aged 
three to four months are 12.6 and in children aged four to five months 17.9. The age at MRI is 
expressed in months. GAA activity was measured in leukocytes with glycogen as substrate in the 
presence of acarbose, and expressed as nmol/mg/h (normal range 30-160 nmol/mg/h). 
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especially the calves. None of the patients were treated with ERT at the 
time the MRIs and muscle biopsies were taken. Table 1 shows the age at 
time of the MRI, the GAA activity and GAA genotypes of all patients. An 
MRI of the upper leg of an eight month-old boy was used as a control. 
muscle imaging
The T1 and T2-weighted images did not show signal intensity changes in 
the muscles of the upper legs. In patients 1, 3, 4 and 5 the T1-weighted 
images showed symmetric hypertrophic muscles of the upper legs with 
less subcutaneous fat compared to those of the control patient (Figure 1). 
Patient 2 did not have hypertrophic muscles on MRI. 
muscle biopsy
Four of the classic infantile patients underwent muscle biopsies. No biopsy 
was taken from the fifth patient since the parents did not give their consent 
for it (patient 3). In two patients the biopsy was taken within 24 hours of 
muscle imaging and in the other two patients one day and one week before 
muscle imaging, respectively. In all patients the muscle biopsy showed a 
vacuolar myopathy with irregular atrophic and hypertrophic muscle fibers, 
 
 
 
A C 
B D 
Figure 1  muscle mri of two classic infantile patients and a control patient
Image A (patient 1) is an axial T1-weighted image showing hypertrophic muscles of the upper 
legs and little subcutaneous fat. Image B (patient 3) is a coronal T1-weighted image demonstrat-
ing hypertrophic muscles. Images C (axial) and D (coronal) are T1-weighted images of the control 
patient. 
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with positive PAS-material in almost all vacuoles (80-95%). Figure 2 shows 
the muscle biopsies and corresponding MR images of patients 1 and 5.
discussion
In this study we found that muscle MRI taken from the upper legs of pa-
tients with classic infantile Pompe disease showed almost no abnormalities 
except for some hypertrophy of the muscles on T1 and T2-weighted im-
ages. To the best of our knowledge this is the first study to describe muscle 
MRI findings in classic infantile Pompe patients. We were rather surprised 
to find only minor abnormalities on MRI in these patients, while the clini-
cal status was quite advanced in most of them. At clinical examination the 
muscles had a firm constitution on palpation, which we considered most 
likely attributable to the severe glycogen accumulation that we observed 
Patient 1 Patient 5 
Figure 2  muscle mri and histopathology of two classic infantile patients
Muscle MRI of the upper legs and PAS stained biopsies of the lateral vastus muscle of two 
classic infantile patients (patients 1 and 5). The MR images show hypertrophic muscles and little 
subcutaneous fat and the muscle biopsies show severe PAS-positive vacuolar changes in almost 
all muscle fibers. 
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in muscle biopsies.1,2 Interestingly, the only patient whose muscles did not 
have a firm texture on palpation also did not have hypertrophic muscles 
on the MR images. 
In an earlier histopathological study five stages in the pathological pro-
cess of classic infantile Pompe disease based on electron microscopy were 
distinguished.24 Stage 1 was described as small glycogen-filled lysosomes 
between intact myofibrils, Stages 2 and 3 as stages with increased lysosomal 
glycogen with leakage to the cytoplasm and fragmentation of myofibrils 
and abnormal mitochondria. In Stage 4 most glycogen was cytoplasmatic, 
while the contractile elements were severely damaged. In Stage 5 - the end 
stage- there was complete loss of myofibrils, while the cells were bloated 
due to water influx. The muscle biopsies from our patients showed exten-
sive glycogen accumulation contained in vacuoles in virtually all muscle 
fibers, and there was no obvious replacement of muscle tissue by fat or 
connective tissue. It seems likely that the hypertrophic aspect on MRI is 
due to glycogen accumulation and reactive increase of organelles, with se-
vere myopathy signs and beginning of fibril dissolution as observed in the 
histopathology (resembling Stages 2-3 as described by Thurberg et al.).24 
Muscle MRI has been described in more detail in adult patients with 
Pompe disease. In these patients MRI shows fatty infiltration particu-
larly in the spine extensors, abdominal belt and scapular and pelvic girdle 
muscles.16,19,25 Although the disease in these patients is considered to be 
slowly progressive and the process of glycogen accumulation to be spread 
over many years, it apparently results in considerable muscle atrophy, fat 
infiltration and replacement of muscle by connective tissue over longer 
periods of time as shown on MRI. In these adult patients glycogen stor-
age may vary extensively between muscle fibers even within the same 
muscle. Also the extent of tissue damage between muscle groups varies 
greatly.26-28 It remains an interesting topic for future research to study why 
some muscles are more severely affected than others and to investigate the 
effects of ERT by muscle MRI in adult patients. A recent study has shown 
that quantitative whole-body MRI is a feasible technique to use.21
A limitation of our study was that only the upper legs were scanned 
and that only T1 and T2-weighted sequences were used. This was due to 
limited scanning time and because we did not want to administer seda-
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tive drugs considering the anaesthetic risks to these infants. Although it 
might have been more informative to perform a total body MRI, taking 
the homogeneous process of muscle destruction in infants into account we 
consider it unlikely that the results would have been completely different. 
Now patients are living longer due to ERT it will be certainly of interest 
to repeat MRI scans in long-term surviving patients with classic infantile 
Pompe disease. Other MRI techniques could also be of additional value to 
objectively quantify disease severity and progression in Pompe disease; 
these include C-NMR spectroscopy, T2 mapping and 3-point Dixon im-
aging.29-33 It has been shown that C-NMR spectroscopy can demonstrate 
glycogen accumulation in muscle in patients with glycogenosis type III 
and in adult patients with Pompe disease, indicating that this technique 
could also be useful in infants with Pompe disease.32,33 
In conclusion, muscle MRI in patients with classic infantile Pompe disease 
shows a hypertrophic appearance of the muscles, which is in accordance 
with the muscle firmness on clinical examination. Whether the hypertro-
phic appearance is related to glycogen accumulation alone as observed 
in muscle biopsies, and whether muscle MRI can be used as a marker to 
evaluate the effects of ERT requires further investigation.
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abstract
Vascular abnormalities and glycogen accumulation in vascular smooth 
muscle fibres have been described in Pompe disease. Using carotid-femoral 
pulse wave velocity (cfPWV), the gold standard methodology for deter-
mining aortic stiffness, we studied whether aortic stiffness is increased in 
patients with Pompe disease. Eighty-four adult Pompe patients and 179 
age and gender-matched volunteers participated in this cross-sectional 
case-controlled study. Intima media thickness and the distensibility of 
the right common carotid artery were measured using a Duplex scanner. 
Aortic augmentation index, central pulse pressure, aortic reflexion time 
and cfPWV were assessed using the SphygmoCor® system. CfPWV was 
higher in patients than in volunteers (8.8 versus 7.4 m/s, p<0.001). This 
difference was still present after adjustment for age, gender, mean arterial 
blood pressure (MAP), heart rate and diabetes mellitus (p=0.001), and was 
shown by subgroup analysis to apply to the 40-59 year age group (p=0.004) 
and 60+ years age group (p=0.01), but not to younger age groups (p=0.99). 
Except for a shorter aortic reflexion time (p=0.02), indirect indicators of 
arterial stiffness did not differ between patients and volunteers. Relative 
to volunteers (20%), more Pompe patients had a history of hypertension 
(36%, p=0.005), and the MAP was higher than in volunteers (100 versus 92 
mmHg, p<0.001). This study shows that patients with non-classic Pompe 
disease have increased aortic stiffness and blood pressure. Whether this is 
due to glycogen accumulation requires further investigation. To reduce the 
potential risk of cardiovascular diseases, we recommend that blood pres-
sure and other common cardiovascular risk factors are monitored regularly. 
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introduction 
Pompe disease (OMIM 232300: acid maltase deficiency or glycogen storage 
disease type II) is an inheritable lysosomal storage disorder caused by a 
deficiency of acid α-glucosidase that leads to glycogen accumulation in 
various body tissues, predominantly skeletal, cardiac and smooth muscle.1,2 
Patients with the classic infantile form of the disease develop generalized 
hypotonia and a hypertrophic cardiomyopathy. Without treatment, these 
patients die in the first year of life due to cardiorespiratory failure.3 In the 
non-classic form of the disease, which can present at any age, progressive 
muscle weakness is the predominant symptom. In general, there is no 
significant cardiac involvement.4,5 
Over the last two decades, several reports have hypothesized that glyco-
gen accumulation in the smooth muscle tissue of arteries leads to vascular 
abnormalities in non-classic Pompe disease, such as cerebral aneurysms, 
basilar artery dolichoectasia, carotid dissection and dilated arteriopathy 
of the thoracic aorta.6-11 The first indication of increased aortic stiffness in 
non-classic Pompe disease was reported in a study on 17 Pompe patients 
that used transthoracic Doppler echocardiography, a non-invasive tool that 
measures aortic stiffness indirectly.12 The presence of increased aortic stiff-
ness may be relevant, since it is considered to be an independent risk factor 
for cardiovascular disease and mortality.13,14 The emerging gold standard 
for measuring it directly and non-invasively is tonometry of the carotid-
femoral pulse wave velocity (cfPWV).15
To determine whether increased arterial stiffness is a feature of non-
classic Pompe disease, we used various techniques including tonometry of 
the cfPWV to investigate the structural and functional vascular properties 
of different vascular territories in a large group of patients with non-classic 
Pompe disease. We compared the results with those in age and gender-
matched volunteers.
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materials and methods
study population
Between March 2012 and June 2013 we performed a cross-sectional single-
centre case-controlled study in 84 patients with non-classic Pompe disease 
and 179 volunteers. All patients were 18 years or older. As the volunteers 
were matched for gender and age category, there were, per patient, at least 
two volunteers of the same gender and the same age category. The volun-
teers were either the patients’ partners, or were employees or students of 
Erasmus University Medical Center, or otherwise visitors to it. Informed 
consent was obtained from all participants. The study protocol was ap-
proved by the Medical Ethical Committee at Erasmus University Medical 
Center
cardiovascular risk factors
All participants filled out a questionnaire to assess cardiovascular risk fac-
tors, which included gender, date of birth, length, weight, medication use, 
and comorbidities such as hypertension, diabetes mellitus, hypercholes-
terolemia and cardiovascular disease (i.e. transient ischemic attack, stroke, 
myocardial infarction or rhythm disturbances). Body mass index (BMI), 
which was calculated as body weight divided by height squared, was 
expressed as kg/m2. An automatic mercury cuff sphygmomanometer on 
the right arm was used to measure heart rate and blood pressure, including 
the mean arterial blood pressure (MAP), when the patient was in supine 
position after five minutes of rest in a quiet and heat-controlled room. 
Hypertension was defined as a systolic blood pressure (SBP) > 140 mmHg 
and/or diastolic blood pressure (DBP) > 90 mmHg.16
Vascular measurements
Aortic stiffness was measured using arterial tonometry from the right radi-
al, right carotid and right femoral arteries using the SphygmoCor® device 
(Sphygmocor version 7.1, AtCor Medical, Sydney, Australia) according to 
previously described procedures.17 Transit distance was assessed on the 
basis of body surface measurement from the carotid artery to the femoral 
artery: 80% of this distance was used as pulse-wave-travelled distance.15 
The primary outcome measure, cfPWV, was expressed in meters per 
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second (m/s). The secondary and indirect outcome parameters for arte-
rial stiffness measured with pulse wave analysis (PWA) of the right radial 
artery were central pulse pressure (PPc), augmentation index (AIx) and 
aortic reflexion time (ATr). PPc was calculated as the difference between 
aortic systolic and diastolic pressure; AIx was calculated from the aortic 
pressure waveform obtained by applying a general transfer function to the 
radial pressure waveform. For the comparison between two groups, AIx 
was normalized to a heart rate of 75 beats per minute. ATr was calculated 
as the time interval between the foot of the pressure wave and the shoulder 
of the reflected wave.18-20
The distensibility and IMT of the right common carotid artery were 
measured two centimetres below the carotid bifurcation using a vessel-
wall movement-detector system (Art.Lab, Esaote Europe, Maastricht, the 
Netherlands) according to previously described procedures.17 The disten-
sibility coefficient, a local measurement of carotid stiffness, was calculated 
as (2ΔD/D)/PP(10-3/kPa).21 in which D is the diameter during diastole, ΔD 
is the measured distensibility (systolic diameter – diastolic diameter), and 
PP is the aortic pulse pressure derived from radial applanation. Tonometry 
and ultrasonography were performed by two trained physicians (SW or 
EK).
statistical analyses
Unless otherwise specified, data are presented as medians with interquar-
tile ranges (IQR). Because cfPWV, PPc, AIx, ATr, distensibility and IMT 
were not normally distributed, the Mann-Whitney test was used to com-
pare these outcomes between the total groups of patients and volunteers. 
Linear regression analyses were used to study cfPWV separately. First, 
univariate regression analyses were performed. Next, the regression co-
efficients with a p-value less than 0.05 or variables that were considered 
clinically relevant were analyzed in a multivariate regression model using 
bootstrap estimation. The final multivariate model contained age, gender, 
MAP, heart rate and diabetes mellitus. 
We also performed a stratified analysis between patients and volunteers 
in three age groups: 20-39, 40-59 and 60+. To determine whether cfPWV 
was influenced by disease duration, treatment with ERT, and wheelchair or 
ventilator dependency, we also analyzed cfPWV in separate multivariate 
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regression models using bootstrap estimation. The final model for these 
analyses included four variables: age, gender, MAP and heart rate. The 
data were analyzed using SPSS 20. A p-value of less than 0.05 was consid-
ered statistically significant.
results
study population
Table 1 shows the characteristics of the two groups. In total, 84 patients 
with non-classic Pompe disease and 179 volunteers were included in the 
study. Twenty-six percent of the patients were wheelchair dependent, and 
31% needed artificial ventilation. Eighty-two percent of the patients were 
treated with ERT and the median duration of treatment was 5 years (IQR 
4-5). CfPWV could not be measured in nine patients, either because they 
could not lie in supine position due to respiratory failure, or because their 
use of accessory muscles made it difficult to visualize the carotid artery. 
Neither could cfPWV be measured in other eight volunteers due to tempo-
rary technical problems with the SphygmoCor® system.
cardiovascular risk factors
In the past, more patients with Pompe disease than volunteers had been 
diagnosed with hypertension (p=0.005, Table 1). Seventy-seven per cent 
of the Pompe patients with an earlier diagnosis of hypertension used 
antihypertensive medication at the time of evaluation, and 89% in the 
group of volunteers. Despite treatment with antihypertensive medication, 
blood pressure continued to be high in 52% of the Pompe patients who 
were treated for hypertension and in 65% of the volunteers. As Table 2 
shows, MAP was higher in patients than in volunteers (100 mmHg (IQR 
90-111) versus 92 mmHg (IQR 84-103), p<0.001). Thirty-nine per cent of the 
patients met the criteria for hypertension (SBP > 140 mmHg and/or DBP > 
90 mmHg), versus 20% of the volunteers (p=0.001). At group level, patients 
with Pompe disease had a higher heart rate (75 beats per minute (bpm) 
(IQR 68-83)) than the volunteers (65 bpm (IQR 59-71), p<0.001). 
There were no differences in the occurrence of comorbidities such as 
diabetes mellitus or hypercholesterolemia. Seven patients with Pompe 
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Table 1  demographic and clinical characteristics
Pompe patients Volunteers
Number of individuals 84 179
Age in years 54 (42-63) 54 (41-61)
Gender – male (%) 41 (49) 85 (48)
Body mass index in kg/m2 24.7 (22.0-27.3) 24.0 (22.2-26.0)
Smoking status (%)
• Never
• Past
• Current
36 (43)
41 (49)
7 (8)
107 (60)
53 (29)
19 (11)
Medical history
• Hypertension (%)
• Diabetes mellitus (%)
• Hypercholesterolemia (%)
• Cardiovascular disease (%)
30 (36)#
5 (6)
8 (10)
7 (8)
35 (20)
6 (3)
18 (10)
9 (5)
Antihypertensive medication (%) 23 (77) 31 (89)
Disease duration in years 16 (12-23) -
Patients receiving ERT (%) 69 (82) -
Duration of ERT in years 5 (4-5) -
Wheelchair use (%) 22 (26) 0 (0)
Ventilator use (%) 26 (31) 0 (0)
Continuous variables are given as medians with interquartile ranges (IQR), and categorical 
variables as numbers and percentages. #  = In the past, more patients with Pompe disease than 
volunteers were diagnosed with hypertension (p-0.005).
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disease had a medical history of cardiovascular disease: four of them (three 
of whom female) had had a transient ischemic attack between the ages 
of 48 and 62 years; two male patients had developed atrial fibrillation at 
the ages of 37 and 64 years; and one female patient had had a myocardial 
infarction at the age of 74 years. Nine volunteers had a medical history of 
cardiovascular disease. This was not statistically different from the seven 
Pompe patients (p=0.30). 
aortic stiffness
As shown in Table 2, median cfPWV was 8.8 m/s in patients with Pompe 
disease (IQR 7.1-10.7) and 7.4 m/s in volunteers (IQR 6.6-8.6) (p<0.001). 
This difference was still present after adjustment for age, gender, MAP, 
heart rate and diabetes mellitus (p=0.001). Subgroup analysis showed that 
while it occurred in the 40-59 year age group (8.6 m/s in patients versus 
Table 2  functional and structural hemodynamic parameters in patients and volunteers
Pompe patients (n=84) Volunteers (n=179) P-value
Mean arterial pressure (mmHg) 100 (90-111) 92 (84-103) <0.001
Heart rate (beats per minute) 75 (68-83) 65 (59-71) <0.001
Diameter carotid artery (mm) 6.6 (6.1-7.3) 7.1 (6.5-7.8) <0.001
Intima media thickness (μm) 582 (514-683) 592 (506-695) 0.68
Distensibility coefficient (10-3/kPa) 2.9 (1.9-4.1) 2.7 (2.2-4.1) 0.72
Carotid-femoral pulse wave velocity (m/s) 8.8 (7.1-10.7) 7.4 (6.6-8.6) <0.001
Central pulse pressure (mmHg) 38 (31-47) 36 (31-43) 0.30
Augmentation index (%) 21.7 (13.2-30.3) 19.4 (8.5-29.4) 0.23
Aortic reflexion time (ms) 140 (132-149) 144 (135-159) 0.02
Continuous variables are given as medians with interquartile ranges (IQR). The diameter of 
the carotid artery was measured in 179 volunteers and 84 patients; IMT was measured in 179 
volunteers and 83 patients; the distensibility coefficient was measured in 176 volunteers and 80 
patients; cfPWV was measured in 171 volunteers and 79 patients; and PPc, Aix and ATr were 
measured in 178 volunteers and 83 patients.
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7.6 m/s in volunteers, p=0.004) and the 60+ years (11.5 versus 9.3 m/s, 
p=0.01), it did not occur in the 20-39 year age group (Figure 1). PPc and AIx 
did not differ significantly between patients and volunteers, while ATr was 
shorter in patients than in volunteers (p=0.02). 
CfPWV did not differ between Pompe patients whose disease duration 
was shorter than 15 years (n=35) and those whose disease duration was 
longer than 15 years (n=44) (9.1 versus 9.4 m/s, p=0.51). Neither did it dif-
fer between patients treated with ERT (n=64) and treatment-naïve patients 
(n=15) (9.4 versus 8.6 m/s, p=0.17). Similarly, cfPWV did not differ between 
wheelchair dependent patients (n=12) and ambulant patients (n=62) (9.4 
versus 9.2 m/s, p=0.75), or between ventilator dependent patients (n=18) 
and non-ventilated patients (n=56) (9.6 versus 9.1 m/s, p=0.42).  
carotid stiffness and imt
Table 2 shows that there were no significant differences in distensibility or 
IMT between patients and volunteers. The diameter of the carotid artery 
was smaller in patients than in volunteers (6.6 mm (IQR 6.1-7.3) versus 7.1 
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Figure 1  mean values of cfPWV in patients and volunteers per age category
The boxplots represent the mean values and 95% CI of cfPWV per age category
after adjustment for age, gender, mean arterial blood pressure, heart rate and
diabetes mellitus. The number of patients and volunteers per age group are given in
the bars. 
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mm (IQR 6.5-7.8), p<0.001). Subgroup analysis showed that the distensibil-
ity was lower in patients with Pompe disease aged between 20-39 years 
than in volunteers (p=0.03), but not in the other age-related subgroups.
glycogen accumulation in vascular smooth muscle
Figure 2 shows the muscle biopsy of a 50-year-old male patient with 
Pompe disease who participated in this study and had no medical history 
of cardiovascular diseases. He developed the first symptoms at age 44, and 
now has severe limb girdle weakness and decreased pulmonary function 
in sitting and supine positions. The biopsy was stained with periodic acid-
Schiff (PAS) and shows glycogen storage in skeletal muscle fibers and in 
vascular smooth muscle fibers.    
discussion
We found that patients with the non-classic form of Pompe disease have 
increased aortic stiffness and blood pressure. These findings indicate clini-
cal relevant involvement of the cardiovascular musculature in this group 
of Pompe patients.
Glycogen accumulation in smooth muscle fibres and in the endothelial 
layer of arteries has been shown in morphological studies and autopsy re-
ports of patients with Pompe disease.8,22,23 Figure 2 shows glycogen storage 
 
Figure 2  glycogen accumulation in vascular smooth muscle fibres
Muscle biopsies of adult patients with non-classic Pompe disease stained with periodic acid-
Schiff (PAS) to demonstrate glycogen storage in vascular smooth muscle fibres (black arrow-
heads). Original magnification: 630x.
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in vascular smooth muscle fibres in one of our adult patients with Pompe 
disease before start of ERT. While it is likely that the increased glycogen 
storage in smooth muscle fibres results in an increased arterial stiffness, it 
is also possible that glycogen accumulation in the endothelium damages 
the vascular wall, making it more vulnerable to atherosclerosis; in the 
presence of other cardiovascular risk factors, this process might increase 
arterial stiffness. As vascular stiffness has also been described as depend-
ing on the distribution of collagen and elastin, an increase in abnormal 
collagen and a decrease in normal elastin contributes to greater arterial 
stiffness.20 During the course of the disease, patients with Pompe disease 
may develop striated muscle atrophy with some increase in connective 
tissue.  If this process also occurred in the vascular smooth muscle fibers of 
Pompe patients, it would help to explain increased aortic stiffness.  
Increased aortic stiffness has also been described in other lysosomal 
storage disorders such as Fabry disease and mucopolysaccharidosis type 
I (MPS I or Scheie syndrome). In Fabry disease, storage of glycosphingo-
lipids takes place in vascular endothelial and smooth muscle cells, and in 
MPS I, accumulation of glycosaminoglycans in the connective tissue of the 
aortic wall impairs the formation of elastin and leads to changes in collagen 
formation.24,25 It has been shown in Fabry disease that ERT can normalize 
aortic stiffness.25 As most of the patients with Pompe disease enrolled in 
our cross-sectional study were treated with ERT, the difference in cfPWV 
between patients and volunteers might have been even more pronounced 
if it had been measured before the start of ERT. It would thus be interesting 
to establish whether aortic stiffness in Pompe patients decreases during 
ERT, and whether cfPWV can be used as a non-invasive tissue biomarker 
for disease progression and therapy response. 
To the best of our knowledge, this is the first study to show that arterial 
blood pressure is increased in patients with Pompe disease. It is reasonable 
to assume that any structural changes in the blood vessels caused by the 
increased aortic stiffness would lead to higher blood pressure. Increased 
aortic stiffness and hypertension are both independent risk factors for 
cardiovascular disease and mortality.13,14 It has been shown that patients 
with non-classic Pompe disease have improved survival when treated with 
ERT.26 Since cardiovascular diseases are more common at a higher age, 
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Pompe patients will be more likely to develop cardiovascular diseases, as 
they owe their higher age to ERT. In these patients it is therefore important 
to closely monitor risk factors for cardiovascular diseases such as hyper-
tension, hypercholesterolemia, diabetes mellitus and smoking, and to treat 
them when indicated. Although exercise and training, dietary changes and 
pharmacological treatments have sometimes been shown to reduce arterial 
stiffness in healthy individuals and other patient groups,27-29 it has not yet 
been investigated whether they are also beneficial in Pompe patients.  
Although we expected Pompe disease to have a similar effect on the 
vascular structure of all arteries, and thereby to increase cfPWV and reduce 
distensibility, we found changes in carotid distensibility only in patients 
aged between 20-39 years. In those with high blood pressure and diabetes 
it has been reported that the aorta stiffened more than the carotid artery 
with age and with other cardiovascular risk factors such as increased body 
mass index and heart rate.30 These findings may have been paralleled by 
our own finding in most of the Pompe patients whose blood pressure and 
heart rate were increased, who also had greater aortic stiffness without 
decreased distensibility.
A strength of our study is that we used cfPWV, which is currently the 
gold standard for measuring aortic stiffness directly and non-invasively 
in a relatively large group of Pompe patients. A previous study that found 
increased aortic stiffness in a small group of patients with Pompe disease 
used transthoracic echocardiography, an indirect way of measuring aortic 
stiffness.12 
Our study has some limitations. First, due to physical or temporary 
technical problems, measurements of aortic stiffness were not available 
for all subjects. However, as most of the patient data that were missing in 
the group of Pompe patients were those for the elderly and more severely 
affected patients, this would probably have led to an underestimation of 
the real difference in aortic stiffness between Pompe patients and healthy 
volunteers. Second, as this was a cross-sectional study, we do not know 
about the progression of aortic stiffness over time, or about the effects of 
ERT on aortic stiffness. Additionally, rather than measuring glucose or 
cholesterol in blood samples, we used a questionnaire to establish whether 
patients had a history of hypercholesterolemia or diabetes mellitus.
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In conclusion, patients with non-classic Pompe disease have increased 
aortic stiffness and blood pressure. To reduce the potential risk of cardio-
vascular diseases, we recommend that blood pressure and other common 
cardiovascular risk factors are monitored closely. Prospective studies 
should investigate whether ERT reduces aortic stiffness, or whether early 
treatment even prevents it.
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abstract
Introduction Pompe disease is a proximal myopathy. We investigated 
whether exercise training is a safe and useful adjuvant therapy for adult 
Pompe patients, receiving enzyme replacement therapy.
Methods Training comprised 36 sessions of standardized aerobic, resis-
tance and core stability exercises over 12 weeks. Before and after the train-
ing program, the primary outcome measures safety, endurance (aerobic 
exercise capacity and distance walked on the 6 min walk test) and muscle 
strength, and secondary outcome measures core stability, muscle function 
and body composition, were evaluated.
Results Of 25 patients enrolled, 23 successfully completed the train-
ing. Improvements in endurance were shown by increases in maximum 
workload capacity (110 W before to 122 W after training, [95% CI of the 
difference 6.0 to 19.7]), maximal oxygen uptake capacity (69.4% and 75.9% 
of normal, [2.5 to 10.4]), and maximum walking distance (6 min walk test: 
492 meters and 508, [−4.4 to 27.7] ). There were increases in muscle strength 
of the hip flexors (156.4 N to 180.7 N [1.6 to 13.6) and shoulder abductors 
(143.1 N to 150.7 N [13.2 to 35.2]). As an important finding in secondary 
outcome measures the number of patients who were able to perform the 
core stability exercises rose, as did the core stability balancing time (p<0.05, 
for all four exercises). Functional tests showed small reductions in the time 
needed to climb four steps (2.4 sec to 2.1, [−0.54 to −0.04 ]) and rise to 
standing position (5.8 sec to 4.8, [−2.0 to 0.0]), while time to run, the quick 
motor function test results and body composition remained unchanged. 
Conclusions: Our study shows that a combination of aerobic, strength 
and core stability exercises is feasible, safe and beneficial to adults with 
Pompe disease.
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introduction
Pompe disease (glycogen storage disease type II, acid maltase deficiency) 
(OMIM # 232300) is a rare metabolic myopathy caused by glycogen ac-
cumulation resulting from deficiency of lysosomal acid α-glucosidase 
(GAA). It presents as a wide clinical spectrum, the most prominent symp-
toms in adults being proximal skeletal muscle weakness and respiratory 
problems.1,2 Skeletal muscle weakness typically fits a pattern of limb girdle 
myopathy, with the abdominal and paraspinal muscles and the muscula-
ture of the hip being the most affected muscle groups.3–5 
Enzyme replacement therapy (ERT) with recombinant human acid 
α-glucosidase (Myozyme/Lumizyme) was approved for the treatment of 
Pompe disease in 2006. In adults, ERT has been shown to elicit positive 
effects on skeletal muscle strength, walking distance, respiratory function 
and survival.6– 8 Patients’ fitness and physical functioning may be further 
supported by treatments additional to ERT, such as exercise training. Al-
though some recent studies suggest that exercise training may be beneficial, 
evidence is still limited.[9, 10] 
A recent study on common clinical practice in the Netherlands showed 
that there is a lack of uniformity in the type of physical therapy training 
programs applied, and that physical therapists and patients all seek guid-
ance and standardization.11 We therefore aimed to determine whether a 
standardized and well structured exercise intervention program combin-
ing aerobic, resistance and core stability exercises was feasible and safe, 
and whether it added value to treatment with ERT alone. In a group of 
relatively mildly affected adult Pompe patients receiving ERT for more 
than a year, we evaluated the effects of such a regime on endurance, muscle 
strength and function, core stability, and body composition. 
methods
Patients 
Patients were recruited at the Centre for Lysosomal and Metabolic Diseases, 
Erasmus MC University Medical Centre, Rotterdam, the Dutch national 
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referral centre for patients with Pompe disease. There were three inclusion 
criteria:
1. A confirmed diagnosis of Pompe disease measured by decreased GAA 
activity in leukocytes or fibroblasts, and mutation analysis;
2. Age > 17 years;
3. Treatment with ERT for at least 52 weeks  
There were four exclusion criteria:
1. The use of walking aids or a wheelchair;
2. Ventilator dependency;
3. Concurrent medical conditions;
4. Participation in other exercise-training programs.
The study was approved by the Ethical Committee at Erasmus MC Uni-
versity Medical Centre. Informed consent was obtained from all patients.
study design and intervention
Three times a week for 12 weeks, all patients followed a standardized 
training program that was provided under the supervision of physical 
therapists at carefully selected sports or fitness centres near the patients’ 
homes. To ensure the uniformity of the program and its supervision, all 
therapists attended a one-day instruction program at Erasmus MC Uni-
versity Medical Centre. The training program is depicted in Fig. 1. The 
first training session was on-site supervised by one of the researchers from 
Erasmus MC (LvdB, MF), who subsequently attended each training site 
every two weeks to monitor proper conduct of the program. 
Patients were randomly subdivided into two groups: group 1 (n  = 13), 
which started the training program at week 1; and group 2 (n  = 12), which 
started at week 13. The staggered start of training allowed us to investigate 
whether any improvement observed in the training period could also be 
attributed to ERT. Furthermore, the duration of the effect of the training 
program can be evaluated from the follow-up of patients in group 1 after 
they stop training in week 12.
To assess the effects of the program, each patient visited our centre (Eras-
mus MC) on two separate days in weeks 0, 12 and 24. The primary end-
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Side
Bridge
Warm-up
Duration: 5 minutes
Intensity: HR 100-110 BPM
Strength Training
Initial weight: 70% of 4 RM
Nr. sets: 3
Nr. repeats: 15-20
Adjustment of weight: ↓ if 1 set <15 repeats
↑ if 3 sets >20 repeats
Endurance Training
Duration: 15 minutes
Intensity: HR corresponding 
60% VO2 MAX
Core Stability Training
Nr. sets: 3
Duration  per set: 30 sec
Adjustment of intensity: ↓ if 1 set <30 sec
↑ if 3 sets >30 sec
Cooling-Down
Duration: 5 minutes
Intensity: HR 100-110 BPM
Endurance Training
Duration: 15 minutes
Intensity: HR corresponding 
60% VO2 MAX
Seated Row Chest Press Biceps Curl
Leg Press Leg Curl
Hip 
Abduction
Hip 
Adduction
Abdominal
Bridge
Back
Bridge
Figure 1  flowchart for the standardized exercise-training regime combining aerobic, resistance 
and core stability exercises 
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points of this study were safety, endurance and muscle strength. Secondary 
endpoints were core stability, muscle function, and body composition.
Under the supervision of the physical therapist, training diaries were 
kept by all patients, who recorded the days on which they trained, the 
weight and number of repeats of resistance exercises, and the perceived 
level of exertion. To evaluate training progress and patients’ motivation, 
patients were telephoned weekly.
assessments
Safety: Plasma CK was measured every two weeks as a safety marker for 
exercise-induced muscle damage.12 and patients were contacted every 
week to record potential side effects such as pain and fatigue.
Endurance: Aerobic (endurance) exercise capacity was determined using 
an incremental cycle ergometer. After 4 min of unloaded cycling on the 
cycloergometer (Jaeger ER 800; Erich Jaeger, Würzburg Germany) exercise 
intensity was increased progressively until exhaustion (i.e. ramp protocol), 
during continuous measurement of patients’ heart rates and ventilator pa-
rameters using spiroergometry equipment (Oxycon Pro, Jaeger, Würzburg, 
Germany). The rate of increase was determined considering the patient’ s 
functional capacities and ranged from 5– 20 Watts/minute. The duration 
of every individual test exceeded 6 min but did not take longer than 12 
min. At exhaustion, the rating of exertional symptoms was assessed using 
the Borg scale (scale 6– 20).13 Maximum workload capacity (WMAX) and 
peak oxygen uptake capacity (VO2 PEAK) were measured. The ventila-
tory threshold (VT) was assessed independently by two clinical exercise 
physiologists using the ventilatory equivalents method.14 The test was 
considered to be maximal when one of the following criteria was met:
1. heart rate > 90 % of that predicted,
2. respiratory exchange ratio (RER) > 1.11, or
3. VO2  stabilized despite increased workload.
Walking distance on the 6-min walk test (6MWT) was evaluated accord-
ing to the American Thoracic Society guidelines.
Core Stability: To assess the dynamic balance, which reflects core stabil-
ity, one physical therapist (MF) measured time in balance (in seconds) for 
each of the four core stability exercises of the training program (Fig. 1).15
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Muscle strength: Muscle strength was assessed by one investigator (SW) 
using Hand-held Dynamometry (HHD). Assessments were performed in a 
standardized manner, and sum scores were calculated as described previ-
ously.6
Muscle Function: Functional activity assessments comprised three timed 
tests: 10 meter running, climbing four steps, and rising from supine to 
standing positions16 and the Quick Motor Function Test (QMFT), a test spe-
cifically designed and validated for Pompe patients.17 The QMFT consists 
of 16 specific motor skills related to daily activities. A total score is achieved 
by summing the scores for each item (ranging from 0 “cannot perform” to 
4 “can perform with no effort”), and is expressed as a percentage of the 
maximum score.
Body composition: Bone-mineral density (BMD) and body-composition 
measurements were performed conform DXA technology using a Lunar 
DPX densitometer and analyzed with Encore 2002 software (GE Lunar 
DPX, GE Health Care). Bone densitometry was performed in a standard-
ized manner as described previously.18 Body composition was described in 
terms of the mineral, lean and fat body mass (kilograms). The percentage 
of fat mass and, more specifically, android and gynoid fat, were calculated.
statistical analysis
Patient characteristics were summarized using descriptive statistics. Data 
for the two groups were combined after verifying that there were no 
significant differences between outcome measures before the start of the 
training (group 1 – week 0; group 2 – week 12; student’s t-test for normally 
distributed, and Mann–Whitney for not normally distributed data). Mean 
differences before and after the training were compared using the paired t-
test for normally distributed data, and otherwise the Wilcoxon signed rank 
test for paired samples. For group 2, we also used these tests to compare 
the outcome measures before and after 12 weeks of ERT only (week 0 to 12). 
Significance level was set at p<0.05. Statistical analyses were performed 
using SPSS for Windows (release 17.0; SPSS, Inc., Chicago, IL).
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results
Patients
A total of 25 patients fulfilled the inclusion criteria to participate in this 
study. Two patients did not complete the training program because they 
were insufficiently motivated. This left 23 patients, who successfully 
completed the study. Their ages ranged from 20 to 71 years (median of 46 
years). They had been receiving ERT for 1 to 6 years with a median of 3 
years (Table 1).
effect of ert only
During the 12 weeks before training started, patients in group 2 (ERT only) 
underwent the same set of assessments as in the 12 weeks of training (ERT 
plus training). This enabled us to use group 2 to compare the effects of ERT 
only with the combined effects of ERT and training. During the first 12 
weeks of ERT only, we detected no significant improvements in the main 
outcome measures.
effect of training
Patients in the two randomly assigned groups were comparable in terms 
of age, gender, disease duration, time on ERT, number of training sessions 
completed, and baseline test results. This allowed us to analyse the effect 
of training in the total group of 23 patients.
Table 1  Patient characteristics
Group 1
(n=12)
Group 2
(n=11)
Total group
(n=23) p-value*
Male gender (%) 7 (58%) 5 (45%) 12 (52%) 0.54
Age in years (range) 45.4 (19.6-70.5) 46.6 (32.9-66.1) 46.0 (19.6-70.5) 0.85
Disease duration in years (range) 15.5 (8.1-28.1) 16.1 (6.0-32.1) 15.8 (6.0-32.1) 0.83
ERT duration in years (range) 3.3 (1.4-6.5) 3.0 (1.3-3.6) 3.1 (1.3-6.5) 0.96
Training sessions (max. 36) 33 (27-36) 32 (24-35) 32  (24-36) 0.70
ERT = enzyme replacement therapy
Group 1 trained in weeks 1-12 and group 2 trained in weeks 13-24
*For the difference between group 1 and 2 (chi-2 test for proportions and Wilcoxon signed rank 
test for continuous data)  
147
Safety and efficacy of exercise training in adults with Pompe disease
8
Safety: During the first week of training, two patients had a high plasma 
CK level (10125 U/l and 6149 U/l), and also experienced muscle pain and 
fatigue. Over the following week, their CK-values dropped to their normal 
range, and the fatigue and pain disappeared. Both patients continued train-
ing. None of the other patients had pain, fatigue, or increases in plasma CK 
levels during the study period.
Endurance: All patients were able to complete the incremental cycle 
test without adverse events. One was excluded from the analysis because 
he did not reach the required maximum intensity defined in the method 
section. After 12 weeks of training WMAX, VO2peak and VT improved 
significantly (Table 2). VO2peak and VT increased both in absolute values 
and adjusted for body weight or as a percentage of normal values. The 
Table 2 aerobic fitness measured in an incremental cycle test and a 6-min walk test before and 
after 12 weeks of training
 Before training After training p-value**
 Mean ± SD Mean ± SD  
Incremental cycle test (N=22*)
   Ventilatory threshold (VT) 
•	 Absolute values (l/min) 1.25 ± 0.36 1.38 ± 0.36 <0.01
•	 Adjusted for body weight (ml/min/kg) 16.7± 4.3 18.5 ± 4.7 <0.01
•	 VT/VO2 peak (%) 77.6 ± 12.1 78.3 ± 12.3 0.742
   Data at exhaustion
•	 Maximum workload (Wmax, Watt) 110 ± 52 122 ± 53 <0.01
•	 Maximum heart rate (bpm) 156 ± 25 161 ± 20 0.16
•	 Pulmonary ventilation (l/min) 59.6 ± 20.2 68.2 ± 21.0 <0.01
•	 Tidal volume (l) 1.85± 0.48 1.85± 0.44 0.91
•	 Gas exchange ratio 1.15± 0.09 1.14± 0.08 0.71
   Peak oxygen uptake (VO2 peak)
•	 Absolute values(l/min) 1.67 ± 0.62 1.82 ± 0.60 <0.01
•	 Adjusted for body weight (ml/min/kg) 22.1 ± 7.0 24.1 ± 7.1 <0.01
•	 As % of normal 69.4 ± 17.4 75.9 ± 18.0 <0.01
6-min walk test (N=22)
Maximum walking distance (6MWT, m) 492 ± 89 508 ± 97 0.01
Pulmonary function test (N=23)
Forced vital capacity (FVC, % of normal) 89.2 ± 12.6 90.0 ± 14.0 0.51
* One patient was excluded because he did not reach the required maximum intensity
** For the difference before and after training (paired samples t-test)
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ratio VT/VO2peak did not change, as both the numerator and the denomi-
nator increased. There were no significant differences between patients’ 
maximum heart rates before and after 12 weeks of training, indicating that 
the results were truly based on an increase in fitness rather than on greater 
exertions by the patients towards the end of the training period. FVC did 
not change. Average walking distance on the 6MWT increased by 16 meters 
([4.4-27.7], p=0.01). 
Core stability: Figure 2 shows the results of the core stability tests. At the 
start of the program, many patients experienced difficulties in performing 
the core stability exercises, reporting problems with initiating movement 
and controlling balance. During the training program, the number of pa-
tients who were able to perform the exercises increased for three of the four 
exercises (from 17 to 21 for the abdominal bridge, 15 to 16 for the left side 
bridge and 13 to 16 for the right side bridge). The average time they were 
able to remain in balance improved for all four positions (by 58% for the 
back bridge, 229% for the left and 223% for the right side bridges, and 86% 
for the abdominal bridge; p<0.05). 
Figure 2  effects of training on core stability tests
Time patients (N=23) were able to remain in balance for the four different core stability exercises 
before (white bars) and after training (black bars).
149
Safety and efficacy of exercise training in adults with Pompe disease
8
Muscle strength: Of the nine muscle groups tested, there were increases 
in the strength of the hip flexors and shoulder abductors (Table 3).
Muscle function: Twelve weeks of training significantly reduced the time 
taken by patients to climb four steps (on average 0.3 sec less, [−0.54 to 
−0.04], p=0.02 Table 4) and to rise from supine to a standing position (1 sec 
less, [−2.0 to 0.01], p=0.05). The QMFT sum score and the time to run 10 
meters did not change. 
Body composition: There were no changes in mineral bone mass (2.83 
kg ± 0.58 before training vs. 2.82 kg ± 0.57 after training), in lean body 
Table 3  muscle strength measured by hand-held dynamometry (hhd) before and after 12 
weeks of training
Before training
Mean ± SD
After training
Mean ± SD p-value*
HHD of individual muscle groups (Newton) (N=23)
•	 Neck extensors 142.1±18.4 140.4±13.8 0.65 
•	 Neck flexors 124.7±40.2 132.1±33.9 0.09 
•	 Shoulder abductors 143.1±29.1 150.7±35.4 0.02 
•	 Elbow flexors 226.4±41.5 230.8±42.3 0.42 
•	 Elbow extensors 180.5±20.1 176.2±25.3 0.27 
•	 Hip flexors 156.4±61.9 180.7±57.7 <0.01 
•	 Hip abductors 159.4±58.3 158.0±68.1 0.75 
•	 Knee extensors 189.2±34.1 193.0±31.8 0.27 
•	 Knee flexors 121.2±57.2 122.6±56.7 0.51
* For the difference before and after training (paired samples t-test and the Wilcoxon signed-ranks 
test for paired data)
Table 4  muscle function measured by the quantitative motor function test (Qmft) and timed 
tests before and after 12 weeks of training
Before training
Mean ± SD
After training
Mean ± SD p-value*
QMFT score (N=22**) 51 ± 8 51 ± 9 0.65
Timed Tests (N=22**)
- 10 m running (sec) 4.97 ± 1.50 4.70 ± 1.34 0.16
- Climbing four steps (sec)‡ 2.37 ± 0.80 2.08 ± 0.74 0.02
- Rising from supine to standing 
position (sec)‡
5.83 ± 4.25 4.83 ± 2.38 0.05
*For the difference before and after training (paired samples t-test and the Wilcoxon signed-ranks 
test for paired data‡)
** QMFT score and timed test were not available for one patient
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mass (42.53 kg ± 7.99 vs. 43.14 kg ± 8.28), or in fat mass (30.11 kg ± 9.23 vs. 
29.29 kg ± 9.06). Likewise, there were no changes in bone mineral density, 
overall fat percentage, and android and gynoid fat percentages (results not 
shown). 
duration of training effect
After the initial 12 weeks of training group 1 was planned to discontinue 
training, but 11 of 13 patients chose to continue training with the same or 
slightly modified intensity. Therefore we were not able to assess how long 
the training effect maintained after withdrawal.
discussion
This study provides clinical evidence that a combination of aerobic, resis-
tance and core stability training can be performed safely in patients with 
Pompe disease, and helps to improve endurance, core stability and muscle 
function.
Improved endurance was shown by improved aerobic fitness over 12 
weeks of training. In addition to the 11% increase in maximum workload 
capacity, peak oxygen uptake and ventilatory threshold improved by 
9% and 10%, and the 6MWT by 3%. The increase in peak oxygen uptake 
was relatively small compared to a number of studies in neuromuscular 
dystrophies and metabolic myopathies like McArdle disease, showing an 
increase ranging from 12-47 %.19–22 In these studies, patients spent more 
time per week on endurance training, which might explain the larger in-
crease. A second explanation might be the lower baseline VO2peak than in 
our study. 
The baseline values on VO2peak we found in our study were slightly 
higher than those reported in two Italian studies of Pompe patients (range 
15.1 – 26.4 ml/kg/min).23, 24 These include 8 patients who were assessed 
prior to treatment (median 20.5 mg/kg/min), and one patient assessed 
during ERT (15.7 mg/kg/min), while all our patients had been on ERT 
for at least a year, which might explain the somewhat higher VO2peak 
values in our cohort. Nevertheless, our 6MWT results also suggest that our 
151
Safety and efficacy of exercise training in adults with Pompe disease
8
cohort had a relatively good endurance capacity before the training (77% of 
normal expected). Finally, their ventilator threshold as a percentage of the 
peak oxygen uptake (78%) is relatively high for an untrained population, 
and comparable to that seen in the three Italian patients that reached the 
VT (five did not reach the VT in this study, while all our patients reached 
VT). Our patients thus had relatively good endurance and tolerance capac-
ity before training, which is in agreement with the fact that mildly affected 
Pompe patients were selected for this study. 
So far the 6MWT was used in clinical trials for Pompe disease to assess 
endurance capacity, but since most patients have walking difficulties it 
has been questioned whether the 6MWT fully reflects this.25, 26 Our study 
indicates that the incremental cycle test offers a good alternative to test 
endurance capacity, providing insight into patients’ aerobic capacity. 
Core stability has not been trained previously in neuromuscular disorders 
presenting with limb girdle weakness. One possible reason may lie in the 
assumption that core stability exercises are not feasible for such patients. 
Indeed, on starting training, many patients had difficulty performing the 
exercises. During the program, however, they learned to activate the proper 
muscle groups and were able to remain in balance for longer. Our results 
thus indicate that core stability training is feasible and improves time in 
balance in patients with Pompe disease who are treated with ERT. Feed-
back from patients during the training also suggests that they perceived 
their improved core stability to facilitate daily activities. Further studies on 
how training influences patient reported outcomes such as quality of life 
are needed.
An increase in muscle strength was observed in two of the nine muscle 
groups tested: the hip flexors and shoulder abductors. We are not com-
pletely certain whether the increased strength of the hip flexors resulted 
from strength training, core stability exercises, or both. Core stability may 
support gains in muscle strength by improving proprioception and coor-
dination. 
The combined effects of the training program on endurance, core stabil-
ity, and muscle strength also led to some functional improvement, with 
patients becoming able to climb four stairs and rise to a standing position 
faster.
Chapter 8
152
In our study all patients received ERT. It has been reported that the main 
incremental effects of ERT are observed during the first year. Therefore 
only patients who had received ERT more than 1 year were allowed to par-
ticipate. The study had a staggered design with patients in group 2 starting 
after a period of no training allowing evaluation of the effect of ERT only, 
and patients in group 1 scheduled to stop training after 12 weeks with the 
intention to study how long the effect of training continued. During ERT 
only patients remained more or less stable indicating that training was the 
main driver behind the effects. We were not able to assess how long the 
training effect continued, since all patients in group 1, except two, chose to 
continue training after 12 weeks. Although patients’ choice interfered with 
our study design, it also reflects the positive feedback they have given us 
on the program. 
Compliance was high in our study. It is likely that the beneficial effects 
experienced, the supervision by physiotherapists and weekly telephone 
consultations contributed to this. We therefore recommend that the pro-
gram be incorporated into regular supervised physiotherapy sessions. 
Few studies have been conducted on exercise and training in Pompe dis-
ease. The largest so far was performed before ERT became available.9 For a 
mean duration of four years, 26 patients participated in a combined nutri-
tion and endurance exercise therapy program that led to improved muscle 
function as measured with the Walton score. More recently, a German 
observational study showed that the effect of ERT on walking distance was 
most pronounced in five patients who, incidentally, were also subjected to 
endurance training on a cycle ergometer during ERT infusions.10 Two other 
studies, one in mice and one in five adult patients with Pompe disease, 
however, did not confirm a beneficial effect of endurance training while 
receiving ERT.27, 28 
Previous exercise studies in Pompe disease mainly focused on endur-
ance training. It has been envisaged that resistance training might lead to 
muscle damage, thereby aggravating muscle weakness.29– 31 Prior to our 
study, only Terzis et al. combined endurance with resistance training in 
five patients with Pompe disease receiving ERT. The combined results of 
these five patients showed that both muscular strength and walking dis-
tance improved.28 
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Before starting our study we carefully considered whether we should 
perform exercise-endurance training only, or a combination of different 
types of exercises. We chose the latter, because we not only wanted to im-
prove endurance, but also target all affected muscles (resistance exercises), 
and ameliorate proprioception and the strength of those proximal muscles 
not targeted by resistance training (core stability exercises). Our decision 
to use a combined program was also driven by the fact that our patient 
population was not large enough to run three separate programs. 
Although we cannot rule out the possibility that endurance training 
alone might have had a greater impact on endurance, we observed that 
the extra exercises had positive effects on core stability, and may also have 
improved muscle strength and function. Earlier studies in patients with 
inherited muscular myopathies did not include core stability exercises; 
our study shows them to be both safe and easy to learn. Patients in our 
study were mildly affected; those who are more severely affected may need 
slightly adjusted exercise-training programs but we recommend including 
similar components.
conclusions
Our study shows that a combination of endurance, strength and core 
stability training is feasible and can be performed safely in patients with 
Pompe disease. Such training helps to improve endurance, muscle strength, 
muscle function and core stability. This training program thus seems to 
offer added value for Pompe patients to those of ERT.
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general discussion
During the last decade major developments have been made in treating 
rare genetic diseases, in particular lysosomal storage and muscular disor-
ders. Pompe disease was the first treatable inheritable muscle disorder, and 
Erasmus MC played a major role in the development of this therapy. The 
first clinical trials with recombinant human acid α-glucosidase (rhGAA) in 
Pompe disease started in 1999. In 2006 the EMA and FDA approved enzyme 
replacement therapy (ERT) with rhGAA (Myozyme®, Genzyme), changing 
the perspectives of patients with Pompe disease. In the Netherlands, all 
patients are followed and treated at the ‘Center of Lysosomal and Meta-
bolic Diseases’ at Erasmus MC University Medical Center, which provides 
a unique opportunity to study Pompe disease in a relatively large group of 
patients. Previous studies described the natural course of Pompe disease, 
the development of ERT and the effects of ERT in Dutch Pompe patients. 
The primary aims of this thesis were 1) to study genotype-phenotype 
correlations in patients with non-classic Pompe disease, 2) to investigate 
respiratory functioning in Pompe patients by performing dynamic MRI of 
the diaphragm, and 3) to examine arterial stiffness using carotid-femoral 
pulse wave velocity (cfPWV) in Pompe disease. The secondary aims were 
1) to determine whether increased plasma cardiac troponin T (cTnT) levels 
in Pompe patients indicate cardiac involvement or skeletal muscle damage, 
and 2) to study the effects of exercise training in mildly affected patients 
being treated with ERT. This general discussion summarizes the main find-
ings of our studies and future perspectives are discussed. 
MAIN FINDINGS
- Siblings with Pompe disease often share a similar phenotype, how-
ever, within some families the course and severity of the disease 
varies substantially, indicating that other genetic and environmen-
tal factors play a role in determining the phenotype;
- Lung MRI, which is an innovative technique to visualize diaphrag-
matic dynamics, shows severely impaired diaphragmatic function 
in adult patients with Pompe disease;
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genotyPe-PhenotyPe correlation
In Pompe disease the phenotype is mainly determined by the GAA 
genotype. In general, a combination of two severe mutations results in 
a complete enzyme deficiency causing the classic infantile phenotype.1-3 
Patients with onset of symptoms in childhood or adulthood usually have 
one severe mutation and one less severe mutation, resulting in some re-
sidual enzyme activity.3, 4 Until today more than 400 mutations have been 
described and a list is being tracked at www.pompecenter.nl. In this list 
the effect of a single mutation on the patients’ phenotype is described, 
including a link to the reference. The most frequent detected mutation in 
patients with non-classic Pompe disease is c.-32-13T>G, which is a ‘leaky 
splice’ mutation leading to variable skipping and inclusion of exon 2. This 
results in 5-25% of structurally and functionally normal acid α-glucosidase 
(GAA).4, 5 In patients with non-classic Pompe disease there can be a large 
variation in phenotype despite sharing the same GAA genotype; the age 
of onset of symptoms is variable, as well as the nature of first symptoms 
and the course of the disease.5, 6 Since siblings share the same set of GAA 
mutations and are genetically more related than non-relatives, we expected 
to find less variation in phenotype in sibships with Pompe disease; i.e. the 
age of symptom onset, the course of the disease, presenting symptoms and 
some specific symptoms. In chapter 2 we described that affected siblings in 
families with Pompe disease all developed symptoms either in childhood 
or in adulthood; siblings often had similar presenting symptoms (in 70% 
- Patients with Pompe disease have an increased arterial stiffness 
and blood pressure, which probably results in an increased risk for 
cardiovascular diseases;
- Elevated plasma cTnT levels in patients with Pompe disease are 
associated with skeletal muscle damage rather than myocardial 
damage;
- Exercise training is safe and improves endurance, core stability and 
physical functioning in mildly affected Pompe patients.
161
General discussion
9
of families); and siblings shared the occurrence of specific features such 
as ptosis and bulbar weakness. However, in some families a clear pheno-
typical variation was observed regarding the course and severity of the 
disease. Since these patients share the same GAA genotype, others factors 
must explain the differences between these patients, such as epigenetic 
and environmental effects. Genetic confounding factors may be found in 
genes related to composition and function of muscle fibers. It is known 
that polymorphisms in the ACE-gene can influence fiber type composition, 
biomechanical muscle properties and sport performances in humans.7-9 
Moreover, in other glycogen storage diseases such as McArdle disease it 
was shown that ACE-polymorphisms can affect the phenotype.10, 11 Another 
gene polymorphism that is associated with muscle damage after extreme 
performances and to muscle function decline with age, is the ACTN3 null 
polymorphism (XX genotype).12, 13 Both these polymorphisms have been 
reported to modify the phenotype in patients with Pompe disease sharing 
the same GAA genotype.14-16 It was demonstrated in two relatively large 
groups (n=38 and 85) of patients with Pompe disease, that an earlier and 
more severe clinical picture is associated with the deletion/deletion (DD) 
genotype in the ACE-gene and the ACTN3 null polymorphism.14, 16 In ad-
dition, it was published that Pompe patients with the DD genotype had a 
poor treatment outcome compared to patients with other ACE polymor-
phisms.15 However, this was studied in a small group of patients (n=16). 
Besides differences in gene polymorphisms, environmental factors might 
also modify the clinical course; e.g. high-protein and low-carbohydrate 
nutrition and exercise training have been reported to slow down deteriora-
tion of muscle function in adult patients with Pompe disease.17 To know 
whether these environmental factors and polymorphisms play a role in 
phenotypical variation in patients and siblings with Pompe disease, stud-
ies in larger groups of patients are needed. 
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imaging and laboratory diagnostics
lung mri
Pulmonary dysfunction caused by progressive weakness of the respiratory 
muscles is a characteristic feature of Pompe disease, particularly in supine 
position.3, 18, 19 It has been shown that in the majority of patients forced vital 
capacity (FVC) in sitting position stabilized, while FVC in supine position 
deteriorated in 35% of patients despite initiating ERT.20, 21 In general, pul-
monary function tests are being used to monitor different parameters such 
as FVC in sitting and supine position, postural drop (i.e. the difference 
between FVC in sitting and supine position expressed in percentages) and 
maximum static inspiratory (MIP) and expiratory (MEP) pressures. Pos-
tural drop and MIP are considered to represent diaphragmatic weakness, 
which is thought to be the major cause of respiratory dysfunction in Pompe 
disease.19, 22 However, these parameters provide too little insight into the 
individual contribution of the diaphragm and thoracic musculature to 
respiratory dysfunction in Pompe disease. In chapter 5 we showed that 
lung MRI is an innovative tool to visualize diaphragmatic and chest-wall 
movements directly and in more detail. We observed severe dysfunction 
of the diaphragm in adult patients with Pompe disease. In some patients 
there was hardly any displacement of the diaphragm, while the thoracic 
musculature was far less affected. Similar results were recently found in a 
group of 11 Pompe patients.23 However, in this study only the right lung 
was evaluated in maximum inspiration and expiration, and spirometry was 
not used during the MRI. Lung MRI might be useful to monitor changes 
in diaphragmatic movements in response to ERT, and therefore be helpful 
to identify responders and non-responders. Moreover, it can also be use-
ful in patients who have no or mild limb girdle weakness to evaluate the 
presence of diaphragmatic weakness, so ERT can be initiated in the early 
state of the disease before irreversible respiratory muscle dysfunction has 
occurred. Respiratory insufficiency is even reported as first symptom in a 
small percentage of patients with non-classic Pompe disease, which em-
phasizes the importance of monitoring pulmonary function properly.19, 24-26 
This year an extended study will start at our center using lung MRI in a 
larger group of adult Pompe patients, including both static and dynamic 
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3D MR images. This latter technique was recently studied as an extension 
of our MRI study and showed that diaphragm weakness and ribcage 
expansion can be studied even more accurately. This study showed that 
Pompe patients could compensate diaphragmatic weakness by increasing 
chest-wall movements in the early stages of the disease. As a result, in some 
patients standard pulmonary function tests were relatively normal, while 
MRI already showed decreased displacement of the diaphragm [Mogalle 
et al. submitted]. In our extended study we will not only use lung MRI to 
examine the diaphragm, but we also include ultrasound to measure dia-
phragm thickness at maximum inspiration and expiration. The advantage 
of ultrasound above MRI is that this technique is inexpensive, more widely 
available and can be performed at bedside. In addition, the function as well 
as the structure of the diaphragm can be visualized which is difficult with 
MRI.27, 28 Possible disadvantages of ultrasound compared to MRI are that 
there might be more interobserver variability, only a small part of the dia-
phragm can be visualized, and chest-wall movements cannot be measured. 
To date, there is no clear explanation why FVC in supine position, 
representing diaphragmatic functioning, deteriorates during ERT in a sub-
stantial proportion of patients with the non-classic form of Pompe disease. 
We suggest several hypotheses for this finding. First, the diaphragm in 
patients with Pompe disease might have lost regenerative capacity because 
it is already early affected in the course of the disease. Loss of regenerative 
capacity of the diaphragm could be the result of impaired satellite cell dif-
ferentiation, which was recently described in skeletal muscle of patients 
with Pompe disease and in patients with other myopathies.29, 30 Second, 
the diaphragm in humans might have lower concentrations of mannose 
6-phosphate receptors compared to skeletal muscle, reducing the uptake 
of the enzyme administered during ERT. However, in mice it was shown 
that the diaphragm had more M6PR and responded better to therapy than 
skeletal muscles.31 Third, there might be a shift from fast type II muscle 
fibres to slow type I fibres during the course of the disease, leading to less 
muscle strength of the diaphragm. This process was described in patients 
with COPD, in whom there is an increase in oxidative enzymes and a de-
crease in glycolytic activity, leading to muscle damage and replacement of 
muscle by connective tissue.32, 33 Fourth, there might be an increased failure 
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of productive autophagy in the diaphragm compared to skeletal muscle, 
making ERT less efficient. Autophagy is a regulated process in which cy-
toplasmatic components such as toxic proteins and damaged organelles 
are removed to keep muscle homeostasis. When this process is impaired, 
the autophagic buildup interrupts the architecture of muscle fibers, result-
ing in muscle weakness.34, 35 Autophagic debris has been found in skeletal 
muscle fibers of patients with Pompe disease.36-38 Another hypothesis is 
that the diaphragmatic weakness is not only caused by glycogen accumu-
lation in the muscles of the diaphragm, but also by glycogen accumulation 
in the anterior horn neurons of the spinal cord.39, 40 Since ERT does not cross 
the blood-brain-barrier, it cannot correct pathology in the central nervous 
system (CNS).41 Glycogen accumulation has been demonstrated in the CNS 
of patients with classic infantile Pompe disease, but it is assumed that the 
residual GAA activity of 5-25% in patients with non-classic Pompe disease 
is sufficient to prevent glycogen storage in the CNS. To investigate whether 
the previously mentioned hypotheses are correct, histopathological studies 
of the diaphragm are required. However, taking a biopsy of the diaphragm 
is a high-risk intervention and we did not have the possibility yet to study 
the diaphragm of deceased Pompe patients in our cohort. In literature 
there are only few autopsy reports of patients with Pompe disease. In 
three of these reports the diaphragm was examined post-mortem and 
revealed severe glycogen accumulation in skeletal myocytes. In addition, 
the Schwann cells of small nerves within the diaphragm showed moderate 
glycogen accumulation.42-44
Many Pompe patients require assisted ventilation because ERT has lim-
ited effect on the pulmonary function in supine position. Therefore, alter-
native therapies could be beneficial for these patients such as diaphragm 
pacing, local gene therapy using hematopoietic stem cell transplantation 
(HSCT) and the use of induced pluripotent stem (iPS) cells.45-47 Diaphragm 
pacing has been studied in patients with amyotrophic lateral sclerosis 
(ALS) and in patients with spinal cord injuries.45 Although it was thought 
to be a promising technique, a recent publication showed that addition 
of diaphragm pacing to standard care with non-invasive ventilation was 
associated with decreased survival in patients with ALS.48 Currently, an 
observational study is recruiting patients with Pompe disease to examine 
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the response to diaphragm pacing (www.clinicaltrials.gov: NCT02354651). 
The use of HSCT and iPS cells showed to be effective in mice with Pompe 
disease. HSCT using lentiviral vectors resulted in obvious glycogen 
clearance in several tissues, improving respiratory function and skeletal 
muscle strength.46, 49, 50 In another study direct delivery of the recombinant 
adeno-associated virus GAA gene into the diaphragm of mice increased 
respiratory function.51 At this moment, a Phase I/II safety study with 
adeno-associated virus-mediated GAA gene therapy is being performed 
in ventilator dependent children with Pompe disease (www.clinicaltrials.
gov: NCT00976352). In these patients the recombinant adeno-associated 
virus-mediated GAA gene is delivered into the diaphragm. The first results 
of this trial indicate that the treatment was safe and may modestly improve 
ventilatory performance measures; i.e. increased tidal volumes and longer 
periods of unassisted breathing.52 One of the latest developments is the use 
of iPS cells in Pompe disease. These cells can theoretically differentiate into 
any type of cell in the body.  In one study iPS cells were generated from fi-
broblasts of mice with Pompe disease and subsequently differentiated into 
skeletal muscle cells.47 Future studies need to show whether these invasive 
therapies are safe, effective and could be used in clinical practice in patients 
with Pompe disease. Lung MRI in combination with spirometry could be 
used to monitor the effects of these therapies on pulmonary function. A 
non-invasive therapy that could be useful is respiratory muscle strength 
training. This type of training has the potential to increase inspiratory and 
expiratory muscle strength.53, 54 However, it has only been described in case 
reports, not in a larger group of patients with Pompe disease and definitely 
requires further evaluation.  
increased arterial stiffness and plasma ctnt levels
Cardiovascular involvement is a familiar feature in classic infantile Pompe 
disease.1-3 In juvenile and adult Pompe patients this is still a topic of dis-
cussion, however, there are several reports about cardiovascular morbidity 
such as dilated thoracic arteriopathy and the occurrence of cerebral aneu-
rysms.55-58 These observations could be the result of glycogen accumulation 
in vascular smooth muscle fibers.42, 43, 59 Increased aortic stiffness was found 
in 17 patients with non-classic Pompe disease using transthoracic Doppler 
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echocardiography.60 This is a technique to measure aortic stiffness indi-
rectly, while nowadays tonometry of the carotid-femoral pulse wave veloc-
ity (cfPWV) is considered to be the golden standard to directly measure 
arterial stiffness.61 Using cfPWV we studied whether structural changes in 
the arteries of adult Pompe patients result in an increased arterial stiffness. 
We described in chapter 7 that these patients indeed have an increased 
arterial stiffness, which is an indirect risk factor for cardiovascular disease 
and mortality.62, 63 Additionally, Pompe patients had an increased blood 
pressure compared to age and gender-matched volunteers. We assume 
that glycogen accumulation in smooth muscle fibers resulted in increased 
arterial stiffness leading to hypertension, however, we did not examine 
this hypothesis. Other possibilities could be that glycogen accumulation in 
the endothelium damages the vascular wall making it more vulnerable to 
atherosclerosis, or that glycogen accumulation in vascular smooth muscle 
fibers impairs the formation of elastin leading to changes in collagen 
formation as in Fabry disease and mucopolysaccharidosis type 1.64, 65 Our 
findings of increased arterial stiffness and hypertension in Pompe disease 
are important, because as a result of the introduction of ERT Pompe pa-
tients have a prolonged survival, resulting in an increased lifetime risk 
on cardiovascular complications. Therefore, it is important to register 
whether cardiovascular events occur more often than in the past in Pompe 
patients and to treat and monitor other cardiovascular risk factors such 
as hypertension, hypercholesterolemia, diabetes, obesity and smoking. In 
patients with Fabry disease it has been demonstrated that arterial stiffness 
decreased during ERT.65 Whether arterial stiffness decreases in patients 
with Pompe disease during ERT and if cfPWV can be used as a biomarker 
for disease progression or therapy response, requires further investigation.
There are several biomarkers for skeletal muscle damage, such as creatine 
kinase (CK), myoglobulin, lactate dehydrogenase and aminotransferases.66 
Troponin is also a known biomarker of muscular damage, from which vari-
ous subtypes exist that are expressed from closely related genes.66, 67 cTnT is 
an important biomarker in patients with acute myocardial infarction (AMI), 
however, increased plasma cTnT concentrations have also been observed 
in the general population.68, 69 We found increased plasma cTnT levels in 
one of our adult Pompe patients who reported atypical chest pain, while 
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additional cardiac evaluation did not reveal any abnormalities. Generally, 
in patients with non-classic Pompe disease it is considered that there is no 
significant cardiac involvement.70-72 Therefore, the question arose whether 
increased plasma cTnT levels in Pompe patients indicate cardiac involve-
ment or skeletal muscle damage. We demonstrated in chapter 4 that 
plasma cTnT levels were increased in the majority of patients with Pompe 
disease. In the absence of increased cTnI levels, a strong correlation with 
CK levels, normal cardiac evaluation in almost all patients, and RNA and 
protein expression of cTnT in skeletal muscle biopsies taken from Pompe 
patients, we assume that plasma cTnT levels were increased as a result of 
skeletal muscle damage and not due to myocardial damage. Our findings 
are supported by a recent paper which describes that adult Pompe patients 
do not have abnormalities on cardiac MRI.72 In addition, increased cTnT 
levels were also demonstrated in other neuromuscular disorders and it was 
suggested that this is the result of re-expression of fetal isoforms of cTnT 
in regenerating skeletal muscle.73-77 AMI should be diagnosed if a rise and/
or fall of cTnT or cTnI is detected, with at least one value above the 99th 
percentile cutoff value.78 It has been described that cTnI has a higher speci-
ficity for cardiac tissue than cTnT and cTnI has not been found in diseased 
or regenerating skeletal muscle.68, 73, 79 Together with the fact that we found 
normal plasma cTnI levels in all Pompe patients, we suggest determining 
plasma cTnI instead of cTnT levels in patients with Pompe disease and 
other neuromuscular diseases when there is a suspicion of AMI. 
muscle mri
Neuromuscular imaging techniques are helpful tools and they are increas-
ingly being used to create a better understanding of pathophysiological 
processes of neuromuscular diseases, to monitor disease progression and 
to evaluate effects of therapy. These techniques, including CT, ultrasound 
and MRI, provide extra information in addition to the physical examina-
tion. Since CT exposes patients to ionizing radiation and ultrasound is 
too time consuming and does not have the possibility to study multiple 
muscles into detail, MRI has become the preferred neuromuscular imag-
ing technique to use.80-83 Several studies demonstrated that muscle MRI is 
useful in non-classic Pompe disease to study muscle involvement, monitor 
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disease progression and treatment effects, even in patients who are Ven-
tilator dependent.84-87 We used MRI to examine the upper leg muscles of 
patients with classic infantile Pompe disease. In chapter 6 we described 
that MRI showed a hypertrophic appearance of the muscles in these pa-
tients. We assume this is caused by glycogen accumulation as observed in 
muscle biopsies of patients with classic infantile Pompe disease, but we did 
not demonstrate this assumption. To examine this hypothesis other MRI 
sequences should be used in future studies; e.g. glycogen accumulation 
could be demonstrated using C-NMR spectroscopy.88, 89 A major advantage 
of MRI is that muscles can be studied which are difficult to examine dur-
ing neurological examination; e.g. tongue muscles, trunk and abdominal 
muscles.84, 86, 90 Most studies showed that T1-weigthed sequences are suit-
able for assessing the pattern and severity of affected muscles in patients 
with non-classic Pompe disease, since these sequences detect both muscle 
atrophy and fatty replacement of muscle fibers.84, 86, 90 Other MRI techniques, 
such as T2 mapping and 3-point Dixon imaging, showed to be objective 
quantitative methods to monitor disease activity in Duchenne muscular 
dystrophy.91, 92 During a recently performed open-label multicenter study, 
3-point Dixon imaging was used to measure changes in the degree of 
fatty infiltration in skeletal muscle of patients with non-classic Pompe 
disease (www.clinicaltrials.gov: NCT01288027). In another study it was 
demonstrated with proton-density fat-fraction (PDFF) whole-body MRI 
that the fat fraction of individual muscle groups in Pompe patients can be 
calculated and quantified.93 This technique was even more sensitive for the 
detection of muscle abnormalities in some muscle groups than physical 
examination. Therefore, muscle MRI in Pompe disease could be used for 
several purposes in addition to the physical examination. First, it could be 
a feasible technique to monitor the effects of ERT.94 Second, it could be used 
to study muscle involvement in clinically asymptomatic patients since 
it has been shown that muscles can already be affected in these patients 
before onset of symptoms has occurred.89, 90, 95 This is important since it is 
known that the best responders on ERT are likely patients who are mildly 
affected.96 Third, some studies describe that muscle MRI has the potential 
to shorten the diagnostic delay of approximately seven years in patients 
with non-classic Pompe disease by recognizing patterns of muscle involve-
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ment, so treatment can be initiated in an early stage of the disease.86, 90, 97 
In Dutch neuromuscular centers, a guideline of the Dutch Neuromuscular 
Research Center (ISNO) is used for patients presenting with limb girdle 
weakness. This guideline suggests that GAA activity should be measured 
in any patient with limb girdle weakness having increased CK levels and 
without a clear family history of neuromuscular diseases. We expect that 
by using this guideline the diagnostic delay will decrease, whereby limit-
ing the use of MRI for this purpose in the Netherlands. 
theraPies
enzyme replacement therapy 
In 2006, when the use of ERT was approved in patients with Pompe disease, 
a clinical benefit was demonstrated only in patients with the classic infan-
tile form of the disease. In these patients the hypertrophic cardiomyopathy 
decreased, patients reached motor milestones and had a prolonged surviv-
al.98-100 The first results in a large group of patients with non-classic Pompe 
disease were published in 2010. In a randomized, placebo-controlled trial 
in 90 patients it was demonstrated that after 1.5 years of therapy patients 
gained an improved walking distance and the pulmonary function stabi-
lized.20 These results were supported by several other studies in which the 
duration of treatment fluctuated from 6-54 months.101-106 In 2012 the effects 
of ERT after a median duration of two years in a group of 69 adult patients 
were published. This study showed that muscle strength increased and 
pulmonary function in sitting position stabilized. Patients who responded 
best were younger, more often female and were less severely affected be-
fore start of therapy.96 In 2013 it was shown that adult patients also had an 
improved survival after receiving ERT.107 Most studies showed that ERT 
positively alters the natural course in patients with non-classic Pompe 
disease on the relatively short-term, however, the long-term effects in 
larger groups of patients are unknown and currently topic of investigation. 
Pending on these results, researchers try to improve the effects of ERT in 
several ways: increasing the dose of rhGAA and frequency of dosing, in-
creasing levels of M6P on rhGAA (www.clinicaltrials.gov: NCT01898364), 
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using immunomodulation therapy to induce immune tolerance, and using 
adjuvant therapies to ERT such as clenbuterol (www.clinicaltrials.gov: 
NCT01942590), GAA fused to the glycosylation-independent lysosomal 
targeting (GILT) tag which contains a portion of insulin-like growth factor 
II (www.clinicaltrials.gov: NCT01924845) and chaperone therapy.108-118
Physical therapy and exercise training
In the past, clinicians were often afraid that exercise training in patients with 
neuromuscular disorders would result in progression of muscle weakness. 
However, moderate-intensity strength training and aerobic exercise train-
ing were shown to do no harm in patients with various neuromuscular dis-
orders such as myotonic dystrophy type I, facioscapulohumeral muscular 
dystrophy, inflammatory myopathies and neuropathies.119-121 Until recently 
there was little evidence that exercise training in Pompe disease would 
be beneficial. In a group of 34 Pompe patients receiving a combination of 
a high-protein/low-carbohydrate diet and submaximal aerobic training 
there was a positive effect on muscle strength and pulmonary function. 
Particularly patients who were fully compliant to the program stabilized 
or showed a slight improvement in muscle function.17 Another study in 
five patients receiving ERT showed an improvement in muscle strength 
and endurance after completing a 20-week training program.122 We showed 
that twelve weeks of exercise training indeed significantly improves muscle 
strength, endurance and physical functioning in mildly affected patients 
with Pompe disease who were treated with ERT (chapter 8). It also reduced 
fatigue and pain.123 The training program that we used comprised aerobic 
training, strength training and core stability training three times a week. 
Patients performed the program safely. Since our study lasted twelve 
weeks and only mildly affected patients were included, future studies are 
needed to explore the effects of exercise training on a longer term and in a 
larger group of patients including the whole spectrum of the disease.
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future PersPectiVes
Pompe disease is a rare disorder. To study the effects of ERT and any future 
therapy in a larger patient population, it would be best to collect patient 
data in a European or worldwide cohort. Other advantages of collabora-
tion between multiple centers are that 1) genotype-phenotype correlations 
and the effect of polymorphisms and environmental factors can be studied 
more reliable, 2) the use of neuromuscular imaging techniques can be ex-
amined in a larger group of Pompe patients before and during ERT, and 3) 
more definite criteria for starting and stopping of ERT can be developed. 
We have already discussed the first two points earlier in this discussion. In 
the next section we will discuss our vision on how to develop starting and 
stopping criteria, and the importance of studying prognostic factors. 
In patients with classic infantile Pompe disease who are diagnosed soon 
after birth, there is no discussion whether to start with ERT, since it was 
shown that without treatment these patients die in the first year of life.1-3 
It was also demonstrated that ERT should be started as soon as possible, 
since survival was best in patients receiving ERT before the age of six 
months.124, 125 In patients with non-classic Pompe disease there is a broad 
clinical spectrum, making it more difficult to decide when to initiate treat-
ment. However, it was shown that younger patients with mild limb girdle 
weakness and pulmonary dysfunction responded best to ERT, indicating 
that ERT in principle should be started as early as possible after onset 
of symptoms.96, 126-128 An important issue is that ERT is a very expensive 
treatment and especially therefore, it should not be started too early in the 
course of the disease. On the other hand, ERT should also not be initiated 
too late once muscle weakness has become irreversible. The consensus at 
our center is that patients who have clinical signs of limb girdle weak-
ness or respiratory dysfunction, which both could be mild, should start 
with ERT when they deteriorate over time. A difficult group of patients are 
those who are severely affected, i.e. requiring a wheelchair or ventilation, 
or patients who are deteriorating despite treatment with ERT. Nowadays, 
there are no clinical studies providing evidence whether these patients 
should start or continue with ERT, or treatment should be stopped. These 
are difficult ethical dilemmas. Recent meetings between experts within the 
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European Pompe Center (EPOC) help to formulate these criteria. Currently, 
we recommend treating these patients for a period of two years and subse-
quently judging their responses to ERT. Treatment should be continued if 
patients improve, stabilize or deteriorate less than before start of ERT. This 
is consistent with current recommendations of other expert groups.129-131 
Finally, there are patients with Pompe disease who are still asymptomatic. 
At our center these patients are assessed once a year, including measuring 
muscle strength, pulmonary function, biomarkers of skeletal muscle dam-
age and in the future lung and muscle MRI. Once there are clinical signs of 
disease activity, the possibility of starting with ERT is discussed with the 
patient. In general, this is also the consensus at other centers.95, 129-131              
To better predict the effect of ERT in an individual patient before start 
of treatment, we are trying to develop prediction models that enable us to 
predict the individual response on muscle strength and pulmonary func-
tion. For this purpose, prognostic factors need to be determined in a larger 
group of patients; e.g. the influence of age, gender, genotype, polymor-
phisms and environmental factors. This project is a collaborative action 
between the European neuromuscular centers within EPOC. Hopefully 
these prediction models will be helpful to make these difficult decisions. 
173
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summary
Pompe disease is a progressive metabolic myopathy with an autosomal re-
cessive inheritance pattern. Mutations in the GAA gene result in a complete 
or partial deficiency of the lysosomal enzyme GAA that leads to glycogen 
accumulation in various tissues.
In chapter 1 Pompe disease is introduced and different aspects of the 
disease are summarized such as the etiology, pathophysiology, diagnostics 
and treatment options. In addition, the broad clinical spectrum of this 
disease is described. At the one end of the spectrum there are patients with 
the classic infantile form of the disease. These patients have a complete 
GAA deficiency. They have a rapidly progressive course of the disease and 
without treatment these patients die in the first year of life. On the other 
end of the spectrum there are adult patients with the non-classic or late-
onset form of the disease. These patients develop symptoms in adulthood 
and have a slowly progressive course of the disease.
The genotype-phenotype correlation is addressed in more detail in chap-
ter 2. The GAA genotype is the first level at which clinical heterogeneity 
arises. Patients with the classic infantile form of the disease have two severe 
mutations in the GAA gene and patients with the non-classic form harbor 
one severe mutation and a second mutation that is not fully deleterious. 
The clinical phenotype in classic infantile patients is rather homogeneous, 
while in patients with non-classic Pompe disease there is a large variation 
in phenotype, even among patients with the same GAA genotype. Over 
90% of adult patients and 50% of children with Pompe disease harbour 
the c.-32-13T>G mutation in combination with a severe mutation. In this 
group of patients there is no clear correlation between residual enzyme 
activity and phenotype. Probably, other factors such as environmental and 
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genetic factors play an important role. To have a better understanding of 
the genotype-phenotype correlation in patients with non-classic Pompe 
disease we studied 22 Dutch families with two or more affected siblings. 
Siblings affected with Pompe disease all developed symptoms either in 
childhood or in adulthood. In addition, siblings often have similar present-
ing symptoms and in some families specific clinical features such as ptosis 
and bulbar weakness are present in all of them. However, within other 
families there is still a substantial variation in the course and severity of the 
disease, as also observed between families with the same GAA genotype. 
This phenotypical variation and consistency within families indicates that 
other genetic background or environmental factors than the GAA genotype 
influence the course of the disease. Additional studies are needed to iden-
tify these factors.  
Chapter 3 focuses on the genotype-phenotype correlation in three adult 
patients with Pompe disease with residual GAA activity measured in fibro-
blasts in the range that is normally observed in classic infantile patients. 
None of these patients carried the common mutation c.-32-13T>G. To have 
a better understanding of the clinical course in these three patients enzyme 
activity was measured in leukocytes, fibroblasts and muscle tissue, and 
glycogen content was measured in fibroblasts and muscle tissue. In all 
three cases enzyme activity and glycogen content in fibroblasts were within 
the same range as in classic infantile Pompe disease, but the activity and 
glycogen content in muscle tissue were within the range as in non-classic 
Pompe disease. The higher enzyme activity and less glycogen storage in 
muscle might explain why these three patients have a slowly progressive 
course of the disease.   
Chapter 4 describes the finding of increased plasma cardiac troponin T 
(cTnT) levels in 122 patients with Pompe disease. Troponin is a protein 
involved in muscle contraction. Both a skeletal muscle-specific and cardiac 
muscle-specific troponin form exist. Cardiac troponins are important bio-
markers in patients with acute myocardial infarction, however, in patients 
with neuromuscular disorder such as Pompe disease these troponins can 
also arise from an alternative source. We demonstrated that in 82% of the 
Dutch Pompe patients cTnT was elevated and correlated well with cre-
atine kinase levels, a marker of skeletal muscle damage. cTnI, which is a 
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specific for cardiac damage, was normal in all patients. Left ventricular 
hypertrophy is also associated with increased cTnT, however, this finding 
was present in only one patient with classic infantile Pompe disease as 
demonstrated by cardiac evaluation of most patients. RNA expression 
analysis demonstrated the presence of cTnT in skeletal muscle tissue taken 
from Pompe patients. We concluded that most patients with Pompe disease 
have elevated plasma cTnT levels reflecting skeletal muscle damage rather 
than myocardial damage.      
Chapter 5 presents a study of the respiratory function using MRI. Patients 
with non-classic Pompe disease not only develop slowly progressive limb 
girdle weakness, but also respiratory insufficiency, most prominent in su-
pine position. In this chapter we describe a pilot study in ten adult patients 
in whom the respiratory function is measured by lung MRI in combination 
with spirometry. This non-invasive technique allows to directly assess the 
contribution of the diaphragm and other respiratory muscles during the 
breathing cycle. MRI showed that most patients with Pompe disease have 
a severely impaired diaphragmatic function. In some of them there was 
hardly any movement of the diaphragm. This might indicate that the dia-
phragm is already involved early in the disease process. We hypothesize 
that lung MRI might be an useful tool in decision making when to start 
with ERT, and also to monitor treatment effects. Further studies will be 
performed in the near future.
In chapter 6 the results of muscle MRI of the upper legs of patients with 
classic infantile Pompe disease are described. Five patients were included 
and MR images were compared to muscle histopathology sections taken 
from quadriceps muscle. MRI showed almost no abnormalities except 
for some hypertrophy of the upper leg muscles, while the clinical status 
was quite advanced in most patients and muscle biopsies were strikingly 
abnormal. Future investigation is required to study if the hypertrophic ap-
pearance of the muscles on MRI is related to glycogen accumulation only 
and if MRI is an effective technique to evaluate the effects of ERT in classic 
infantile Pompe disease. 
Chapter 7 shows the results of a cross-sectional case-controlled study 
in 84 patients with non-classic Pompe disease in whom we investigated 
arterial stiffness. We performed this study since it has been shown that gly-
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cogen not only accumulates in skeletal muscle, but also in smooth muscle 
fibers and in the endothelial layer of arteries. We hypothesized that gly-
cogen accumulation in these structures would result in increased arterial 
stiffness. Arterial stiffness is an independent risk factor for cardiovascular 
disease and mortality. Pompe patients did not only have an increased arte-
rial stiffness, but also an increased blood pressure compared to age and 
gender-matched volunteers. To reduce the potential risk of cardiovascular 
disease, we recommend that blood pressure and other cardiovascular risk 
factors are closely monitored. The effects of ERT on arterial stiffness need 
to be investigated in future studies. 
In chapter 8 we focused on exercise training in patients with non-classic 
Pompe disease receiving ERT. The training program comprised 36 sessions 
of standardized aerobic, resistance and core stability exercises during 12 
weeks. We studied whether a standardized and structured exercise inter-
vention program has added value to ERT and also whether patients with 
a neuromuscular disorder such as Pompe disease can safely perform this 
type of exercises. Overall there was an improvement in endurance and core 
stability. In most patients muscle strength stabilized or slightly improved. 
We concluded that exercise training is safe and can serve as a beneficial 
adjuvant treatment in mildly affected patients with non-classic Pompe 
disease, when it is performed under the supervision of a trained physical 
therapist. 
Finally, chapter 9 summarizes the main findings, discusses the signifi-
cance, and provides suggestions for future research.
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samenVatting
De ziekte van Pompe is een progressieve metabole myopathie en erft 
autosomaal recessief over. Mutaties in het GAA gen resulteren in een vol-
ledige of gedeeltelijke deficiëntie van het lysosomale enzym GAA. Deze 
deficiëntie leidt tot glycogeenstapeling in verschillende weefsels.
In hoofdstuk 1 wordt de ziekte van Pompe geïntroduceerd en verschil-
lende aspecten van de ziekte samengevat zoals de etiologie, pathofysio-
logie, diagnostiek en behandelingsopties. Daarnaast wordt het klinische 
spectrum van de ziekte beschreven. Aan het ene eind van het spectrum 
bevinden zich patiënten met de klassieke vorm van de ziekte van Pompe. 
Deze patiënten hebben een complete deficiëntie van het enzym GAA. De 
ziekte is snel progressief en zonder behandeling overlijden deze patiënten 
in het eerste levensjaar. Aan het andere eind van het spectrum bevinden 
zich volwassen patiënten met de niet-klassieke vorm van de ziekte van 
Pompe. Deze patiënten ontwikkelen symptomen tijdens de volwassenheid 
en hebben een langzaam progressief ziektebeloop.
De correlatie tussen genotype en fenotype wordt in hoofdstuk 2 in meer 
detail behandeld. Het GAA genotype is het eerste niveau waarop klinische 
heterogeniteit ontstaat. Patiënten met de klassieke vorm van de ziekte van 
Pompe hebben twee ernstige mutaties in het GAA gen en het fenotype in 
deze groep is vrij homogeen. In patiënten met de niet-klassieke vorm is 
er een grotere variatie in fenotype, zelfs tussen patiënten met hetzelfde 
GAA genotype. Meer dan 90% van de volwassen patiënten en 50% van 
de kinderen met de ziekte van Pompe dragen de c.-32-13T>G mutatie bij 
zich in combinatie met een ernstige tweede mutatie. Aangezien er geen 
correlatie is tussen de resterende enzymactiviteit en het fenotype moeten 
er andere factoren zijn die een belangrijke rol spelen zoals genetische en 
omgevingsfactoren. Om de correlatie tussen genotype en fenotype verder 
te bestuderen hebben we 22 Nederlandse families met twee of meer aange-
dane broers of zussen onderzocht. In de meeste families hebben patiënten 
hetzelfde fenotype en ontwikkelen ze symptomen tijdens de jeugd of in de 
volwassenheid. Vaak presenteren ze zich met dezelfde eerste symptomen 
en binnen sommige families komen dezelfde klinische kenmerken voor zo-
als ptosis en bulbaire zwakte. Echter in een aantal families is er een evidente 
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variatie qua beloop en ernst van de ziekte, zoals ook wordt gezien tussen 
families met hetzelfde GAA genotype. De variatie en overeenkomsten in 
fenotype binnen families wijzen erop dat andere genetische en omgevings-
factoren naast het GAA genotype het ziektebeloop beïnvloeden. Hiervoor 
zijn aanvullende studies nodig om deze factoren te identificeren.
Hoofdstuk 3 beschrijft de correlatie tussen het genotype en fenotype in 
drie volwassen patiënten met de ziekte van Pompe met een enzymactiviteit 
in fibroblasten die normaal wordt gemeten in patiënten met de klassieke 
vorm. Geen van deze drie patiënten heeft de mutatie c.-32-13T>G welke 
het meest voorkomt onder volwassen patiënten. Om een beter inzicht te 
krijgen van het klinisch beloop in deze patiënten werd de enzymactiviteit 
en/of de hoeveelheid glycogeenstapeling gemeten in leukocyten, fibro-
blasten en spierweefsel. In alle drie de gevallen was de enzymactiviteit 
en hoeveelheid glycogeenstapeling in fibroblasten in dezelfde range als 
in die van klassiek-infantiele patiënten met de ziekte van Pompe. Echter 
de enzymactiviteit en hoeveelheid glycogeenstapeling gemeten in spier-
weefsel was in de range van patiënten met de niet-klassieke vorm van de 
ziekte, wat verklaart waarom deze drie patiënten een langzaam progressief 
beloop hebben.
In hoofdstuk 4 wordt de bevinding van een verhoogd cardiaal troponine 
T (cTnT) in 122 patiënten met de ziekte van Pompe besproken. Tropo-
nine is een eiwit dat is betrokken bij spiercontractie en ruwweg bestaan 
er twee vormen, namelijk skelet- en hartspier specifiek troponine. Car-
diale troponines zijn belangrijke biomarkers in patiënten met een acuut 
myocardinfarct. Echter, in patiënten met neuromusculaire aandoeningen 
zoals de ziekte van Pompe zijn alternatieve oorzaken aannemelijk. 82% 
van de Nederlands patiënten met de ziekte van Pompe hebben een ver-
hoogd cTnT, wat correleert met het creatine kinase (een biomarker voor 
skeletspierschade). Daarnaast werd gekeken naar cTnI, een specifieke 
biomarker voor hartspierschade, welke normaal was in alle patiënten. 
Tevens vond er een uitgebreide cardiale evaluatie plaats waarbij er slechts 
in één patiënt met de klassiek-infantiele vorm linker ventrikelhypertrofie 
werd gevonden als verklaring voor het verhoogde cTnT. Aanvullend werd 
RNA expressie van cTnT aangetoond in skeletspierweefsel van patiënten 
met de ziekte van Pompe. Wij concluderen dat het overgrote deel van de 
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patiënten met de ziekte van Pompe een verhoogd plasma cTnT heeft, wat 
het meest waarschijnlijk veroorzaakt wordt door skeletspierschade en niet 
hartspierschade.
Hoofdstuk 5 beschrijft een studie waarbij er gekeken is middels MRI 
naar de longfunctie van volwassen patiënten met de ziekte van Pompe. 
Deze patiënten ontwikkelen naast langzaam progressieve spierzwakte ook 
respiratoire insufficiëntie, het meest uitgesproken in liggende houding. In 
een pilot studie in tien volwassen patiënten hebben we een MRI van de 
longen verricht in combinatie met spirometrie. Door middel van deze non-
invasieve techniek is het mogelijk om op een directe manier  het diafragma 
en de overige ademhalingsspieren te bekijken. Bij Pompe patiënten toonde 
de MRI een ernstig verminderde functie van het diafragma en in sommige 
patiënten was er nauwelijks beweging van het diafragma. Dit kan erop 
wijzen dat het diafragma al vroeg betrokken is in het ziekteproces. Of MRI 
in de toekomst een bruikbare techniek is om te beslissen wanneer te starten 
met ERT en om de effecten van deze therapie te monitoren moet verder 
worden onderzocht in toekomstige studies.
Hoofdstuk 6 beschrijft de bevindingen van MRI van de bovenbeenspie-
ren bij vijf klassiek-infantiele patienten met de ziekte van Pompe. De MRI 
beelden werden vergeleken met spierbiopten genomen uit de musculus 
quadriceps. De MRI’s lieten nagenoeg geen afwijkingen zien behoudens 
enige hypertrofie van de bovenbeenspieren, terwijl de meeste patienten 
een ernstig klinisch beeld hadden en een zeer afwijkend spierbiopt. Toe-
komstig onderzoek moet uitwijzen of de hypertrofisch uitziende spieren 
op MRI het gevolg zijn van alleen glycogeenstapeling en of MRI van de 
spieren een effectieve techniek is om de effecten van ERT te evalueren in 
patienten met de klassiek-infantiele ziekte van Pompe.  
In hoofdstuk 7 worden de resultaten besproken van een cross-sectionele 
case-controlled studie naar de arteriële vaatstijfheid in 84 patiënten met 
de niet-klassieke vorm van de ziekte van Pompe. Deze studie werd ver-
richt omdat er niet alleen glycogeenstapeling is in skeletspierweefsel, 
maar ook in gladspierweefsel en in de endotheellaag van arteriën. Wij 
veronderstelden dat glycogeenstapeling in deze structuren zou leiden tot 
een verhoogde arteriële vaatstijfheid; een onafhankelijke risicofactor voor 
cardiovasculaire ziekten en mortaliteit. Deze studie toont aan dat patiën-
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ten met de ziekte van Pompe naast een verhoogde vaatstijfheid ook een 
verhoogde bloeddruk hebben in vergelijking met voor leeftijd en geslacht 
gecorrigeerde vrijwilligers. Wij adviseren om de bloeddruk en andere car-
diovasculaire risicofactoren goed te monitoren en eventueel te behandelen 
om zo het cardiovasculaire risicoprofiel te verlagen. Het effect van ERT op 
de arteriële vaatstijfheid dient verder te worden onderzocht in toekomstige 
studies.
Hoofdstuk 8 behandelt de effecten van een trainingsprogramma in 
patiënten met de niet-klassieke vorm van de ziekte van Pompe. Het pro-
gramma bestond uit 36 sessies van gestandaardiseerde aerobics oefeningen, 
uithoudingstesten en rompstabiliteitsoefeningen. Wij hebben onderzocht 
of zo’n gestandaardiseerd en gestructureerd trainingsprogramma een 
toegevoegde waarde heeft naast ERT en of dit veilig kan worden uitge-
voerd in patiënten met een neuromusculaire aandoening zoals de ziekte 
van Pompe. Na het trainingsprogramma was er een verbetering van het 
uithoudingsvermogen en de rompstabiliteit. In de meeste patiënten was 
er tevens een stabilisatie danwel lichte verbetering van de spierkracht. Uit 
het onderzoek blijkt dat dit type trainingsprogramma veilig en voordelig is 
naast ERT in mild aangedane patiënten met de ziekte van Pompe, mits het 
wordt uitgevoerd onder de begeleiding van een getrainde fysiotherapeut. 
Het afsluitende hoofdstuk 9 geeft een samenvatting van de belangrijkste 
bevindingen, bediscussieert het belang van deze bevindingen aan de hand 
van gegevens uit de literatuur, en bespreekt suggesties voor toekomstig 
onderzoek naar de ziekte van Pompe.
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Dankwoord
danKWoord
Na een periode van 5.5 jaar is het eindelijk zover, ‘mijn’ proefschrift ligt 
voor u. Ik heb het woord ‘mijn’ tussen haakjes gezet, omdat dit proefschrift 
niet tot stand zou zijn gekomen zonder de hulp van velen. Daarom wil ik 
nu van de gelegenheid gebruik maken om een aantal personen te bedan-
ken voor de geboden mogelijkheden, medewerking en ondersteuning de 
afgelopen jaren om dit proefschrift te krijgen zoals het is geworden.
Allereerst gaat mijn dank uit naar alle patiënten met de ziekte van Pompe 
in Nederland. De bereidheid en het enthousiasme waarmee u allen heeft 
deelgenomen aan de diverse onderzoeken vind ik bewonderingswaardig 
en motiveert mij en heel veel andere collega’s binnen ons team om door 
te blijven zoeken naar mogelijkheden om de kwaliteit van leven verder te 
verbeteren. Daarnaast wil ik partners en familieleden van de patiënten be-
danken voor het meedoen als controle persoon met diverse onderzoeken. 
Vervolgens wil ik mijn beide promotoren en copromotor bedanken. 
Prof.dr. P.A. van Doorn, beste Pieter. Bedankt voor de kans om onder 
jouw begeleiding dit onderzoek te hebben mogen doen. Ondanks je over-
volle agenda is er altijd wel een gaatje om klinische problemen, onder-
zoeksvoorstellen of de inhoud van een manuscript te bespreken. Ik heb 
door de jaren heen veel van je kunnen leren, zowel op het klinische als 
wetenschappelijke vlak. Bedankt voor de fijne samenwerking en ik weet 
zeker dat ik nog veel van je zal leren in mijn opleiding tot neuroloog.
Prof.dr. A.T. van der Ploeg, beste Ans. Als ik van iemand kan leren wat 
het is om hard te werken en voor patiënten door het vuur te gaan, dan ben 
jij het wel. Zonder jouw toewijding en energie zou het Centrum voor Ly-
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sosomale en Metabole Ziekten niet zo’n goed geoliede machine zijn zoals 
het nu is. Ik wil je bedanken dat ik deel uit mocht maken van het Pompe 
onderzoeksproject en ik hoop in de toekomst nog verder met je te kunnen 
samenwerken.
Dr. E. Brusse, beste Esther. Je bent zo’n beetje tegelijk met mij begonnen 
met je werkzaamheden binnen het Pompe team. Je hebt in korte tijd laten 
zien dat je een aanwinst voor het team. Het was voor mij erg fijn dat je 
copromotor werd, zodat sommige artikelen hierdoor sneller tot stand zijn 
gekomen dan dat zonder jou was gelukt. Bedankt en ik weet zeker dat ik 
nog veel van je zal leren tijdens mijn opleiding.
De leden van de kleine commissie. 
Prof.dr. R.M.W. Hofstra, Prof.dr. J.C. de Jongste en Prof.dr. J.H.J. Wokke, 
wil ik graag bedanken voor de bereidheid dit proefschrift te beoordelen 
en plaats te nemen in de promotiecommissie om van gedachte te wisselen 
over de  inhoud van dit proefschrift. 
Paranimfen.
Beste Yordi. Bedankt dat je mijn paranimf wil zijn. We kennen elkaar al 
vanaf de kleuterschool en hebben door de jaren heen nagenoeg dezelfde 
weg afgelegd qua opleiding. Wat begon met een veterstrikdiploma bij 
juffrouw Corrie op de Toverfluit, het krijgen van gele en rode kaarten bij 
juffrouw Corina op de Mariaschool, het zelf bier brouwen op het Markland 
College als afstudeeronderzoek, het afronden van de Geneeskunde oplei-
ding in Rotterdam, maakt nu dat we ons ‘bijna’ medisch specialist mogen 
noemen. Ik denk dat we in de toekomst nog regelmatig onder het genot 
van een biertje anekdotes uit het verleden zullen aanhalen en wie weet 
eindigen we nog in hetzelfde ziekenhuis, jij als longarts en ik als neuroloog.
Beste Ralph. Ik ben trots dat je als grote broer paranimf wil zijn. We heb-
ben totaal verschillende richtingen gekozen in ons werk, maar toch zijn er 
veel overeenkomsten. Hard werken, studeren in de avonden en weekenden 
(soms tot ongenoegen van onze vrouwen) en klaarstaan voor andere men-
sen. Hierdoor kunnen we af en toe ook lekker klagen over hoe druk het is 
en dat het soms zoeken is naar tijd voor leuke dingen met de kinderen. Hoe 
dan ook, het wekelijks avondje squashen houden we erin, want het is toch 
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wel even lekker om je verstand op nul te zetten en die bal zo hard mogelijk 
tegen de muur aan te slaan als vorm van ontspanning. Oh, en ga door voor 
die vierde, wie weet toch een keer een jongetje.   
Het onderzoek naar de ziekte van Pompe zou niet mogelijk zijn zonder 
mensen gespecialiseerd in klinische biochemie en genetica. Allereerst Dr. 
A.J.J. Reuser, beste Arnold. Als de titel Pompeloog bestond dan zou jij deze 
toch mogen dragen. De kennis die jij bezit over deze aandoening en de ma-
nier waarop je deze kennis kan overdragen naar collega’s, maar met name 
ook naar patiënten toe is bewonderingswaardig. Daarnaast wil ik Marian 
en Marianne bedanken voor het uitvoeren van diverse experimenten, het 
meedenken en schrijven aan enkele artikelen en het discussiëren over 
mutaties, enzymactiviteit, titers, etc. Ook wil ik het trio Gerben, Pim en 
Tom bedanken voor het uit de hand gelopen troponine project. Wat begon 
met een observatie in het bloed van één patiënt, eindigde een jaar later in 
het onderzoeken van tientallen spierbiopten en het meten van eiwitten en 
RNA middels voor mij ingewikkelde technieken. Dank voor alle tijd en 
effort die jullie in dit project hebben gestopt. 
Het Centrum van Lysosomale en Metabole Ziekten is inmiddels zo ge-
groeid dat ik niet iedereen persoonlijk kan bedanken, maar een deel wil ik 
wel even noemen. Juna en Nadine, bedankt voor de samenwerking en dat 
jullie hebben gezorgd dat ik op een rijdende trein hebben kunnen springen 
waardoor alles een stuk makkelijker is verlopen. Mijn opvolger, Esther, we 
hebben samen een leuk project gedaan met de echo’s en je zelfstandige 
manier van werken als keuze-onderzoekster was opmerkelijk. Het zal geen 
probleem zijn voor jou om binnen een paar jaar ook je proefschrift klaar te 
hebben. Ik ben erg benieuwd naar het stuk over de lange termijn effecten. 
Tineke, Vanessa en Wendy, dank voor jullie hulp in de kliniek en daarbui-
ten. Door jullie goede planning, het overnemen van een aantal klinische 
taken en het beantwoorden van vele vragen van patiënten was er voor mij 
zo nu en dan toch tijd om te schrijven aan mijn artikelen en dit proefschrift. 
Dank daarvoor. Overige promovendi: Audrey, Carin, Chris, Deniz, Esther, 
Johanekke, Laurike, Linda, Marein, Marion, Merel, Rachel en Tim, bedankt 
voor de fijne samenwerking en de gezelligheid tijdens congressen. Veel 
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succes met het afmaken van jullie proefschriften en/of opleidingen. Verder 
wil ik Janneke, Francois, Jan-Dietert, Nicolette, Hannerieke, Michelle, Iris, 
Nathalie, Marianne, Wilma, Jacqueline Hardon, Jacqueline Habermehl 
en de verpleegkundigen op de dagbehandeling onder leiding van Gonda 
bedanken voor de prettige samenwerking. 
Voor een aantal projecten hebben we samen moeten werken met andere 
afdelingen binnen het Erasmus MC. Vanuit de Interne Geneeskunde wil 
ik in het bijzonder Francesco en Evelien bedanken voor hun hulp tijdens 
het onderzoek naar de arteriële vaatstijfheid. Voor de pilot studie over het 
onderzoek van het diafragma middels MRI wil ik Prof.dr. H.A.W.M Tid-
dens, Pierluigi, Adria, Karla, Elizabeth, Piotr en Marleen bedanken voor 
alle tijd die ze in dit project hebben gestoken. Daarnaast wil ik Rob Verdijk 
bedanken voor het beoordelen van de vele spierbiopten en het verzorgen 
van de mooie histologische plaatjes in dit proefschrift.   
Ik heb de afgelopen jaren gemerkt dat promotie onderzoek doen nog een 
stuk leuker is wanneer er een gezellige sfeer is. Al was het die drie jaren 
met nagenoeg alleen maar vrouwen op de kamer, ik heb het toch erg naar 
mijn zin gehad. Bianca, Christa, Christine en Joyce, veel succes met jullie 
onderzoek naar GBS. Danielle, Immy, Julia, Naghmeh en Tessel, het was 
een welkome afwisseling om het af en toe ook over het centrale zenuwstel-
sel te hebben. De buren op de ‘vasculaire en neurodegeneratieve’ kamer: 
Inger, Susanne, Elise, Janne, Janneke, Tsz en Wan Zheng, het waren ge-
zellige lunch pauzes en koffie breaks. Daarnaast wil ik Lourens en Eric 
bedanken voor het oplossen van problemen met de database of andere ICT 
vraagstukken.       
Mijn ouders, jongste broer Jurgen, familie en schoonfamilie wil ik bedan-
ken voor de interesse en steun tijdens mijn onderzoeksproject. Al was het 
misschien niet altijd goed te begrijpen wat ik aan het doen was of waar 
ik het over had, het was leuk om jullie op de hoogte te houden van mijn 
vorderingen in een veld waar niemand anders binnen onze familie in 
participeert. Tevens bedankt voor het oppassen op Indy en Liam, vooral in 
de laatste fase van mijn onderzoeksperiode zodat ik veel tijd kon besteden 
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aan dit proefschrift. Ten slotte willen Bianca en ik jullie vanuit het diepste 
van ons hart bedanken voor de liefde en steun die wij hebben gekregen in 
de moeilijkste periode uit ons leven met het verlies van onze Romy. Hoe 
moeilijk deze tijd ook was, het heeft het allemaal iets dragelijker kunnen 
maken.  
En als allerlaatst de belangrijkste personen in mijn leven. Liefste Bianca, 
ik denk dat zonder jouw steun dit boekje er nooit van was gekomen. Het 
waren hectische jaren met af en toe een diep dal, maar daarnaast louter 
hoogtepunten: eerst een eigen huis, daarna de bruiloft, gevolgd door de 
geboorte van Indy en het afgelopen jaar van Liam. Wat ik je in ieder geval 
wil zeggen is: bedankt, vooral voor je geduld deze afgelopen tijd en voor 
het zijn van een geweldige moeder en partner. Indy en Liam, ik ben trots 
jullie papa te zijn en wie weet vinden jullie dit proefschrift ooit in de toe-
komst de moeite waard om te lezen. Papa zal nu nog meer tijd hebben voor 
leuke dingen!
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4-MU	 	4-methylumbelliferyl-α-D-glucopyranoside
6MWT	 	Six-Minute	Walk	Test
ΔFVC	 	Postural	drop	in	forced	vital	capacity	from	sitting	to	
supine	position
AAV	 	Adeno-associated	viruses
ACTN3	 Alpha-actinin-3
ACE	 	Angiotensin-converting	enzyme
ACS	 	Acute	coronary	syndrome
AIMS	 	Alberta	infant	motor	scale	
Aix	 	Augmentation	index
ALS	 	Amyotrophic	lateral	sclerosis
ALT	 	Alanine	aminotransferase
AST	 	Aspartate	aminotransferase
ATr	 	Aortic	reflexion	time
CI	 	Confidence	interval
CfPWV	 Carotid-femoral	pulse	wave	velocity
CK	 	Creatine	kinase
CK-MB	 Creatine	kinase	myocardial	band
CNS	 	Central	nerve	system
CT	 	Computed	tomography
cTnT	 	Cardiac	Troponin	T
cTnI	 	Cardiac	Troponin	I
DBP	 	Diastolic	blood	pressure
DD	 	Deletion/deletion
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ERT	 	Enzyme	replacement	therapy
FDA	 	Food	and	drug	administration
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FVC	 	Forced	vital	capacity
GAA	 	Gene	encoding	for	acid	α-glucosidase
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QMFT	 	Quantitative	motor	function	test
RhGAA	 Recombinant	human	acid	α-glucosidase
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Pompe disease is a progressive metabolic myopa-
thy. It is caused by a deficiency of the enzyme acid 
α-glucosidase and leads to glycogen accumulation, 
predominantly in skeletal muscle. All Dutch patients 
diagnosed with Pompe disease are referred to the 
‘Center of Lysosomal and Metabolic Diseases’ at 
Erasmus MC University Medical Center, which makes 
it possible to study features of this orphan disease 
in a relatively large cohort. The aims of the stud-
ies described in this thesis were to have a better 
understanding of the clinical heterogeneity, geno-
type-phenotype correlations and the role of modifiers 
in Pompe disease. In addition, laboratory diagnostics 
and imaging techniques were studied, such as lung 
MRI in combination with spirometry to obtain insight 
into the function and strength of the respiratory mus-
cles, tonometry of the carotid-femoral pulse wave 
velocity to study arterial stiffness, and the meaning of 
increased plasma cardiac TnT levels.
